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General Abstract 
Background 
Athletes are frequently exposed to training- and competition-induced risk factors that 
increase the risk of injury and illness, including venous thromboembolism (VTE). 
Whilst VTE is frequently associated with physical inactivity and non-athletic 
populations, approximately 1 in 1000 athletes will experience a post-exercise 
thrombotic episode, similar to that of the general population.  
Aims 
The overarching aim of the series of studies completed in this thesis was to investigate 
factors that may influence the overall haemostatic response, as demonstrated by 
activation of the coagulation and fibrinolytic systems in well-trained athletes. To 
investigate this aim, four studies were undertaken. The first study aimed to examine 
the validity of a new cycling ergometer, the Wahoo KICKR Power Trainer (KICKR). 
The second study aimed to investigate the reliability of a performance test, a 4km 
cycling time trial (TT). Once the ergometer was validated and TT performance test 
deemed to be reliable, a third study used both to investigate the influence of time of 
day on coagulation responses to a short-duration high-intensity bout of exercise, whilst 
investigating the potential existence of diurnal rhythms within markers of coagulation 
in well-trained cyclists. The final study aimed to investigate if sports compression 
clothing when worn during a longer bout of exercise could influence the haemostatic 
responses to exercise.  
Results 
Study One / Study Two: The KICKR displayed accurate measurements of power 
between 250 and 700Watts (W) at cadences of 80-120revolutions per minute (rpm), 
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with an ergometer error/bias of -1.1% (95% Limits of Agreement (LoA): -3.6% to 
1.4%). Average power was shown to be highly reliable within the 4km cycling TT, 
with an average Intraclass Correlation Coefficient (ICC) and typical error of 
measurement (CV) of 0.94 (95% Confidence Intervals [CI]: 0.85-0.98) and 3.4% 
(95%CI: 2.7-4.7%) respectively. These results indicate the KICKR is a suitable 
ergometer and a 4km TT a suitable performance test for the completion of further 
studies utilising well-trained cyclists.   
Study Three: A 4km TT was shown to significantly increase plasma concentrations of 
tissue factor (TF: p<0.0005), tissue factor pathway inhibitor (TFPI: p<0.0006), 
thrombin anti-thrombin complexes (TAT: p<0.0012) and D-Dimer (p<0.0003), 
regardless of the time of day the exercise was performed. A time of day response was 
observed in pre-exercise TF (p=0.004) and TFPI (p=0.031), with 0830 h higher than 
1730 h (p<0.001), whilst levels at 1730 h were less than those at 2030 h (p=0.008). 
However, no significant effects for time of day for TAT (p=0.364) and D-Dimer 
(p=0.228) were reported. 
Study Four: When worn during a marathon, compression socks (SOCKS) significantly 
attenuated the post-exercise increase in D-Dimer compared to the control group 
(median (range) SOCK: +9.02, (-0.34 to 60.7) ng/mL, CONTROL: +25.48, (0.95 to 
73.24) ng/mL, p=0.008). TF was increased following the marathon run (median 
(range), SOCK: +1.19, (-7.47 to 9.11) pg/mL, CONTROL: +3.47, (-5.01 to 38.56) 
pg/mL, p=0.001), but there was no significant difference between the compression and 
control groups. No significant post-exercise changes were observed for TAT and TFPI 
(p>0.05).  
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Conclusions 
The major conclusions of this thesis are:  
1. The KICKR is a valid ergometer for measuring cycling power output.  
2. A 4km cycling TT, when completed on the KICKR, is a reliable performance 
test for well-trained cyclists.  
3. A short-duration high-intensity TT significantly activates the coagulation and 
fibrinolytic systems in well-trained cyclists, regardless of the time of day the 
TT is performed.  
4. TF and TFPI are influenced by time of day, suggesting an increased potential 
for coagulation activation in the morning.  
5. When worn during a marathon, compression socks reduce exercise-associated 
fibrinolytic activity as reflected by lower D-Dimer concentrations. 
The significance of this series of studies is that they have demonstrated the duration 
of exercise and the time of day exercise is performed influence coagulation responses 
within a well-trained population. In addition, this thesis contributes to the scarce 
literature on the use of compression garments and haemostatic responses in endurance 
based exercise, establishing that the use of sports compression socks may be beneficial 
in the prevention of VTE. The findings of this thesis may assist coaches, sports 
scientists and the athletes themselves to consider preventative measures for VTE, 
especially in athletes who are genetically predisposed to hypercoagulability.  
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Common Abbreviations 
Selected abbreviations throughout the text 
aPTT activated partial thromboplastin time 
AROM active range of motion 
AST aspartate transminase 
Bla blood lactate 
bpm  beats per minute 
BW body weight 
CALRIG calibration rig 
CG compression garments 
CI confidence intervals 
CK creatine kinase 
CMJ counter movement jumps 
CV coefficient of variation 
DOMS delayed onset of muscle soreness  
DVT deep vein thrombosis 
ELISA enzyme-linked immunosorbent assay 
ES effect size 
F female  
F 1+2 prothrombin fragment 1+2 
FPA fibrinopeptide A 
FV factor five 
FVII factor seven 
FVIII factor eight 
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FVL factor five leiden mutation 
FIX factor nine 
FX factor ten 
FXII factor twelve 
h hour  
Hct haematocrit  
Hgb  haemoglobin  
HR heart rate 
ICC intraclass correlation coefficient 
KICKR Wahoo KICKR Power Trainer 
km kilometre 
LDH lactate dehydrogenase 
LoA limits of agreement 
m  metres 
M  males  
min  minutes 
mmHg millimetres of mercury 
ng/mL nanograms per millilitre 
PAI-1 plasminogen activator inhibitor 
PC protein C 
PS protein S 
pg/mL pictograms per millilitre 
PLT platelets  
PTT partial thromboplastin time 
RBC red blood cell 
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RM repetition maximum 
RPE rating of perceived exertion 
RPM revolutions per minute 
s seconds 
SCN suprachiasmatic nucleus 
submax  submaximal 
TAT thrombin anti-thrombin complexes 
TF tissue factor 
TFPI tissue factor pathway inhibitor 
t-PA tissue plasminogen activator 
TT time trial 
TTE total time to exhaustion 
µg/L microgram per litre 
VE ventilation  
VO2max maximal oxygen uptake 
VT ventilatory threshold 
VTE venous thromboembolism 
W  watts  
 
Infrequent abbreviations used through the thesis are defined in situ. 
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Chapter One: Thesis Introduction and Overview 
1.1 Thesis Organisation 
This doctoral thesis contains a series of four studies aimed at investigating factors that 
may influence the overall haemostatic responses in well-trained athletes. 
Chapter One: Contains a general introduction of the factors comprising the themes 
of this thesis, identifying the individual aims and significance of the research, in 
addition to the general layout of the thesis. 
Chapter Two: Comprises a review of the literature, providing background 
information supporting the research studies of this doctoral thesis.  
Chapter Three: Contains study one of this thesis, which involved the investigation 
of the validity of power output generated by a cycling ergometer, the Wahoo KICKR 
Power Trainer, in comparison to power generated by a dynamic calibration rig, over 
power outputs and cadences typically observed within cycling (100-999W at cadences 
of 80-120rpm).  
Chapter Four: Contains study two of this thesis. Once the KICKR was shown to 
provide valid measures of power output, study two investigated the reliability of a 4km 
cycling TT using well-trained cyclists over three separate occasions, when performed 
on the Wahoo KICKR Power Trainer.  
Chapter Five: Contains study three of this thesis. Once deemed suitable, the KICKR 
and a 4km cycling TT was used in study three to investigate the influence of time of 
day on the coagulation and fibrinolytic responses to exercise in fifteen well-trained 
cyclists, over five separate time points (0830, 1130, 1430, 1730 and 2030 h). In 
addition, potential diurnal rhythms in resting markers of coagulation and fibrinolysis 
were investigated.  
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Chapter Six: The fourth and final study of this thesis aimed to investigate if 
compression socks attenuated haemostatic responses when worn during a marathon 
run. Sixty-seven participants (43 males and 24 females) were allocated into a 
compression or control (no socks) group and completed the 2016 Gold Coast 
Marathon, with pre- and post-exercise venous blood samples collected and analysed 
for coagulation and fibrinolytic activation.  
Chapter Seven: The discussion chapter comments on the major findings of this thesis, 
and discusses the potential implications of the research undertaken, providing 
directions for future research and an overall conclusion. 
1.2 Background 
Athletes are frequently portrayed as the epitome of health and well-being due to their 
high level of physical fitness [1]. To maintain their competitive and elite-level status, 
athletes are constantly exposed to training- and competition-induced thrombogenic 
risk factors including injury and inflammation, dehydration and haemoconcentration, 
and long-haul travel [2-5]. The combination of these risk factors could lead to the 
development of a venous thromboembolisms (VTE), however, as VTE is rare within 
the athletic population, VTE is often misdiagnosed and poorly treated, leading to death 
in the worst case scenario [2, 6]. Indeed, investigations into fatalities in 243 football 
players revealed that five deaths resulted from VTE [6], with four of these cases 
precipitated by a traumatic injury and surgery.  However, known risk factors for VTE 
have previously been examined in untrained, healthy populations [7-9], which may 
not be applicable to an athletic population. Furthermore, there are methodological 
questions not addressed by these studies, including the duration and intensity of the 
exercise, and the time of the day that exercise is completed, making interpretation of 
findings difficult.  
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1.2.1 Haemostasis, Exercise and Compression  
Exercise has considerable effects upon haemostasis, with transient increases in blood 
coagulation [8, 10, 11], platelet aggregation [12] and fibrinolytic activity [8, 13, 14], 
with the degree of activation dependent on the duration and intensity of the exercise 
bout, the study population investigated and the time of day the exercise is performed 
[9, 15-17]. Whilst activation of the coagulation system has been reported in extremely 
short (15-90 s) [18] and longer (>20 min) [19] duration exercise bouts as indicated by 
significant increases in thrombin anti-thrombin (TAT) complexes and prothrombin 
fragment 1 + 2 (F 1+2), consensus is lacking with regards to exercise bouts between 
90 s to 20 min. Many sporting events such as cycling time trials are completed within 
this duration of time, however the response of the coagulation system during this 
period is yet to be extensively investigated.  
In longer-duration, low to moderate intensity exercise (i.e. marathon running, 
triathlons and ultramarathons), multiple studies report significant activation of the 
coagulation and fibrinolytic systems [10, 20, 21]. With VTE associated with a 
simultaneous increase in coagulation activation and a decrease in fibrinolysis, 
disrupting the dynamic haemostatic balance, research on how to prevent or lower this 
coagulation activation, within and immediately following exercise, is relatively scarce. 
Due to the proposed benefits of compression garments used in the treatment and 
prevention of lower extremity pathologies including deep vein thrombosis (DVT) 
within a clinical population [22, 23], it has been suggested that similar outcomes may 
be observed when combined with exercise, despite a lack of clear scientific evidence 
of their effects on physiology. Whether compression garments influence haemostatic 
activation during endurance exercise is yet to be extensively investigated. To date, 
only one study has examined the efficacy of compression socks on coagulation 
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responses during a marathon run. The authors reported an overall decrease in 
haemostatic activation when compression socks were worn [24].  
1.2.2 Haemostasis, Time of Day and Exercise 
As well as exercise duration and intensity, the time of day exercise is completed may 
play an essential role in the degree of coagulation and fibrinolytic activation. Markers 
of coagulation and fibrinolysis have been demonstrated to possess circadian rhythms, 
with hypercoagulability, hypofibrinolysis and increased platelet aggregation observed 
to occur between 0600 and 1200 h [7, 25-27], coinciding with an increase in the 
frequency of thromboembolic events [28, 29]. Therefore, it has been suggested that 
the safest time of day to exercise to prevent the incidence of VTE is the afternoon 
(1200 h onwards), whilst all morning exercise should be avoided completely (0600-
1200 h) [30]. The time of day in which an athlete exercises is often unavoidable, as 
they are required to compete and train over the course of a 24-hour day based upon 
the scheduling of training and competition, with this suggestion consequently 
unrealistic in elite and well-trained athletes. For this reason, research investigating the 
influence of exercising at different times of the day on haemostatic responses in an 
athletic population are warranted. 
1.2.3 Conclusion 
Given the limited research on haemostatic responses to exercise within an athletic 
population [9, 19, 31], the need to investigate “athlete-specific” risk factors utilising 
an athletic population is therefore required. To date, there is scarce evidence of 
coagulation and fibrinolytic responses to an exercise bout between 90 s to 20 min of 
duration, with this duration of exercise frequently employed in most training and 
competition requirements. Subsequently, with markers of coagulation demonstrated 
to possess their own circadian rhythms [25, 26] and with exercise well-documented to 
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activate both the coagulation and fibrinolytic systems [20, 21], it remains unclear if 
exercising at different times of the day may influence the degree in which these 
systems are activated, especially within an athletic population. Despite a lack of clear 
scientific evidence of their effects on physiology within sporting performance and 
recovery, compression garments are frequently used within a clinical setting for the 
prevention and treatment of lower extremity pathologies [23]. Therefore, the use of 
compression garments, when implemented within a sporting environment, may have 
the potential to reduce the risk of VTE [24]. Whether compression garments 
favourably influence haemostatic responses within exercise remains relatively 
unknown, highlighting the need for further research within this field. Subsequently, 
the primary purpose of this thesis was to investigate factors that have the potential to 
influence overall haemostatic responses in well-trained athletes.  
1.3 Significance of the Research 
In general, athletes have a low risk of VTE, occurring at a rate of ~ 1 in 1000 people 
[32, 33], similar to that of the general population. In general, athletes have a low risk 
of VTE; however, this population is exposed to many acquired thrombogenic risk 
factors as a direct result of training and competition [32, 34] which can negatively 
impact overall performance outcomes. Furthermore, diagnosis of VTE within an 
athletic population is often overlooked with symptoms of VTE often mistaken for 
general training soreness and sporting injuries, which in the worst scenario, can result 
in death [6, 35]. Whilst numerous “athlete-specific” risk factors have been identified, 
these investigations typically employ “apparently-healthy” populations only, with 
these findings difficult to interpret and apply to an athletic population. With extremely 
short-duration and high-intensity exercise frequently employed by athletes regardless 
of the sport completed, the coagulation and fibrinolytic responses within this 
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population are poorly understood. Therefore, the overall aim of this thesis was to 
contribute to the lack of research on haemostatic responses within a well-trained 
population, especially with regards to short-duration high-intensity exercise. 
Additionally, the influence of exercising at different times of day on coagulation 
responses may be of importance for athletic populations, especially in athletes 
predisposed to hypercoagulability, with athletes required to train and compete at 
different times of the day. The findings from this thesis may inform guidelines for 
scheduling of training on an individualised basis. With a surge in popularity of 
endurance events (including marathons, triathlons and ultramarathons), the potential 
for VTE is significantly increased. Therefore, the ability to minimise the potential risk 
for thrombosis formation is of high priority. The use of compression garments is 
potentially a cost effective, preventative measure of VTE during and following 
exercise. While compression garments are used for the enhancement of sporting 
performance and recovery, the influence of compression garments on haemostatic 
responses to exercise has not been extensively investigated. Whilst widely employed 
in a clinical setting in the prevention of lower-limb pathologies including DVT, 
wearing compression garments whilst exercising has been suggested to reduce the 
overall risk of VTE. The findings of this research may highlight the beneficial effects 
of compression garments on haemostatic responses whilst undertaking endurance 
exercise.  
1.4 Research Aims  
The overarching aim of the series of four studies was to investigate factors that may 
influence haemostatic responses in well-trained athletes. The first two studies 
determined the validity and reliability of a relatively new cycling ergometer, the 
Wahoo KICKR Power Trainer (KICKR) required for a performance test and a 4km 
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cycling time trial (TT), to be used in subsequent studies. Once validated and proven 
to be reliable, the KICKR and the 4km TT was used in study three to: 1. Investigate 
the influence of time of day on coagulation responses to a shorter-duration high-
intensity bout of exercise, and 2. Investigate the potential existence of diurnal rhythms 
within markers of coagulation over five individual time points. The fourth and final 
study then investigated the effect of sports compression clothing (i.e. compression 
socks), when worn during endurance exercise on the haemostatic response to exercise. 
The specific aims of each study are presented below. 
Study One and Study Two: To enable the investigation of coagulation in athletes, study 
one aimed to determine the validity of a cycling ergometer and study two examined 
the reliability of a performance test. 
1. Does the Wahoo KICKR Power Trainer (KICKR) provide valid measures 
of power output? 
2. Is a 4km cycling time trial (TT) reliable when completed on the KICKR? 
Study Three: The KICKR and a 4km cycling TT was then used to investigate the 
influence of time of day on the coagulation responses to exercise. In addition, the 
potential diurnal rhythms in markers of coagulation were investigated.  
1. When completed by well-trained cyclists, will a short-duration high-
intensity bout of exercise (4km cycling TT) influence the coagulation and 
fibrinolytic systems? In addition, will these responses vary when exercising at 
different times of the day (0830, 1130, 1430, 1730 and 2030 h)? 
2. Is a time of day response/ diurnal rhythm present within thrombin anti-
thrombin complexes (TAT), tissue factor (TF), tissue factor pathway inhibitor 
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(TFPI) and D-Dimer, markers associated with the coagulation and fibrinolytic 
systems? 
Study Four: To investigate if compression socks attenuates haemostatic responses, 
study four aimed to examine the influence of compression socks on coagulation and 
fibrinolysis when worn during a marathon run. 
1. When worn during a marathon (42.2km), can compression socks alter the 
overall haemostatic response? 
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Chapter Two: Literature Review 
2.1 Introduction 
Venous thromboembolism (a collective term for DVT: a blood clot located in the deep 
veins) and/or pulmonary embolism (a blood clot located in the lungs)) [36], is 
frequently associated with physical inactivity and a sedentary lifestyle. Significantly, 
several case studies of high-level and elite-level athletes developing a VTE have been 
reported [2, 5, 37, 38]. While exercise is associated with numerous health benefits [39-
42], exercise disrupts haemostasis, and when combined with other thrombogenic risk 
factors, increases the risk of VTE. This may result from a temporary increase in the 
activation of coagulation [8, 11, 43] immediately upon exercise completion [20], with 
a subsequent decrease in fibrinolytic activity. Although exercise-induced disturbances 
in the haemostatic balance may not be detrimental to most participants, approximately 
1 in 1000 athletes will experience a post-exercise thromboembolic incidence, similar 
to that of the general population albeit in the absence of exercise [44]. 
While athletes are considered to be healthy due to their high levels of physical fitness, 
they are frequently exposed to acquired individual-specific risk factors associated with 
hypercoagulability, including long-haul travel, dehydration, post-exercise 
haemoconcentration, and polycythaemia [3]. Furthermore, athletes are exposed to 
“athlete-specific” risk factors including exercise (duration and intensity), trauma, and 
the time of day at which exercise is performed [7, 31, 45], potentially enhancing the 
risk for VTE. When these factors are considered in conjunction with genetic pre-
dispositions to hypercoagulability present in some athletes, an overall increased risk 
for VTE is present [32, 46, 47]. Furthermore, diagnosis of DVT within an athletic 
population is often overlooked with symptoms of a DVT (i.e. pain, tenderness and 
swelling), often mistaken for general training soreness and sporting injuries.  
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To date, the majority of research examining the mechanism of coagulation activation 
(as measured by in-vivo markers of thrombin generation (i.e. TAT and F 1+2) 
following exercise, have only used “apparently-healthy” and untrained populations 
[16, 18, 48, 49]. Indeed, the majority of these studies have failed to report factors that 
may influence overall outcomes, including the time of day that exercise is completed. 
Therefore, studies investigating coagulation responses to exercise in well-trained 
athletic populations when completed at different times of the day are clearly required. 
In addition, conflicting responses of post-exercise coagulation activation have been 
observed in studies of varying duration and intensities [14, 49], with several studies 
demonstrating post-exercise activation [11, 19, 20, 50], whilst others have failed to 
demonstrate this activation of the coagulation system [51, 52]. Thus, the conflicting 
responses of coagulation activation with varying durations and intensities highlights 
the need for further investigation, especially within a well-trained and athletic 
population. This chapter therefore aims to identify significant gaps within the 
literature, whilst critiquing and discussing factors that may influence haemostasis in 
an athletic population.  
2.2 Overview of Haemostasis 
Haemostasis is the physiological process that maintains the balance between excessive 
bleeding and clotting, maintaining normal blood circulation [53-56]. This mechanism 
is continuously active at low levels and is achieved through a dynamic equilibrium 
between activators and inhibitors of haemostasis, including, 1) the vascular system, 2) 
blood platelets, 3) the coagulation system, 4) physiological inhibitors of coagulation, 
and 5) the fibrinolytic system [9, 53, 57].  
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2.3 Overview of Virchow’s Triad  
Virchow’s Triad comprises three factors that broadly contribute to the development of 
thrombosis. These were first postulated, then formally described by Rudolf Virchow 
in the mid-19th century [1]. Virchow’s Triad was initially proposed for the 
development of VTE, however the same three factors contribute to the development 
of arterial thrombosis and disseminated intravascular coagulation [58]. The factors of 
Virchow’s Triad favourable to VTE consist, of 1) hypercoagulability, 2) vessel wall 
injury, and 3) stasis [1, 57, 59] (Figure 2.1). In addition to these factors, activation of 
coagulation may arise from acquired or hereditary risk factors (Table 2.1). With 
haemostasis constantly active at low levels, changes to one or more factors associated 
with Virchow’s Triad may contribute to the increased risk of thrombosis [53].  
 
 
 
 
 
 
 
 
 
Figure 2. 1 Illustration of Virchow’s Triad, highlighting the three factors 
contributing to thrombosis development. 
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Table 2.1 Acquired and inherited risk factors demonstrated to pre-dispose individuals 
to venous thromboembolism [60]. 
Acquired Age 
Pregnancy 
Hormonal changes  
(oral contraceptive/ hormone replacement therapy) 
Obesity 
Injury and immobilisation 
Surgery  
Prior VTE 
Varicose veins 
Inherited  
 
 
Protein C deficiency 
Protein S deficiency 
Anti-thrombin deficiency 
Factor V Leiden mutation 
Prothrombin (G20210A) gene mutation 
Activated Protein C resistance 
Frequency (%) of 
thrombophiliac syndromes 
(general population) 
0.14-0.17 
Not specified 
0.02-0.17 
4-6 
1.7-3.0 
3.6-6.0 
 
2.4 Major Components of Haemostasis 
2.4.1 Vascular System (Endothelium) 
The vascular system, lined by endothelial cells, plays a pivotal role in the regulation 
of haemostatic balance by providing an interface between tissues and the blood [27, 
55]. Endothelial cells are involved in each of the major haemostatic pathways [27, 55, 
57], helping to prevent thrombosis by various anticoagulant and antiplatelet 
mechanisms (Figure 2.2) [27, 55-57]. They do this by maintaining blood viscosity via 
vasodilation, through the release of endothelium derived relaxing factor (nitric oxide) 
and prostacyclin (PGI2), inhibiting adhesion and activation of blood platelets, 
inhibiting coagulation, and triggering fibrinolysis [27, 55, 57] . 
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Figure 2.2 Schematic representation of the role played by the vascular endothelium 
in the platelet, coagulation and fibrinolytic systems. a) Platelet mediated haemostasis 
is triggered via the exposure of the sub-endothelial to the blood. In response, vWF 
initiates the adhesion of platelets to the sub-endothelium, acting as a bridge between 
tissue and platelets, binding to collagen [55]. b) The exposure of TF to the blood 
stream initiates activation of the coagulation system through a cascade of events, 
resulting in the generation of thrombin. The natural anticoagulant TFPI and the main 
inhibitor of thrombin, anti-thrombin III, help to regulate thrombin generation. c) t-PA 
is produced by vascular endothelial cells and is released into the blood stream 
following vascular damage, initiating the activation of fibrinolysis. t-PA activates 
plasminogen forming plasmin, with plasmin then digesting fibrin, resulting in the 
production of fibrin degradation products and D-Dimer [61]. Abbreviations: NO 
nitric oxide; ADP adenosine diphosphate; vWF von Willebrand Factor; TF tissue 
factor; TFPI tissue factor pathway inhibitor; t-PA tissue plasminogen activator; Plg 
plasminogen; PGI2 prostacyclin. 
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2.4.2 Platelets 
 
Blood platelets are the first responders upon damage to the vascular endothelium. The 
exposure of platelet activating substances, i.e. collagen to the bloodstream, promotes 
the adherence of platelets to the damaged site, with von Willebrand factor (vWF) 
mediating the initial adhesion of platelets (haemostatic plug) to the sub-endothelium 
[54, 55]. Once adhered, they undergo activation, releasing agonists such as 
thromboxane A2, and adenosine diphosphate, inducing vasoconstriction and resulting 
in the recruitment of other platelets to the site of vessel injury [54, 55, 62]. The 
activation of the platelet system results in simultaneous activation of the coagulation 
system and is discussed in further detail below (2.4.3. Blood Coagulation: the Cell-
Based Model of Coagulation). 
2.4.3 Blood Coagulation: The Cell-Based Model of Coagulation  
Blood coagulation comprises a complex series of interactions between proteases and 
cofactors that are present within the circulation [54, 57]. Historically, the two main 
pathways, known as the intrinsic (all components present within the blood) and 
extrinsic (exogenous factors required) pathways, were activated by foreign surface 
contact via factor XII (FXII) and the release of tissue factor (TF) from endothelial 
cells, respectively [54]. Through either pathway, coagulation converged at the 
common pathway with factor X (FX), resulting in the FXa:FVa (prothrombinase) 
complex and the formation of low amounts of thrombin [40, 52, 63]. From this 
historical model the extrinsic and intrinsic pathways have formed the basis of 
diagnostic coagulation screening tests, still used by clinicians to screen for 
abnormalities of haemostasis [64].  
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More recently, it has been proposed by Monroe and Hoffman [63] and described in 
detail by Versteeg et al. [54], that haemostasis occurs in three distinct, but overlapping 
phases, termed the cell-based model of coagulation. These include, i) initiation, where 
low amounts of TF are produced on cells such as monocytes and endothelial cells, ii) 
amplification, where platelets provide a pro-coagulant surface for increased 
coagulation and thrombin generation, and iii) propagation, where large amounts of 
thrombin are generated on the platelet surface, resulting in fibrin-rich blood clots 
(Figure 2.3).  
In this cell-based model, the initiation of coagulation (also termed the TF pathway) 
begins via disruption or damage to the vasculature, exposing TF to the bloodstream 
[56] (Figure 2.3). TF binds coagulation FVII, promoting proteolysis and activation of 
FVII to FVIIa, resulting in the formation of the TF:FVIIa complex [54]. TF:FVIIa 
proteolytically cleaves traces of FIX and FX into FIXa and FXa, respectively. FXa 
and FVa form a prothrombinase complex on TF-expressing cells, resulting in the 
generation of thrombin [54, 57, 63].  
The amplification phase of coagulation results in the movement from a TF-bearing 
cell to the platelet surface, enhancing coagulation activation [63]. Platelet adherence 
to extravascular matrix components at the site of vascular injury are established [54, 
55], resulting in platelet activation, whilst localising platelets to the primary site of TF 
exposure. This close proximity to thrombin generated by TF-bearing cells amplifies 
the pro-coagulant signal, enhancing platelet adhesion [65] and activating FV, FVIII 
and FXI [66]. With the activation of platelets, and cofactors V and VIII bound to their 
surfaces, thrombin generation is enhanced [63] (Figure 2.3). 
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The final phase of coagulation generates large amounts of thrombin that contributes 
to the formation of a blood clot. It is during this phase that activated proteases combine 
with their cofactors on the platelet surface, with continuous generation of thrombin 
[63]. Platelets express high affinity receptors for activated FIX [67], FX [68] and FXI 
[69]. When FIX is activated to FIXa, it forms a complex with FVIII (FVIIIa:FIXa) 
[70]. This complex is crucial for haemostasis and has been shown to activate FX on 
the platelet surface, resulting in FXa. As described by Hoffman and Monroe [63], FXa 
then moves directly into a complex with activated FVa. This FXa:FVa complex is then 
capable of producing the thrombin required to form a fibrin rich blood clot.  
To ensure the haemostatic balance is maintained, excess fibrin formation is limited by 
numerous anticoagulant mechanisms, including tissue factor pathway inhibitor (TFPI) 
[57] (see sections 2.4.3(2) and 2.4.3(4)). Furthermore, the fibrinolytic pathway is 
activated simultaneously with blood coagulation to prevent excessive clotting [41, 57]. 
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Figure 2.3 Schematic representation of the cell-based model of coagulation. 1) The 
initiation of coagulation takes place on TF-bearing cells. The TF:FVIIa complex 
activates FIX, FX. FXa then combines with FVa forming the prothrombinase 
complexes on TF-bearing cells [66]. FXa that dissociates from TF-bearing cell is 
rapidly inhibited by TFPI or anti-thrombin. 2) Amplification requires the “action” to 
move from TF-bearing cells to the platelet surface. Thrombin generated on TF-
bearing cells amplify the initial pro-coagulant signal, activating FV, FVIII and FXI 
[65]. vWF /FVIII binds to platelets and is cleaved by thrombin to activate FVIII and 
release it from vWF [71]. 3) Propagation phase occurs on activated platelets. The 
tenase (FVIIIa:FIXa) and prothrombinase complexes (FVa:FXa) are assembled on 
the platelet surface and thrombin generation occurs, resulting in fibrin polymerisation 
[63]. Schematic redrawn from Monroe and Hoffman [63]. Abbreviations: TF tissue 
factor, TFPI tissue factor pathway inhibitor, vWF von Willebrand Factor. 
 
2.4.3(1) Tissue Factor 
 
TF is a transmembrane glycoprotein expressed constitutively on cell surfaces, 
including fibroblasts and pericytes in, and surrounding blood vessel walls and 
epithelial cells [54, 57, 72]. TF is the primary physiological initiator of coagulation, 
achieved via a break in the vascular wall allowing plasma to come into direct contact 
with TF-bearing extravascular cells [73, 74]. In addition, monocytes and smooth 
muscle cells can be stimulated to produce TF by cytokines and other inflammatory 
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mediators [75]. The binding of cellular TF to FVII leads to the formation of the 
TF:FVIIa complex, which when attached to the cell membrane, initiates the activation 
of the coagulation system [70, 73]. Once formed, the TF:FVIIa complex is a potent 
activator of FX and FIX, with FXa the preferred substrate for the TF:FVIIa complex, 
resulting in continuous activation of coagulation [54, 76, 77]. Activation of the 
TF:FVIIa complex by FXa is the major initiating feedback loop of coagulation, 
activating circulating FIX into FIXa, resulting in the production of fibrin (blood clot) 
[78]. With TF essential for haemostasis, excessive concentrations of TF leads to 
thrombosis formation, thus regulation of TF activity is required to maintain 
haemostatic balance [73].  
2.4.3(2) Tissue Factor Pathway Inhibitor 
To regulate and prevent excessive clot formation, coagulation is balanced by several 
anti-thrombotic mechanisms [79]. TFPI is the major physiological regulator of TF-
induced coagulation [64], limiting activation by two rapidly occurring mechanisms. 
The first is through the inhibition of the TF:FVIIa complex, and the second is by the 
direct inhibition of FXa (Figure 2.3), limiting the proteolytic activity and the amount 
of thrombin generated [54, 64, 80-82]. TFPI exists as two isoforms; TFPIα and TFPIᵦ. 
TFPIα contains a negatively charged N-terminus, three Kunitz-type inhibitory domains 
(K1, K2, and K3) and a positively charged C-terminus, and is secreted by endothelial 
cells predominantly within the microvascular endothelium, whereas TFPIᵦ comprises 
of two domains only (K1 and K2) [83, 84]. K1 and K2 bind to FVIIa and FXa, 
respectively, to inhibit TF-mediated coagulation, whilst K3 binds to Protein S (a 
cofactor for the direct inhibition of FXa, and in the absence of FXa, a direct inhibitor 
of TF:FVIIa complex). In addition, TFPIᵦ has an altered C-terminus, enabling the 
binding of TFPIᵦ to the endothelium cell surface via a glycosylphosphatidylinositol 
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anchor [85]. As previously described by Broze [64], TFPI is kinetically “slow”, 
meaning that inhibition of coagulation activation is not always immediate or tight-
binding (referring to the fact that TFPI produces significant inhibition at 
concentrations near that of the enzyme being inhibited).  
2.4.3(3) Thrombin Generation 
Following vessel wall injury, blood loss is controlled by the activation of the 
coagulation cascade. During haemostasis, thrombin (a multifunctional serine protease) 
is generated rapidly at the site of injury, playing a pivotal role in the physiological 
formation and removal of thrombi [86, 87]. Thrombin has been described to play an 
important role within haemostasis and various non-haemostatic processes (see Posma 
et al. [88] for review), however this literature review will discuss the haemostatic role 
of thrombin only.  
Thrombin is considered the central enzyme and key regulator in coagulation, and is 
produced by the proteolytic cleavage of prothrombin (the inactive precursor of 
thrombin) by FXa [89]. Upon vascular injury, thrombin initiates haemostatic 
activation through the activation of blood platelets (the first responders and therefore 
regarded as primary haemostasis), resulting in the release of platelet activators (i.e. 
adenosine diphosphate, serotonin and thromboxane A2). Secondary haemostasis 
immediately follows, initiating the coagulation cascade and resulting in the formation 
of thrombin. With multiple functions reported [88], a key function of thrombin is the 
conversion of fibrinogen into fibrin monomers, resulting in the formation of a fibrin-
rich blood clot, preventing excessive bleeding from occurring [88]. Yet thrombin has 
been shown to possess a relatively short-half life and is constantly subjected to 
inhibition [90]. Therefore, a thrombin feedback loop enables the continuous 
generation of thrombin.  
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The thrombin feedback loop results in the activation of FXI into FXIa and additionally 
activates FIX leading to further amplification of the intrinsic cascade [57]. Thrombin 
then activates cofactors V, VIII (the regulatory cofactor for FIXa), and the FXIII 
zymogen, enhancing thrombin and fibrin formation. FVIII requires the feedback 
action of thrombin to enable the formation of the FIXa:FVIIIa complex, which 
continues to convert FX into activated FX (FXa). For FX to become “activated”, the 
activation of FVIII is required. Once activated, FVIII binds to von Willebrand factor, 
resulting in further amplification of the coagulation cascade via the formation of 
thrombin and fibrin [57, 91]. FXa is continuously subjected to rapid inhibition, and is 
relatively inefficient by itself [92]. Therefore, when activated and combined with FV, 
the activity of FXa is enhanced, enabling continuous activation of prothrombin, and 
therefore thrombin, highlighting the importance of the prothrombinase complex [91].  
2.4.3(4) Thrombin Anti-thrombin Complex 
Anti-thrombin is a serine protease inhibitor and the primary inhibitor of many of the 
activated coagulation enzymes [27, 55, 70]. Indeed, FIXa, FXa, TF:FVIIa complex 
and thrombin (key components of the coagulation cascade) are rapidly bound and 
neutralised by anti-thrombin [70] (Figure 2.3). When unbound, anti-thrombin inhibits 
thrombin and FXa more efficiently then when thrombin and FXa are bound to active 
complexes. By itself, anti-thrombin is a poor inhibitor of coagulation, with reactions 
proceeding at extremely slow rates [55, 70]. To limit the formation of thrombin and 
fibrin in a rapid manner, anti-thrombin must bind with thrombin, resulting in the 
formation of the thrombin anti-thrombin complex (TAT) [53]. TAT complex levels 
are also used as a marker of hypercoagulability with high levels of TAT associated 
with increased thrombin generation [10, 19, 52, 70, 93].  
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2.4.4 Fibrinolysis 
 
The fibrinolytic system activates simultaneously with blood coagulation to preserve 
haemostatic balance [94, 95]. It is a tightly controlled series of interactions between 
various activators and inhibitors, resulting in the degradation and dissolution of 
fibrinogen and fibrin monomers into fibrin degradation products (FDP) and D-Dimer 
(the breakdown of cross-linked fibrin, resulting from the action of FXIIIa to form 
covalent bonds between D Domains of adjacent fibrin monomers) [42, 70, 96].   
To ensure adequate activation of the fibrinolytic system, plasminogen, a circulating 
zymogen, is converted to plasmin (the enzyme responsible for the lysis of fibrin-to-
fibrin degradation products, including D-Dimer) and is absorbed into the developing 
clot by binding to fibrinogen [70, 97]. The primary activator for the conversion of 
plasminogen to plasmin in vivo is tissue plasminogen activator (t-PA), a serine 
protease produced by the endothelial cells and released upon damage to the vessel wall 
[57, 70, 98, 99] (Figure 2.4). To prevent excessive unregulated plasmin to 
plasminogen activity, fibrinolytic inhibitors are required. Plasminogen activator 
inhibitor (PAI-1) (primarily synthesised in endothelial cells), is the primary inhibitor 
of fibrinolysis and has been shown to rapidly inhibit t-PA [70]. In contrast, when a 
blood clot is required, a reduction in plasmin generation occurs, favouring fibrin 
stabilisation and thrombosis formation [41]. 
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2.4.4(1) D-Dimer 
 
D-Dimer is a unique marker of endogenous fibrinolysis activation [10, 21, 100, 101] 
and is clinically used as a marker of fibrin clot formation and fibrinolysis in the 
exclusion of VTE [102, 103]. D-Dimer, named due to its structure (two cross-linked 
D fragments of fibrin protein), is a fibrin degradation product formed by the sequential 
action of three enzymes: thrombin, FXIIIa, and plasmin [1, 104, 105].  
Initially and in the presence of thrombin, fibrinogen is proteolytically cleaved into 
fibrin monomers, promoting the polymerisation of fibrin monomers to one another in 
an overlapping and cross-linked fashion, serving as a template for FXIIIa and plasmin 
formation [104, 106, 107]. Additionally, thrombin remains associated with fibrin, 
assisting with the activation of FXIII to FXIIIa, occurring at the site of the fibrin 
polymers [105]. The second step of D-Dimer formation, FXIIIa covalently cross-links 
Figure 2.4 Schematic representation of the fibrinolytic system. Fibrinolysis is initiated 
by t-PA released into circulation upon endothelial damage. PAI-1 binds to t-PA, 
inhibiting fibrinolysis. t-PA activates plasminogen to form plasmin in the presence of 
fibrin; however, this may also be inactivated through binding with α2-antiplasmin. 
Plasmin degrades the fibrin clot forming FDPs and D-Dimer. Abbreviations: t-PA 
tissue plasminogen activator; PAI-1 plasminogen activator inhibitor; FDPs fibrin 
degradation products. 
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fibrin monomers via intermolecular isopeptide bonds [108], whilst in the final step of 
formation, plasmin cleaves substrate fibrin at specific sites [109].  
D-Dimer is currently the best available laboratory marker of coagulation activation, 
with concentrations of D-Dimer >500ng/mL associated with increased risk of VTE 
[110, 111] and is therefore frequently investigated in exercise-based studies [15, 102, 
112].  
2.5. Virchow’s Triad and the Athlete 
 
Due to the competition and training demands of competitive sport, it has been 
postulated that athletes are at an ~85% greater risk for the development and onset of 
VTE [113], when compared to the general population. This is inconsistent with other 
reports that suggest overall VTE risk remains relatively low and does not differ 
between athletes and the general population [32, 114]. Whilst exercise alone is not an 
overwhelming risk factor for VTE formation, athlete-specific thrombotic risk factors 
directly relating to Virchow’s Triad (hypercoagulability, vessel wall injury and venous 
stasis (see Figure 2.5)), provides indirect evidence as to how VTE may develop within 
an athletic population. These risk factors are discussed in further detail in sections 
2.5.1, 2.5.2 and 2.5.3. When these athlete-specific thrombotic risk factors are 
combined with genetic predispositions to blood clotting and oral contraceptive use, 
athletes may be at an even greater risk for VTE.  
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Figure 2.5 Illustration of athlete-specific thrombotic risk factors in relation to 
Virchow’s Triad, pre-disposing athletes to thrombosis development. 
2.5.1 Hypercoagulability 
Hypercoagulability, the increased ability for the blood to coagulate (i.e. clot) has been 
well documented to occur in athletes due to numerous factors including exercise, 
dehydration and haemoconcentration, altitude and hypoxic exposure, in addition to 
oral contrecpetive use in female athletes and performance enhancing supplements, as 
discussed below. 
2.5.1.1 Exercise  
Blood is hypercoagulable immediately post-exercise as demonstrated by an increase 
in markers of in-vivo thrombin generation [48, 50, 93]. Hypercoagulability is 
suggested to occur as a result of increased venous blood flow and increased blood 
viscosity [115], resulting in increased laminar shear stress directly applied to the 
vascular walls, releasing TF. This results in the activation of the coagulation cascade 
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via the TF pathway. The degree of hypercoagulability has been demonstrated to be 
dependent upon the duration and the intensity of the exercise itself (see section 2.7 for 
further information) [10, 19, 93, 112, 116]. 
2.5.1.2 Dehydration and Haemoconcentration  
Dehydration results from insufficient fluid intake in combination with an increase in 
sweating rate, commonly experienced throughout exercise [5, 117]. Dehydration has 
been shown to have direct implications on blood hypercoagulability due to 
haemoconcentration (a thickening of the blood due to an increase in red blood cell 
concentration and a decrease in plasma volume) [118]. Adequate hydration during- 
and immediately post-exercise may reduce the potential for haemoconcentration, with 
the majority of sports providing targeted guidelines to athletes to prevent dehydration. 
The influence of haemoconcentration on thrombotic episodes remains speculative 
[119, 120] and may not play a significant role unless combined with other thrombotic 
risk factors [3].  
2.5.1.3 Altitude/Hypoxic Exposure  
Increased exposure to moderate-high-altitude as well as hypoxic environments is often 
required of elite athletes. To improve overall performance outcomes, athletes 
undertake training at high altitudes within hypoxic environments (~21 days as a 
consensus for duration) to favourably augment physiological variables. When training 
at high altitudes and within hypoxic environments, transient increases in haemoglobin 
concentration (~1% per week) and haematocrit have been demonstrated, increasing 
the potential for blood hypercoagulability due to a rapid decrease in plasma volume, 
as well as increases in erythropoiesis and blood viscosity [121]. Indeed, when elite 
endurance middle-distance runners completed two-weeks of training at a moderate 
altitude (2000m above sea level), haemoglobin concentrations increased by 2% [122], 
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with the duration of time spent at high altitude and hypoxic environments directly 
influencing the concentration of haemoglobin [121, 122]. Training at moderate 
altitudes (1829 to 3048 m) is frequently adopted by athletes from various sporting 
disciplines, whilst training at higher altitudes (>3048 m) may be of less benefit due to 
an increased potential for high altitude sickness [123]. Upon completion of high 
altitude and hypoxic exposure, erythropoietin is immediately increased, followed by a 
decrease approximately one-week later [124]. Therefore, an increased potential for 
hypercoagulability has been suggested to occur within this one-week period post 
altitude and hypoxic exposure.  
2.5.1.4 Oral Contraceptives 
Oral contraceptives are widely used by women (and in particular, female athletes) for 
numerous reasons including birth control and the medical management of amenorrhea 
and osteoporosis [125]. An abundance of evidence exists showing the use of oral 
contraceptives activate both coagulation and fibrinolysis as demonstrated by changes 
in the molecular markers of these systems, resulting  at an increased potential for VTE 
formation [126-129]. Whilst the incidence of VTE occurring in young females (<45 
years) using oral contraceptives is relatively low (~ 1 in 3 per 10,000 per year) [130], 
the combination of oral contraceptives and strenuous exercise have been demonstrated 
to increase the risk of hypercoagulability [125]. Therefore, female athletes may be at 
an increased risk for thrombosis formation [125]. When the aforementioned factors 
are combined with the addition of genetic predispositions to blood clotting, the risk 
for VTE formation is further increased from 30- to 100-fold as demonstrated in 
females heterozygous and homozygous for Factor V Leiden mutation.  
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2.5.1.5 Performance Enhancing Supplements 
Throughout the history of sport, a minority of athletes have engaged in unethical 
practices to obtain an ‘edge’ over their competitors. Certain practices have been shown 
to increase the risk of VTE through subsequent decreases in concentrations of 
anticoagulant and antifibrinolytic markers [131-133]. Anabolic androgenic steroids 
have been linked to hyperaggregable platelets in addition to a marked increase in 
cholesterolemia [134], whilst androgens have been demonstrated to augment 
thrombosis in animal based studies [135]. The use of performance enhancing 
supplements currently on the prohibited list by the World Anti-Doping Agency [136] 
include ephedra [133] and erythropoietin [132], which have been shown to increase 
hypercoagulability, potentially through an increase in blood viscosity.  
2.5.2 Vessel Wall Injury 
Within an athletic population, endothelial dysfunction/trauma has emerged as the most 
important factor of Virchow’s Triad, promoting thrombosis formation due to its ability 
to influence the systems present within haemostasis (Figure 2.2) [8, 10, 11, 57]. 
Trauma to the vessel wall may be dependent upon numerous factors including effort 
induced venous thrombosis (repetitive micro-trauma) and lower limb injuries, and 
surgery (as discussed in further detail below). 
2.5.2.1 Effort-Induced Venous Thrombosis (Repetitive Micro-Trauma) 
Numerous studies have reported on effort-induced thrombosis [137-139], referred to 
as Paget-Schroetter’s syndrome. Paget-Schroetter’s syndrome is characteristically 
observed in young athletes (aged 15-30 years, regardless of gender), and is limited to 
the upper extremity, potentially resulting from strenuous and repetitive exercise 
involving the affected arm. This results in compression (venous stasis) and micro-
trauma (vessel wall injury) directly to the axillary-subclavian vessel wall, either 
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throughout the thoracic outlet or costo-clavicular space (the first rib) [137, 139]. 
Repeated trauma to a vein increases inflammation and depositions of fibrin, leading to 
the progressive narrowing of the vessel, resulting in the activation of the coagulation 
system [59, 140]. This type of effort-induced VTE is typically seen in sports requiring 
extensive use of the upper body, and has been reported in rowers, weightlifters, 
baseball players, gymnasts, basketball players and swimmers [32]. 
2.5.2.2 Lower-Limb Injuries/ Trauma 
DVT within the lower-limb veins (i.e. popliteal, posterior tibial and peroneal veins), 
typically results from a traumatic event or injury obtained during training and 
competition [32, 141]. However, the risk of trauma is sport dependent. Non-contact 
sports result in inadvertent and unexpected trauma, whereas sports with limited contact 
(baseball, volleyball) pose a higher risk of trauma, with this contact remaining 
unintentional and occurring infrequently. In contact sports (basketball, soccer) and 
collision sports (ice hockey, rugby), some degree of trauma routinely occurs during 
play, providing a greater risk for trauma related injuries. Whether these factors are 
associated with an increased risk of thrombosis in an athletic population are yet to be 
determined [142]. In a population based study [143], recent trauma of the lower-limb 
(including muscle strains and sprains) was demonstrated to be associated with a 13-
fold increased risk for VTE. Direct trauma to the lower limb may stimulate the TF 
pathway of coagulation activation through the release of TF from the vessel wall 
following injury. The incidence of VTE is at its highest, in the first month following 
lower-limb injuries [141]. This may result from prolonged periods of immobility due 
to direct or indirect trauma, further increasing venous stasis and pre-disposing the 
athlete to thrombin generation.  
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2.5.2.3 Surgery 
With athletes frequently exposed to traumatic injuries (as described above), surgical 
interventions are routine in nature and may vary throughout the training and 
competition cycles. Surgery to the lower extremity possesses higher risks for the 
development and onset of DVT [60], resulting from factors including: 1) the location, 
type and duration of the surgical intervention performed, 2) direct trauma to the vessel 
wall, and 3) the recovery timeframe, resulting in prolonged periods of immobility. 
However, minimally invasive procedures including arthroscopic knee surgery (a 
common procedure in athletes), are considered to be low to moderate risk for VTE 
[144]. 
2.5.3 Venous Stasis 
Venous stasis is associated with the slowing of blood flow within the vascular system, 
and is not considered a risk factor for VTE within an athletic population [59, 142]. 
Nevertheless, several factors associated with high-level sport may result in venous 
stasis, promoting venous formation within this population including bradycardia and 
low blood pressure, overdevelopment of musculature, sports specific compression and 
prolonged periods of immobility due to long haul travel. These are discussed in further 
detail below. 
2.5.3.1 Bradycardia and Low Blood Pressure 
In elite and trained athletes, the cardiovascular system is well developed, undertaking 
physiological remodelling due to frequent and prolonged bouts of training and 
exercise [145]. As a result, numerous adaptations occur including left ventricular 
hypertrophy and a decrease in both heart rate (bradycardia) and blood pressure [36, 
145]. This has been postulated to increase VTE risk due to an increased potential for 
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blood pooling and venous stasis [36]. At present, the relationship between bradycardia, 
low blood pressure and VTE remains unclear.  
2.5.3.2 Overdevelopment of Musculature 
Muscular hypertrophy is required within an athletic population to improve overall 
performance outcomes. Consequently, this may result in compression of the venous 
system, promoting venous stasis and enhancing VTE risk [3]. Indeed, hypertrophy of 
the gastrocnemius muscle, may result in entrapment of the popliteal vein (Popliteal 
Venous Entrapment: PVE), increasing venous stasis and acting as a 
pathophysiological risk factor for DVT. PVE is especially prevalent in cyclists, with 
consistent intermittent compression and decompression of the popliteal vein with each 
revolution of the pedal [146]. Additionally, several case reports of athletes developing 
arm thrombosis resulting from overdevelopment and hypertrophy of the pectoralis 
minor and anterior scalene muscles, have been reported (see section 2.5.2.1 Effort-
Induced Venous Thrombosis (Repetitive Micro-Trauma)) [147, 148], due to the 
compression of the axilosubclavian artery.  
2.5.3.3 Sports Specific Compression 
Sports specific compression of blood vessels (resulting in reduced blood flow and 
venous stasis) may occur as a direct result of postural and equipment requirements. 
For example, the aerodynamic posture assumed in prolonged periods of cycling has 
been linked with compression of the external iliac artery [149, 150], whilst Paget-
Schroetter Syndrome is extremely common in sports requiring extensive use of the 
upper limbs [137, 139].  
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2.5.3.4 Long-Haul Travel and Immobilisation 
Athletes frequently undertake long-haul travel for training and competition, resulting 
in exposure to factors influencing Virchow’s Triad. During recent years, the 
relationship between prolonged travel and VTE has been widely investigated [151, 
152], with the incidence of VTE dependent upon the duration and distance of travel 
[153]. The activation of coagulation has been reported to occur in athletes flying four 
or more hours [152]. Indeed, prolonged periods of immobility associated with long-
haul travel, is thought to result in venous stasis, decreased venous return and 
haemoconcentration due to the cramped seating environment [154]. Additionally, 
flight specific factors including the hypobaric and hypoxic nature of air travel may 
result in activation of the coagulation system [155]. When combined with 
hypercoagulability (dehydration) and trauma to the vessel wall (possibly through 
sporting injuries), an increased risk for VTE may be present when undertaking long-
haul travel. 
2.6 Hereditary and Genetic Mutations 
 
In addition to acquired and athlete-specific risk factors associated with Virchow’s 
Triad (Figure 2.5), athletes may possess an inherited or genetic pre-disposition to 
hypercoagulability, increasing their risk for VTE [3, 60]. When investigating 
hereditary thrombophilia in 173 elite athletes, 12 cases of activated Protein C 
resistance (11 heterozygous and 1 homozygous) and 10 cases of Prothrombin 
G20210A mutation (all heterozygous) were documented [44], potentially placing 
these athletes a greater risk of VTE when undertaking exercise. [32]. Indeed, De 
Caterina et al. [156] reported four cases of DVT after strenuous exercise in athletes 
diagnosed with PC deficiency and APC resistance (aged 24 (x3) and 40 years, 
respectively). 
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The two most prevalent forms of genetic thrombophilia include Factor V Leiden and 
Prothrombin G20210A mutations, resulting in hyperactivity (hypercoagulability) of 
coagulation factors [32]. Other thrombophilia’s including Anti-thrombin III, Protein 
C and Protein S deficiencies are also associated with an increased thrombotic risk 
(Table 2.2) [157]. Carriers of Protein S, Anti-thrombin III and Protein C deficiencies 
possess higher risks for the onset of VTE when compared to Factor V Leiden and 
Prothrombin G20210A (Table 2.2). Whilst genetic thrombotic disorders are rare, 
caution is required for athletes possessing these conditions.  
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Table 2.2 Hereditary and genetic forms of thrombophilia: incidence and occurrence of thrombosis formation.  
Hereditary/ 
Genetic 
Mutation 
What is it? Probability of  
developing 
thrombosis 
Occurrence 
Protein C 
deficiency 
 
• A defect in the anticoagulant system, ↑ the risk 
for thrombosis.  
• Protein C works with protein S to inactivate the 
activated forms FV and FVIIIc. 
• 8 to 10-fold ↑ 
risk for carriers 
[158] 
 
• 0.2-0.4% in the 
general population 
[159] 
Protein S 
deficiency 
 
• ↓ levels of Protein S, ↓ its function. 
• Protein S functions as a cofactor to Protein C in 
the inactivation of FVa and FVIIIa. 
• 8.5 times ↑ risk 
for carriers 
[160] 
• 0.005-2.3% in the 
general population 
[160] 
Anti-
thrombin III 
deficiency 
• Anti-thrombin III provides anticoagulation effects 
by inactivating proteins of the coagulation 
pathway including FVIIa, FIXa, FXa, FXIa, 
FXIIa and thrombin. 
• Leads to a higher risk of VTE than PC or PS 
deficiencies [161] 
• 8.1 times ↑ risk 
for carriers 
[162] 
• 0.02-0.17%; 1 in 
2000 individuals 
[163] 
Factor V 
Leiden 
Mutation 
(FVL) 
• FVL mutation is the most prevalent inherited 
thrombophilia [60].  
• ~4-6% of the general population are 
heterozygous.  
• 2.2 times ↑ risk 
for carriers [47] 
 
• 7-fold ↑ risk in 
heterozygotes [164] 
• 25-80-fold ↑ risk in 
homozygotes [47] 
Prothrombin 
G20210A 
• Second most common form of inherited 
thrombophilia.  
• Prothrombin G202010A ↑ levels of prothrombin 
by ~one-third.  
• 2.8 times ↑ risk 
for carriers 
[162] 
• 2 to 5-fold ↑ risk in 
the general 
population [46] 
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2.7 Exercise and Haemostasis 
Exercise has been recognised to possess a variety of health benefits, including 
cardiovascular protective elements [165] whilst reducing the development and onset 
of chronic diseases [39]. Yet exercise also has considerable effects upon haemostasis, 
resulting in transient increases in blood coagulation [8, 10, 50], platelet aggregation 
[12] and fibrinolytic activity [8, 13, 14, 40]. Whilst exercise-induced disturbances in 
the haemostatic balance may not be detrimental to most participants, approximately 1 
in 1000 athletes [33, 44] will experience an exercise related thrombotic event, with 
athletes exposed to many underlying and acquired risk factors associated with the 
components of Virchow’s Triad (Figure 2.5 and Table 2.1).  
Haemostasis remains active at low levels to maintain the overall dynamic equilibrium 
of the haemostatic system. However if the activation of the coagulation and 
fibrinolytic systems are not balanced, a predisposition to thrombus formation may 
result, especially when combined with other thrombogenic risk factors [42]. The 
degree to which the coagulation, platelet and fibrinolytic systems are activated appear 
to be related to the intensity and duration of the exercise, the study population assessed 
(i.e. healthy, trained or sedentary, age and gender) [9, 44, 166] and the time of day the 
exercise is performed [7, 31, 45]. 
2.7.1 Duration and Intensity 
 
During exercise, the coagulation and fibrinolytic systems activate simultaneously to 
preserve haemostatic balance [152]. The degree to which these systems are activated 
is dependent upon the duration and intensity of the exercise [15, 166]. Indeed, 
activation of the coagulation system as indicated by markers of in-vivo thrombin 
generation, have been shown to increase following extremely short-duration maximal 
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exercise (90 s) [19] (Table 2.3) and longer-duration strenuous exercise (>2 h) (Table 
2.4) [7, 10, 52]. However, conflicting responses for coagulation activation in regards 
to exercise duration have been reported [51, 52], suggesting that exercise-induced 
coagulation activation is most likely dependent on exercise intensity [40]. It is 
important to note however, that the activation of the coagulation system following 
exercise may not directly result in the formation of DTV.  
2.7.2 Short-Duration, High-Intensity Exercise and Haemostatic Responses 
Activation of coagulation due to an increase in post-exercise hypercoagulability, has 
been well established to occur within short-duration (<60 min) exercise [8, 19, 43, 
167] (Table 2.3). Yet many of the findings from previous research are difficult to 
compare due to discrepancies in defining exercise duration, intensity, exercise mode, 
and the physical training status of the participants. Indeed, when completing extremely 
short-duration high-intensity exercise (i.e. 15 to 90 s) and exercise of 20 min and 
longer, conflicting responses of coagulation activation have been reported [8, 18, 19, 
51]. In healthy male subjects, coagulation activation was observed following a 15 and 
90 s maximal isokinetic exercise test ) [18] and a 30 s Wingate test [8]; however, this 
was not the case following 45 s of maximal isokinetic cycling (p>0.05) within the 
same population [18] (Table 2.3). Whilst coagulation activation has been reported in 
extremely short-duration (90 s) [18] and longer duration exercise (20 min) [19], there 
is a lack of evidence with regards to coagulation activation in exercise durations 
between 90 s to 20 min.  
The intensity of exercise has been shown to play an influential role in shifting the 
equilibrium between coagulation and fibrinolysis, with strenuous (i.e. high-intensity) 
exercise consistently shown to increase haemostatic activation as opposed to low-
moderate intensity exercise [17, 40, 49, 50, 112] (Table 2.3). When investigating the 
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influence of exercise intensity on fibrinolytic activity, El-Sayed [168] found 15 min 
of cycling at 70%VO2max enhanced overall fibrinolytic activity to a greater degree than 
cycling at 40%VO2max, whilst Szymanski and Pate [17] observed ~50% increase in t-
PA activity when cycling 30 min at 80%VO2max when compared to cycling at 
50%VO2max. Of interest, little change in overall fibrinolytic activity has been reported 
by Davies et al. [169] when exercising at intensities below 50-60%VO2max. Similar 
responses for the activation of coagulation in relation to exercise intensity have been 
previously reported [11, 49]. Indeed, Weiss et al. [11] found 60 min of running at 
83%VO2max resulted in significant activation of the coagulation system when 
compared to running at 68%VO2max, whilst Menzel and Hilberg [49] observed 
increased concentrations of TAT when undertaking 60 min of cycling at 100% 
individual anaerobic threshold (IAT), but not at 80%IAT (Table 2.3). Elevated 
concentrations of catecholamines and higher shear stress associated with increasing 
exercise intensity may be responsible for the activation of coagulation [170, 171]. 
Ikarugi et al. [171] found a correlation between elevated coagulation activity with 
rising norepinephrine concentrations, whereas similar findings were observed by 
Menzel and Hillberg [49], with significantly greater increases in norepinephrine 
observed when exercising at ~83%VO2max when compared to ~68%VO2ma.x. This 
suggests that exercise intensity plays an important role in the formation and removal 
of thrombin through activation of both the coagulation and fibrinolytic systems [172].   
When investigating activation of coagulation following graded incremental exercise 
tests only, conflicting responses for TAT have been reported [19, 51]. Indeed, in 
exercise of similar intensities and duration, significant increases in post-exercise TAT 
complexes were observed by Dufaux et al. [19] (p<0.01; effects size: 0.33), but not 
within the study of Hilberg et al. [51] (treadmill: p>0.05, effect size: 0.67: cycling: 
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p>0.05, effect size: 0.81) (Table 2.3). Despite the absence of a significant increase in 
TAT, Hilberg and associates [51] reported significant post-exercise increases in F 1+2 
(treadmill: p<0.05; effect size: 0.63; cycling: p<0.05; effect size: 0.92), demonstrating 
the importance for the correct selection of haemostatic markers to assess coagulation 
activation.  
The selection of coagulation markers play an influential role as the duration of exercise 
increases. Significant elevations (p<0.05) in TAT have been reported immediately 
upon completion of a 30 [173] and 60 min run [16, 50] and immediately following 60 
min of cycling [49]. Indeed, Weiss et al. [77] demonstrated significant increases in 
TAT (p=0.001) and F 1+2 (p<0.05) following a 60 min run, however, they failed to 
demonstrate a significant post-exercise increase in TF (p>0.05, d=0.29). These 
findings suggest an increase in post-exercise hypercoagulability and potential for VTE 
following exercise of 60 min or less, with TAT and F 1+2 suitable markers to assess 
in-vivo thrombin generation following exercise.  
In conclusion, both the coagulation and fibrinolytic systems are activated 
simultaneously following short-duration, high-intensity exercise albeit in an 
apparently healthy, untrained population. Whether haemostatic activation differs 
within an athletic and well-trained population remains unclear, highlighting the need 
for future research. To date, there is scarce evidence of coagulation and fibrinolytic 
responses to an exercise bout between 90 s to 20 min of duration, with this duration of 
exercise frequently employed in most training and competitive events. 
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Table 2.3 Coagulation and fibrinolytic responses to short duration exercise (60 minute and less). 
Author No. of participants; 
sex; training status 
Blood Sample 
Collection 
 Exercise Protocol, Duration and 
Intensity 
Haemostatic Markers 
Analysed 
Main Findings 
(Effect Sizes) 
Hilberg  
et al.  
[18] 
15; M; healthy  1. Pre-exercise 
2. Post-exercise  
 
 Isokinetic maximal tests  
15 s 
 
 
• F 1+2 
• TAT 
• t-PA 
• PAI-1 
• D-Dimer 
 
↑* (d= 0.20) 
↔ (d= 0.09) 
↑* (d= 0.56) 
↔ (d= -0.06) 
↔ (d= -0.06) 
45 s 
 
• F 1+2 
• TAT 
• t-PA 
• PAI-1 
• D-Dimer 
↔ (d= 0.11) 
↔ (d= -0.34) 
↑* (d= 0. 77) 
↔ (d= -0.07) 
↔ (d= -0.21) 
90 s 
 
• F 1+2 
• TAT 
• t-PA 
• PAI-1 
• D-Dimer 
↑* (d= 0.31) 
↔ (d=-0.04) 
↑* (d= 1.36) 
↔ (d= -0.01) 
↔ (d= -0.09) 
Gunga  
et al. 
[8] 
15; M; healthy  1. Pre-exercise 
2. post-exercise  
 30-s anaerobic Wingate test • PTT 
• FVIII 
• t-PA 
• D-Dimer 
↑** (d= -1.41) 
↑*** (d= 1.93) 
↑***(d= 0.94) 
↑*** (d= 1.22) 
Womack  
et al.  
[174] 
13; M; healthy 1. Pre-exercise 
2. Post-exercise 
 GXT treadmill test  
(1 min stages, gradient by 3% per min), 
mean duration un-reported. 
• t-PA 
• PAI-1 
↑* (d= 2.23) 
↑* (d= -1.08) 
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Author No. of participants; 
sex; training status 
1. Blood Sample 
Collection 
 Exercise Protocol, Duration and 
Intensity 
Haemostatic Markers 
Analysed 
Main Findings 
(Effect Sizes) 
Hilberg  
et al.  
[51] 
13; M; healthy 2. Pre-exercise 
3. Post-exercise 
 
 GXT, Treadmill: (3 min stages, 0.5 m/s 
increments), mean duration: 20.2 ± 2.6 
min. 
• F 1+2 
• TAT 
↑* (d= 0.63) 
↔ (d= 0.53) 
GXT, cycling ergometer: (3 min stages, 
50W increments), mean duration 19.4 ± 
3.4 min. 
• F 1+2 
• TAT 
↑* (d= 0.52) 
↔ (d= 0.48) 
Dufaux  
et al.  
[19] 
11; M; moderately 
trained  
1. 30 min pre- 
exercise 
2. Post-exercise 
 Incremental GXT (3 min stages, 30W 
increments) ~24-36 min 
• TAT 
• t-PA 
↑** (d= 0.85) 
↑** (d= 3.65) 
Hegde  
et al.  
[173] 
10; M; healthy  1. Pre- exercise 
2. Post-exercise 
 
 30 min run @70-75%VO2max  
 
 
30 min walk @ 1.2mph 
• D-Dimer  
• t-PA  
• FVIII 
 
• D-Dimer  
• t-PA  
• FVIII 
↑*** (d= 4.00) 
↑*** (d= 7.74) 
↑** (d= 2.44) 
 
↔ (d= 0.00) 
↔ (d= -0.16) 
↔ (d= 0.74) 
Molz  
et al. 
 [14] 
10; M, 10; F; healthy  1. Pre-exercise 
2. Post-exercise 
 30 min cycling (10W increments every 
minute until HR of 120bpm achieved) 
• t-PA (M, F) 
• D-Dimer (M, F) 
 
↑** (d= 1.21+0.57) 
↑** (d= 0.33+0.26) 
Immediately post 30 min cycling, 
workload increased by 25W every 2 min 
until HR= 180-190bpm. 
• t-PA (M, F) 
• D-Dimer (M, F) 
↑** (d= 0.83 +1.15) 
↑** (d=0.69  +0.62) 
Rocker  
et al. 
[172] 
15; M; healthy 1. Pre-exercise 
2. Post-exercise 
 
 30 min cycling (10W increments every 
minute until HR of 130bpm achieved) 
 
Immediately post 30 min cycling, 
workload increased by 25W every 2 min 
until HR= 180-190bpm. 
• t-PA 
• F 1+2 
• TAT 
 
• t-PA 
• F 1+2 
• TAT 
↑*** (d= 0.37) 
↑** (d= 0.24) 
↔ (d= 0.10) 
 
↑*** (d= 0.73) 
↑*** (d= 1.20) 
↑* (d= 0.70) 
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Author No. of participants; 
sex; training status 
Blood Sample 
Collection 
 Exercise Protocol, Duration and 
Intensity 
Haemostatic Markers 
Analysed 
Main Findings 
(Effect Sizes) 
Herren  
et al.  
[48] 
 
18; M; healthy  1. Pre-exercise 
2. Within 3 min 
post-exercise 
 60 min run (intensity self-selected) (n=10) 
 
 
 
• FPA 
• TAT 
• F 1+2 
• ᵝ thromboglobulin 
↔(d= 0.72) 
↑** (d= 2.62)  
↑* (d= 1.08) 
↑* (d= 2.55) 
60 min cycling (intensity self-selected) 
(n=8) 
• FPA 
• TAT 
• F 1+2 
• ᵝ thromboglobulin 
↔ (d= 1.33) 
↑** (d= 2.00) 
↑* (d= 0.32) 
↑** (d= 1.62) 
Hilberg  
et al. 
 [16] 
16; M; healthy  1. 30 min pre-
exercise 
2. Post-exercise 
 60 min run (treadmill) at 90% IAT • F 1+2 
• TAT 
• D-Dimer 
↑* (d= 1.10) 
↑* (d= 2.02) 
↑* (d= 0.80) 
 
Menzel  
et al. 
 [49] 
25; M; healthy  1. Pre-exercise 
2. Post-exercise 
 60 min cycling at 80%IAT  
 
 
 
 
 
60 min cycling at 100%IAT 
• FVIII 
• TAT 
• t-PA Ag 
• D-Dimer 
↑* (d= 0.92) 
↔ (d= 0.33) 
↑* (d= 1.96) 
↑* (d= 0.76) 
 
 
• FVIII 
• TAT 
• t-PA 
• D-Dimer 
↑* (d= 2.08)  
↑* (d= 1.08) 
↑* (d= 2.97)  
↔ (d= -0.21) 
Weiss  
et al. 
[11] 
12; M; well trained  
 
1. After 30 min of 
exercise 
2. Post-exercise  
 
 60 min run (treadmill) at 68%VO2max 
 
 
60 min run (treadmill) at 83%VO2max  
• t-PA  
• F 1+2  
• TAT 
• FPA  
↑* (d= 9.48) 
↔ (d= 0.08) 
↔ (d= 0.33) 
↔ (d=-0.41) 
 
• t-PA  
• F 1+2  
• TAT  
• FPA 
↑* (d=0.33) 
↑* (d= 0.26) 
↑* (d= 2.80) 
↑* (d= 6.34) 
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Author No. of participants; 
sex; training status 
Blood Sample 
Collection 
 Exercise Protocol, Duration and 
Intensity 
Haemostatic Markers 
Analysed 
Main Findings 
(Effect Sizes) 
Weiss  
et al.  
[77] 
12; M; endurance 
trained 
1. Pre-exercise 
1. Post-exercise 
 60 min maximal run (treadmill) at velocity 
corresponding to AnT 
• TF 
• TAT  
• F 1+2 
↔ (d= 0.29) 
↑** (d= 7.33) 
↑* (d= 4.00) 
Weiss  
et al.  
[50] 
11; M; endurance 
trained 
2. + 30 min pre-
exercise 
3. ~1 min post-
exercise 
 60 min swimming 
 
• F 1+2 
• TAT 
• FPA 
↑* (d= 0.29) 
↑* (d= 3.67) 
↑* (d= 2.40) 
 
60 min cycling @75%VO2max 
 
• F 1+2 
• TAT 
• FPA 
•  
↔ (d= 0.07) 
↔ (d= 0.43) 
↔ (d=0 .55) 
 
60 min running @ ~77%VO2max • F 1+2 
• TAT 
• FPA 
↑* (d= 0.50) 
↑* (d= 7.00) 
↑* (d= 4.22) 
 
Abbreviations:  * p<0.05; ** p<0.001; ***p<0.0001; ↑ increase; ↓ decrease; ↔ no change; @ at; AnT anaerobic threshold; ᵝ beta; bpm 
beats per minute; d=effect size; F females; min minutes; F 1+2 prothrombin fragment 1+2; FPA fibrinopeptide A; FVIII factor 8; h hours; 
GXT graded exercise test; IAT individual anaerobic threshold; km kilometres; M males; min minutes; m/s meters per second; n number; 
PC platelet count; PAI-1 plasminogen activator inhibitor; PTT partial thromboplastin time; s seconds; TAT thrombin anti-thrombin 
complex; TF tissue factor;  t-PA tissue plasminogen activator; VO2max maximal oxygen uptake; W watts. 
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2.7.3 Long-Duration, Low-Moderate Intensity Exercise and Haemostatic Responses 
Long-duration low-moderate intensity exercise is continuously growing in popularity, 
with the completion of events including marathon running, triathlons and ultra-
marathons. Indeed, long-duration exercise has been shown to stimulate alterations in 
the haemostatic system, promoting a hypercoagulable and hyperfibrinolytic state, as 
evidenced by increased concentrations of TAT, F 1+2, D-Dimer and t-PA [10, 24, 52, 
95, 102, 167, 175] (Table 2.4).  
The co-activation of fibrinolysis is suggested to occur to maintain the dynamic 
equilibrium of the haemostatic system. This has been shown to be initiated through 
the release of t-PA from the vascular endothelium [176], due to numerous factors 
including thrombin [177], vascular shear stress associated with an increase in blood 
flow [178] and the hormonal release of catecholamines and vasopressin [179]. When 
fibrinolysis is activated, a significant increase in the concentration of D-Dimer is 
frequently demonstrated to occur, especially upon immediate completion of long-
duration strenuous exercise [21, 102, 175, 176, 180] (Table 2.4).  
When undertaking a 42.2km marathon run, significant increases in TAT (p<0.04), F 
1+2 (p<0.001), D-Dimer (p<0.02) and t-PA (p<0.01) were observed by Prisco et al. 
[10] and Parker et al. [102, 152], despite an overall difference in mean finish time 
(2.45 ± 0.15 h v 3.38 ± 0.26 h= 0.53 ± 0.11 h, respectively) (Table 2.4). Whilst the 
majority of studies investigating haemostatic responses to marathon running have been 
conducted on relatively flat terrains, one study by Sumann and associates [95] 
investigated the influence of a downhill speed marathon on haemostasis, using 13 
healthy participants. The findings of Sumann and associates [95] were similar to those 
of the flat terrain marathon runs, with 2.8- and 1.24-fold increase in hypercoagulability 
as demonstrated by plasma concentrations of TAT and D-Dimer, respectively, despite 
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a high percentage of eccentric muscle work. Whilst eccentric muscle exercise is 
considered less metabolically demanding, eccentric exercise has been shown to induce 
greater damage in the form of micro-tears to the associated skeletal muscles, altering 
the extracellular matrix, resulting in an inflammatory response [21, 181]. In addition 
to the haemostatic responses, Sumann and associates [95] reported a 2.5-fold increase 
in creatine kinase (CK) (a marker of muscle damage [182]), potentially initiating an 
inflammatory response. Since there is a strong correlation between the activation of 
coagulation and inflammation [95, 180], the findings of Sumann and associates [95] 
are expected, with a high contribution of eccentric work providing a potent stimulus 
for activation of the haemostatic system. This coagulation activation resulting from 
the inflammatory response has been proposed to occur via a direct interaction with the 
TF coagulation pathway [43, 183]. Whilst haemostatic activation is similar regardless 
of the terrain, the topography of the marathon itself may influence the intensity, load 
and type of muscle contraction in which the marathon is completed, ultimately 
determining the degree to which the coagulation and fibrinolytic systems are activated. 
Conversely, no comparable haemostatic data between a flat terrain marathon and a 
downhill marathon is available, making comparisons with other long distance runs 
difficult to interpret, highlighting the need for further research within this area.  
As the duration of exercise extends beyond the standard marathon distance (i.e. 
42.4km), greater coagulatory, fibrinolytic and muscle damage has been reported. For 
example, after a 67km mountain run, Schobersberger et al. [21] reported significant 
increases in markers of TAT (1.4-fold) (p<0.01), D-Dimer (1.4-fold) (p<0.05), t-PA 
(3.7-fold) (p<0.05) and CK (16.5-fold) (p<0.001) in healthy male runners. Similar to 
the findings of Schobersberger et al. [21], albeit after a run of significantly greater 
distance (total: 161km), Kupchak et al. [20] also reported significant increases in the 
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plasma concentrations of TAT (2.4-fold increase; p<0.001), F 1+2 (3.9-fold increase; 
p<0.001), D-Dimer (2.2-fold increase; p<0.001), t-PA (4-fold increase; p<0.001) and 
CK (154-fold increase; p<0.05) from baseline measures. Although these are separate 
studies, as the distance and the duration is increased from 67km to 161km, the relative 
increase in the activation of the haemostatic system was larger as demonstrated by 
greater increases in TAT, D-Dimer and t-PA. In addition, when exercising for a longer 
duration, extensive muscle damage was reported as shown by 154-fold increase in CK 
concentrations (p<0.0001), potentially initiating the activation of the coagulation 
system. This therefore suggests that the duration of the exercise bout plays an 
influential role in the dynamic equilibrium between coagulation and fibrinolysis.  
Whilst post-exercise hypercoagulability and hyperfibrinolytic activity are well 
documented (Table 2.4), there are conflicting reports on the duration of haemostatic 
activation from ~24 h onwards post-exercise. Elevated concentrations of TAT, F 1+2 
and D-Dimer have been described the day after completion of long-duration and 
strenuous exercise bouts [10, 20, 21, 24, 102], suggesting an increased potential for 
thrombin generation and adverse outcomes within this 24 h period [184]. However, 
this was not observed in all studies, with Rocker et al. [52], Bartsch et al. [94], Parker 
et al. [152] and Sumann et al. [95] reporting markers of coagulation to have returned 
to baseline values within 3, 21, 24 and 24 h respectively, of exercise completion 
(marathon, triathlon and downhill marathon run) (Table 2.4). Within 48 h of exercise 
completion, markers of haemostasis were typically reported to have returned to 
baseline values [10, 167] in all but one study [20]. 48 h upon completing an ultra-
marathon run, D-Dimer was reported to have remained increased by ~2.1-fold in 
comparison to baseline measurements, suggesting the time frame of haemostatic 
activation may be dependent upon the duration (time) and distance (kilometres) of the 
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exercise bout itself. Indeed, the 161km ultra-marathon in the study of Kupchak et al. 
[20] was completed in 24.64 hours, providing a possible explanation as to why D-
Dimer remained substantially elevated 48 h later.   
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Table 2.4 Pre- to Post-exercise haemostatic responses to long-duration (>90 minutes) low-moderate intensity exercise. 
Author No. of 
participants; sex; 
sport 
Exercise Protocol, 
 Duration and Intensity 
Blood Sample Collection Haemostatic Markers  
Analysed 
Main Findings 
Arai 
 et al. 
[167] 
15; M; triathletes  Triathlon (3.8km swimming, 179.2km 
cycling, 42.2km run). 
 
Mean finish time: unreported 
1. 48 h pre-exercise  
2. Post-exercise  
 
• PT 
• Fibrinogen 
• Anti-thrombin III 
• t-PA 
• D-Dimer 
↔ (1.0-fold) 
↑* (1.1-fold) 
↔  
↑* (2.9-fold) 
↑* (1.9-fold) 
Bartsch 
 et al.  
[94] 
10; M; triathletes  Triathlon  
 
Mean duration/ finish time: 128-163 min 
1. 24 h pre-exercise  
2. Post-exercise  
 
• TAT 
• F 1+2 
• FPA 
↑** ( 2.1-fold) 
↑** (1.5-fold) 
↑* (1.8-fold) 
Kupchak  
et al.  
[20] 
12; M, 4; F; ultra-
marathon runners 
 
Ultra-marathon (161km trail foot-race)  
 
Mean finish time: 24.64 h (range: 16.89-
29.46 h) 
1. 20 h pre-exercise  
2. Post-exercise  
 
• F 1+2 
• TAT 
• t-PA 
• D-Dimer  
PAI-1 
↑* (3.9-fold) 
↑* (2.4-fold) 
↑* (4.0-fold) 
↑* (2.2-fold) 
↑* (4.5-fold) 
Parker  
et al.  
[102] 
24; M, 17; F; 
marathon runners 
 
Boston Marathon run (42.2km) 
 
Mean finish time: 3.38 ± 0.26 h 
1. 24 h pre-exercise  
2. Post-exercise  
 
Travel  
• D-Dimer 
• P-selectin 
• Microparticles 
Control  
• D-Dimer 
• P-selectin 
• Microparticles 
 
↑** (2.7-fold) 
↑** (1.8-fold) 
↑* (2.5-fold) 
 
↑** (2.7-fold) 
↑** (1.8-fold) 
↑* (2-fold) 
Parker  
et al. 
[152] 
24; M, 17; F; 
marathon runners 
Boston Marathon run (42.2km) 
 
Mean finish time: 3.38 ± 0.26 h 
1 24 h pre-exercise  
2 Post-exercise  
 
Travel 
• TAT 
• t-PA 
Control 
• TAT 
• t-PA 
 
↑**  (3.1-fold) 
↑** (4.6-fold) 
 
↑** (1.5-fold) 
↑** (4.9-fold) 
Prisco  
et al.  
[10] 
12; M; marathon 
runners  
Marathon run (42.2km) 
 
Mean finish time: 2.45 ± 0.15 h 
1. 24 h pre-exercise 
2. Post-exercise 
 
• F 1+2 
• TAT 
• t-PA antigen 
• D-Dimer 
↑*** (8.8-fold) 
↑*** (12.5-fold) 
↑*** (3.5-fold) 
↑** (1.9-fold) 
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Abbreviations: * p<0.05; ** p<0.001; *** p>0.0001; ↑ increase from baseline values; ↓ decrease from post exercise values; ↔ no 
significant difference (p>0.05); F females; F 1+2 prothrombin fragment 1+2; FPA fibrinopeptide A; h hour; km kilometre; M male; m 
metre; min minute; PAI-1 plasminogen activator inhibitor; TAT thrombin anti-thrombin complexes; t-PA tissue plasminogen activator.
Author No. of 
participants; sex; 
sport 
Exercise Protocol, 
Duration and Intensity 
Blood Sample Collection Haemostatic Markers 
Analysed 
Main Findings 
Rocker  
et al.  
[175] 
16; M; marathon 
runners 
Marathon (42.2km) 
 
Mean finish time (range): 2.25 to 2.49 
1. 30 min pre-exercise  
2. Post-exercise  
  
• t-PA 
• t-PA antigen 
• PAI-1 
• D-Dimer 
TAT 
↑*** (31.0-fold) 
↑*** (6.0-fold) 
↔ 
↑* (1.7-fold) 
↑***  (1.8-fold) 
Schobersberger 
et al.  
[21] 
11; M; 
ultramarathon 
runners 
Ultramarathon (67km) 1. 24 h pre-exercise  
2. Post-exercise  
3. 24 h post-exercise  
• TAT 
• D-Dimer 
• t-PA 
• PAI-1 
↑* (1.4-fold) 
↑** (1.4-fold) 
↑** (3.7-fold) 
↔ 
Sumann  
et al.  
[95] 
12; M, 1; F; 
marathon runners 
Downhill marathon (795 m vertical 
difference) 
 
Median finish time: 223 min (range: 211-
247 min) 
1. 3 h pre-exercise 
2. ~ 30 min post-
exercise 
 
• TAT 
• F 1+2 
• D-Dimer 
• t-PA 
 
↑* (2.8-fold) 
↑* (1.35-fold) 
↑* (1.24-fold) 
↑* (11.0-fold) 
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2.8 Circadian Rhythms and Haemostasis 
The superchiasmatic nuclei (SCN) within the anterior hypothalamus has been well 
documented to regulate and maintain circadian rhythms (i.e. the overt expression of 
an internal timing mechanism measuring daily time) [31] present within numerous 
biological functions, including core body temperature, the sleep-wake cycle, blood 
pressure and the synthesis and secretion of several hormones (i.e. melatonin and 
cortisol) [31, 185, 186]. These intrinsic circadian rhythms are slightly longer than a 
standard 24 hour day (~24.2 hours), hence the term circadian (circa meaning ‘around’, 
and dies meaning ‘day’) [186], with circadian rhythms demonstrating peaks and 
troughs for numerous biological functions. Remarkably, the haemostatic system has 
been well demonstrated to possess its own circadian rhythms [187]. When measured 
under resting conditions, fluctuations in coagulation, fibrinolysis, platelet aggregation 
and blood viscosity are well documented, with increases in hypercoagulability, platelet 
aggregation, blood viscosity and hypofibrinolysis reported to possess an acrophase 
(the time at which the peak of a rhythm occurs) between 0600 and 1200 h [7, 25, 26, 
31, 45, 188-190] (Table 2.5). Therefore, it is unsurprising that numerous 
cardiovascular diseases [191, 192], cerebrovascular events [193] and pulmonary 
embolisms [194] possess their own circadian variations, with greater occurrences 
reported during the morning, and a secondary smaller peak observed in the afternoon 
[195]. However, the underlying mechanisms of circadian rhythms within haemostasis 
are not yet fully understood.  
Whilst several haemostatic factors appear to be influenced by a variable degree of 
circadian or diurnal (occurring during the daytime) variations, it remains unclear if 
every marker associated with the haemostatic system possess their own circadian 
rhythms [196]. It is suggested that variations in the coagulation and fibrinolytic factors 
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may influence overall dynamic haemostatic balance [31]. When investigating TAT 
complex, previous studies have demonstrated inconsistent findings as to whether a 
circadian rhythm is present [136, 190, 197, 198]. When investigated over several 
different time points (i.e. 0730 to 2100 h) in healthy male and female individuals, Jafri 
et al. [190] and Deguchi et al. [136] observed a notable absence of circadian rhythms 
within TAT (p>0.05). Of interest, increased concentrations of TAT were observed at 
0900 ( ES when compared to 1500h: d= 0.48) [136] and 1000 h (ES when compared 
to 1500h: d= 0.70) [190], however these findings were not statistically significant. 
This may be a direct result of the studies being underpowered with relatively small 
sample sizes (n=9 [190] and n=10 [136, 190]) reported. It is important to note that in 
the study of Jafri et al. [190], the peak in TAT at 1000 h was due to abnormally 
elevated levels in a single participant, with no statistical analysis run with the removal 
of this individual.  
In contrast to TAT, anti-thrombin III (a primary inhibitor of thrombin), has been 
clearly demonstrated by Casale et al. [197] and Pasqualetti et al. [198] to possess a 
diurnal rhythm, possessing an early afternoon acrophase (1200 noon) and late evening 
troughs (the lowest point of a rhythm) when observed in healthy male participants of 
varying ages (23-87 years). When directly comparing the afternoon acrophase for anti-
thrombin III within young (23 ± 3.5 years) and elderly (83 ± 4 years) male participants, 
a significant increase (p=0.01) of ~17.5% in the amplitude of the acrophase was 
observed within the young males [197] (Table 2.5). This variation between the two 
different age groups is unsurprising, with increasing age generally associated with a 
reduced circadian amplitude and easily altered circadian acrophase [199]. Therefore, 
the findings of the abovementioned research confirm the existence of a diurnal rhythm 
within anti-thrombin III, supporting the notion for a morning increase in 
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hypercoagulability. With age demonstrated to play a key role in circadian responses 
for anti-thrombin III [197], future investigations are required to investigate this 
potential relationship within other markers of haemostasis. 
In addition to anti-thrombin III, a clear morning acrophase (0800 h) and afternoon 
trough (1400 h) has been identified for TFPI and FVII activity, with an 11% and 6% 
increase respectively, observed within the morning in healthy male subjects [31]. 
When investigating TFPI, a similar pattern for a morning acrophase in TFPI as 
reported by Pinotti et al. [31] was observed by Dahm and colleagues [196] (Table 
2.5). However, no statistical analysis was completed in the study by Dahm and 
associates [196], therefore these findings should be regarded with caution. In support 
of a morning peak in FVII are the findings of Kapiotis et al. [45], in which higher 
values of FVII were observed at 0800 h (2.03 ng/mL, (CI 1.16 to 2.88 ng/mL)), with 
FVII concentrations significantly decreasing throughout the day to 1.16 ng/mL (CI 
0.81 to 1.5 ng/mL; p=.005) at 2000 h. A similar pattern for a morning peak (~0900 h) 
and an afternoon trough for FVIII and FIX have been identified in three separate 
studies [26, 45, 200], supporting the notion for a hypercoagulable state within the 
morning.  
In contrast to coagulation, previous studies have shown that overall fibrinolytic 
activity possess clear diurnal variations, with significantly reduced activity within the 
morning, whilst peaking in the afternoon and evening [200-202] (Table 2.5). This is 
believed to be due to the diurnal variations present within individual markers of the 
fibrinolytic system itself, including PAI-1 (the primary inhibitor and regulator of t-
PA) and t-PA (the protein responsible for initiating fibrinolysis). Indeed, PAI-1 has 
been shown to possess significant circadian variations, with two- to four-fold higher 
concentrations of circulating PAI-1 observed within the morning (0600-0800 h), 
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versus the afternoon and evening (1800 h) as demonstrated by Juhan-Vague et al. 
[203], Grimaudo et al. [204], Kluft et al. [202] and Huber et al. [205]. In contrast to 
PAI-1, t-PA has been well acknowledged to possess opposite troughs and peaks to that 
of PAI-1. Several studies have demonstrated identical troughs and peaks within 
healthy adults, with t-PA concentrations (and therefore fibrinolytic activity) at its 
lowest within the morning, whilst possessing an afternoon acrophase, as demonstrated 
by higher concentrations of t-PA [200, 202] (Table 2.5). With diurnal rhythms well 
established in PAI-1 and t-PA, data on the diurnal variations within D-Dimer is 
currently limited, and when reported, often conflicting. When investigated over the 
course of a 24 h day in healthy adults, Johansen et al. [206] and Jafri et al. [190] failed 
to demonstrate variations in D-Dimer, whereas,  peaks at 0900 and 2300 h (p<0.05) in 
D-Dimer was observed by Iversen et al. [26]. Of interest and the only point of 
difference between the studies, are the sample collection procedures implemented by 
the authors, with Johansen et al. [206] and Jafri et al. [190] using repeated 
venepunctures, whilst indwelling venous cannulas were used within the study by 
Iversen et al. [26]. When directly comparing the methods of venepuncture and an 
indwelling cannula on the response to coagulation activation, no significant 
differences were reported in patients receiving heparin infusion [207], suggesting the 
method of collection was unlikely to influence the morning increase in D-Dimer 
concentrations observed by Iversen et al. [26]. Although large variations have been 
observed within PAI-1 and t-PA, whether a true diurnal variation is present within D-
Dimer warrants further investigation, especially due to the clinical significance of D-
Dimer. 
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2.8.1 Haemostasis, Exercise and Time of Day 
Although diurnal rhythms have been identified in numerous markers of coagulation 
and fibrinolysis under resting conditions, the influence of exercise completed at 
various times of the day and its role on haemostasis, is rarely reported. To investigate 
the diurnal rhythms in response to exercise completed at different times of the day, 
three separate investigations [7, 9, 17] have employed similar exercise protocols with 
varying exercise intensities over two different time points (Table 2.6). The findings 
of Syzmanski and Pate [17] followed the diurnal rhythms previously reported for t-PA 
and PAI-1, with both markers significantly increased post-exercise (p<0.05), with 
greater concentrations observed immediately following evening exercise (p<0.001). 
In contrast to Szymanski and Pate [208], Siahkouhian and associates [9] failed to 
demonstrate a time of day response in markers of coagulation and fibrinolysis 
following both morning and evening exercise, despite significant increases (p<0.05) 
in post-exercise plasma concentrations of haemostasis. When investigating the platelet 
system in response to exercise at two different times of the day, platelet count, mean 
platelet count and platelet aggregation were demonstrated to display significant time 
of day differences, with significantly greater increases observed following morning 
exercise [7] (Table 2.6). Whilst the research into haemostatic responses to exercise at 
different times of the day is scarce, it is important to note these variations regarding 
exercise and diurnal rhythms in markers of haemostasis have primarily been 
investigated within non-athletic, apparently healthy populations, and may not be 
applicable to a well-trained or athletic population. Indeed, when comparing trained 
versus untrained individuals, higher fibrinolytic activity has been reported to occur 
within the trained population [208, 209], whilst no direct comparisons between these 
populations exist for the platelet and coagulations systems, with investigations limited 
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to training interventions in untrained individuals only [15, 210, 211]. The time of day 
at which an athlete exercises is often unavoidable, as they are required to compete and 
train over the course of a 24 h day based upon the scheduling of training and 
competition. Therefore, further investigations into coagulation and fibrinolytic 
responses to exercise completed at varying times of the day within this population are 
essential and may assist in providing targeted guidelines to this specific population.  
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Table 2.5 Diurnal variations in markers of haemostasis (investigated in the absence of exercise). 
Author No. of participants; sex; age 
(y) 
Time of day  
(blood sample collection) 
Haemostatic markers  
analysed 
Main findings 
Angleton 
 et al.  
[200] 
33; M; 31 (21-92 y) 0800 h ± 1 h 
1930 h ± 1 h 
• t-PA activity 
• PAI-1 
Evening peak, morning trough (p<0.01) 
Morning peak, evening trough (p<0.01) 
Casale  
et al.  
[197] 
Young: 6; M; 23 (± 3.5y) 
Aged: 6; M; 83 (± 4y) 
0000 h 
0400 h 
0800 h 
1200 h 
1600 h 
2000 h 
Young 
• Anti-thrombin III 
 
Aged 
• Anti-thrombin III 
 
Afternoon peak (1200 h) (p=0.008)*** 
 
 
Afternoon peak (1200 h) (p=0.01) 
Dahm 
 et al. 
[196] 
8; M; undisclosed 1 hourly (0700-1200 h) 
2 hourly (1200- 1800 h) 
• TFPI 
 
Mid-morning to afternoon peak (1000 to 1600 
h)  
Deguchi  
et al.   
[136] 
10; M; undisclosed 0900 h 
1200 h 
1500 h 
• TAT ↔ greater TAT concentrations at 0900 vs 
1200 & 1500 h 
Grimaudo  
et al. 
[204] 
8; M; undisclosed 0800 h 
1000 h 
1200 h 
1600 h 
2000 h 
• t-PA 
• PAI-1 
Evening peak, morning trough (p<0.01) 
Morning peak, evening trough (p<0.01) 
Huber  
et al. 
[205] 
 
11; M; 20-38 y 0600 h 
1200 h 
1800 h 
• PAI-1 
• t-PA antigen 
Morning peak, evening trough (p<0.05) 
Morning peak. evening trough (p<0.05) 
Iversen  
et al.  
[26] 
8; M; undisclosed 12 separate times over  24 h  
(times not specified) 
• F 1+2 
• FVII 
• D-Dimer 
• PAI-1 
• vWF 
Bimodal peak at 0900 h and 2300 h 
↔ 
Bimodal peak at 0900 h and 2300 h 
Morning peak, evening trough  
↔ 
Jafri  
et al.  
[190] 
4; M, 5; F; 51 ± 10 (51 ± 10 y) D1: 1500, 1800, 2100 h 
D2: 0700, 0800 h 
 
• TAT 
• D-Dimer 
↔  
↔  
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Author No. of participants; sex; age 
(y) 
Time of day  
(blood sample collection) 
Haemostatic markers 
analysed 
Main findings 
Juhan-
Vague  
et al. 
[203] 
10; M; 10; F; 34 (24-55 y) 0800 h 
1600 h 
• PAI-1 antigen 
• t-PA antigen 
morning peak, afternoon trough (p<0.01) 
morning peak, afternoon trough (p<0.001) 
Kapiotis  
et al.  
[45] 
5; M, 5; F; 19-40 y 0800 h 
1200 h 
1600 h 
2000 h 
• FVIIa 
• F 1+2 
• PAI-1 
morning peak, evening trough (p=0.005) 
morning peak, evening trough (p=0.005) 
morning peak, evening trough (p<0.005) 
Kluft 
et al. 
[202] 
10; M; 22-34 y 0900 h 
1200 h 
1500 h 
• t-PA activity 
• t-PA antigen 
• PAI-1 antigen 
• PAI-1 activity 
afternoon peak, morning trough (p<0.05) 
morning peak, evening trough (p<0.05) 
morning peak, evening trough (p<0.05) 
morning peak, evening trough (p<0.05) 
Pasqualetti  
et al. 
[198] 
15; undisclosed 3 hourly over a 24 h  
(midnight →) 
• Anti-thrombin III mid-day/ early afternoon peak (p<0.001) 
Pinotti  
et al.  
[31] 
13; M; 25-35 y 0800 h 
1400 h 
• TFPI 
• FVII 
morning peak, afternoon trough (p<0.05) 
morning peak, afternoon trough (p<0.05) 
 
 
Abbreviations:  *** Significant difference (p=0.01) in amplitude observed between young and aged; ↔ no circadian/ diurnal rhythm 
present; D day; F females; F factor; F 1+2 prothrombin fragment 1+2; h hour; M males; n number; PAI -1 plasminogen activator  inhibitor; 
TAT thrombin anti-thrombin complexes; TFPI tissue factor pathway inhibitor; t-PA tissue plasminogen activator; FVII factor seven; 
FVIIa activated factor seven; FVIII:C factor eight antigen; vs versus; vWF von Willebrand factor; y years. 
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Table 2.6 Haemostatic responses to exercise at different times of the day. 
Author No. of 
participants; 
sex; fitness 
level 
Study design Blood sample collection Haemostatic 
markers  
analysed 
Main findings 
(pre- to post-
exercise) 
Exercise protocol Time of day 
Aldemir 
 et al.  
[7] 
10; M; 
moderately/ 
active  
30 min submax 
cycling 
(70%VO2max) 
 
0730 h 
1700 h 
• Pre-exercise 
• Post-exercise 
• 30 min post-exercise 
• PC 
• MPV 
• PA 
↑m 
↓e 
↓m  
Siahkouhian  
et al.  
[9] 
15; M; healthy/ 
sedentary  
30 min submax 
cycling 
(70%VO2max) 
0730-0830 h 
1730-1830 h 
• Pre-exercise 
• Post-exercise 
• 30 min post-exercise 
• PC 
• aPTT  
• PT 
• t-PA 
• PAI-1 
↔ 
↔ 
↔ 
↔ 
↔ 
 
Szymanski and 
Pate  
[208] 
14; M   
 
30 min submax 
exercise 
(50%VO2max)  
0630-1000 h 
1600-1900 h 
• Pre- exercise 
• Post-exercise 
• t-PA 
• PAI-1 
↑e  
↑e 
 
Abbreviations: ↔ no time of day effect; ↑e significantly higher (p<0.05) in evening trials; ↑m significantly higher (p<0.05) in morning 
trials; ↓e significant decrease (p<0.05) post-evening trials; ↓m significant decrease (p<0.05) post-morning trials; aPTT activated partial 
thromboplastin time; h hour; M males; min minute; MPV mean platelet count; PA platelet aggregation; PAI-1 plasminogen activator 
inhibitor 1; PC platelet count; PT partial thromboplastin time; submax submaximal; t-PA tissue plasminogen activator; VO2max maximal 
oxygen uptake.
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2.9 Compression and Haemostasis 
2.9.1 Overview 
Compression garments (i.e. stockings, pneumatic compression devices, compression 
bandaging) have been used in clinical based settings as the preferred prophylaxis [212, 
213] in the prevention and treatment of DVT [214] pulmonary embolism and 
lymphedema [215, 216], and in the management of wound, scar and venous leg ulcers 
[217]. Numerous studies have demonstrated an increase in deep venous velocity, 
reduced venous stasis, and an improved venous return (components associated with 
Virchow’s Triad) in hospital patients when compression garments were worn [212, 
218-221]. Additionally, the use of compression garments have been demonstrated to 
maintain the dynamic balance between the coagulation and fibrinolytic systems, 
through increases in both arterial [222] and venous blood flow [223]. Compression 
garments apply a mechanical pressure at the bodies’ surface, directly applied to the 
muscle, bone and connective tissue, resulting in a reduced transmural pressure of the 
superficial veins. This then causes the superficial veins to dilate, redistributing 
superficial blood flow from the peripheries to the deep venous system, resulting in 
improved venous blood flow and peripheral circulation [219, 224]. 
 
The efficacy of compression garments may be dependent on different factors. 
including; their style (i.e. stocking, sleeves, upper and lower body garments) [225], 
size, and the method of compression. This includes graduated (highest pressure 
exerted at the distal end of the limb, decreasing to a lower pressure exerted at the 
proximal end of the limb) [222], uniform (even pressure applied to both the proximal 
and distal ends), or progressive (pressure is greatest at the proximal end of the limb, 
decreasing to a lower pressure at the distal end of the limb) compression [219]. 
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Graduated compression has been shown to be “most beneficial” for reducing venous 
pooling and improving venous blood flow velocity within a clinical setting [219, 222, 
226]. Despite a lack of clear scientific evidence on the effects of compression garments 
on physiology, their use within the sporting industry continues to grow in popularity 
due to proposed ergogenic effects for exercise performance and recovery [227, 228].  
2.9.2 Compression Garments and Haemostasis 
With exercise well documented to disturb the haemostatic balance (see section 2.7. 
Exercise and Haemostasis), research on the use of compression garments to maintain 
a favourable haemostatic state within, and immediately following exercise is relatively 
scarce. Indeed, Zaleski and colleagues [24] aimed to investigate the influence of 
compression socks on haemostatic responses when worn during the 2013 Hartford 
Marathon (42.2km). Endurance-trained runners were randomly allocated to a 
compression (compression socks worn during the marathon; n=10) or control group 
(no compression socks worn during the marathon; n=10) and blood was collected from 
runners pre- and post-marathon. When worn during the marathon, compression socks 
failed to significantly lower overall haemostatic activation, yet significantly lower 
concentrations of t-PA in the sock versus control group (sock: 8.9 ± 0.7 ng/ml, control: 
11.2 ± 0.7 ng/ml p=0.04) were observed. Whilst not significantly different (p=0.07), 
average TAT tended to be lower in runners assigned to the sock group (2.8 ± 0.2 µg/L) 
when compared to the control group (3.4 ± 0.2 µg/L), with the authors concluding that 
compression socks do not have a negative impact on haemostatic activation and 
overall haemostatic balance. Additionally, Zaleski and associates [24] highlighted the 
need for studies with a larger sample size to confirm the preliminary findings of their 
small investigation. 
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Of interest, Zaleski and associates [229] also conducted a case study investigating the 
effect of compression socks on haemostatic activation in an individual with a 
predisposed susceptibility to thrombosis formation. Within this case study, a single 
female endurance athlete heterozygous for Factor V Leiden mutation (7-fold increased 
risk for thrombosis (Table 2.2)) completed two separate marathons, one marathon 
wearing compression socks (2XU Compression Performance Run Sock; 19-25mmHg 
at the ankle) and one marathon without compression socks. When compression socks 
were worn, haemostatic activation was reduced as demonstrated by lower post-
exercise concentrations of t-PA (~56%), TAT (~63%) and D-Dimer (~30%), 
suggesting compression reduced the risk for thrombosis in an athlete with a genetic 
mutation for hypercoagulability. This case study was not without limitations as the 
two marathons were completed three years apart (control marathon: 2010 and 
compression sock marathon: 2013), whilst the course elevation of the two marathons 
also varied greatly (control marathon: 470 feet, sock marathon: 101 feet). The findings 
of this case study should be interpreted with caution, and highlights the need for 
tighter-controlled studies within populations pre-disposed to blood clotting.   
Whilst the findings of Zaleski et al. [24, 229] have “set the scene” for research into the 
effect of compression socks on haemostatic responses in endurance exercise, further 
research investigating haemostatic responses with a larger sample size representative 
of the general population is warranted. With long-duration endurance-based exercise 
continuously growing in popularity and frequently favoured by master level athletes, 
the potential to prevent adverse thrombotic events upon exercise completion is of the 
utmost importance. It has been widely reported that markers of coagulation including 
F 1+2, TAT complex, and D-Dimer are altered with increasing age, with the risk of 
VTE two to five-times higher in people aged 60 years and over, and four to six–times 
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greater in individuals aged 70 years and older [230]. Compression garments may 
mitigate the potential for exercise associated VTE risk and therefore further 
investigation is required. 
3.0 Literature Review: Conclusion 
The review of literature in this chapter has critiqued the role of haemostasis and the 
factors that may influence haemostasis. More specifically, the review focuses on 
numerous factors that may influence coagulation responses within a well-trained 
population including the duration and intensity of exercise, the time of day exercise is 
performed, and coagulation and fibrinolytic responses to the use of compression 
garments during exercise. 
This review has identified four key markers of haemostasis frequently used in the 
assessment of coagulation and fibrinolysis in exercise-based studies: TAT, TF, TFPI, 
and D-Dimer. These markers represent key stages in blood coagulation, i.e. initiation 
(TF) and regulation (TFPI), thrombin generation (TAT) and fibrinolysis (D-Dimer), 
and will be central to the studies presented in chapters five and six.  
Although exercise has numerous health benefits, it has considerable effects on 
haemostasis, including transient increases in blood coagulation, platelet aggregation 
and fibrinolytic activity. The degree of activation of these pathways is dependent on 
the duration and intensity of the exercise bout [51, 52], the study population (i.e. 
healthy, trained or sedentary, age and gender) [9, 44, 166] and the time of day the 
exercise is performed [7, 31, 45]. Whilst the activation of coagulation during exercise 
of very short duration (15-90 s) [8, 18] and longer duration (> 20 min) [20, 21, 95] has 
been identified within this literature review, a lack of consensus for responses to 
exercise with durations of 90 s to 20 min currently exists. Of particular interest, the 
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research surrounding haemostatic responses to exercise is performed using apparently 
healthy and untrained participants only, and as such, coagulatory responses to exercise 
within an athletic population are unknown.  
The time of day in which exercise is performed may also play a key role in the degree 
of haemostatic activation. Within the literature, significant increases in coagulation 
with a corresponding decrease in fibrinolysis in the absence of exercise have been 
reported, between 0600 and 1200 h [7, 25, 26, 31, 45]. It is therefore likely an increase 
in coagulation responses should be observed within this period when undertaking 
exercise; however, only three separate investigations have sought to investigate this 
theory [7, 9, 17]. Upon completion of a morning and evening exercise bout, the 
author’s findings confirm the presence of a morning peak and afternoon trough in 
coagulation and platelet aggregation, with a morning trough and afternoon peak 
observed in fibrinolytic parameters. Yet similar limitations as reported for exercise 
duration and intensity exist for the examination of time of day influences on 
haemostasis including similar duration of exercise bouts (all 30 min), and the training 
status of study participants (untrained or apparently healthy individuals). With current 
time of day training suggestions provided for “at-risk” individuals (i.e. afternoon 
exercise with the avoidance of morning exercise [30]), these suggestions are often 
unrealistic in athletic populations, with athletes required to compete and train over the 
course of a 24 h day. Whether the degree of haemostatic activation varies over the 
course of a day within an athletic population remains unknown and of interest.  
Due to the proposed benefits of compression garments including improved venous 
velocity, venous return and venous stasis within a clinical population [212, 218-221], 
it has been suggested that similar outcomes will be observed with the transfer of 
compression garments towards a sport setting. This transfer has arisen due to the 
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potential for improved performance and recovery outcomes and not for the potential 
haemostatic protective measures. Furthermore, whether compression garments 
influence the haemostatic balance when combined with exercise is currently scarce. 
To date, only a single case study [229] and one original investigation [24] has been 
conducted, investigating the influence of compression garments on haemostasis when 
combined with endurance-based exercise [24], with the authors reporting positive 
findings with an overall decrease in haemostatic activation reported. Of interest was 
the finding for TAT, with no significant differences observed between groups 
(compression socks worn versus not worn during a marathon run). With TAT 
considered the gold standard in the haematological assessment of thrombin generation, 
further studies investigating the use of compression socks in prolonged endurance 
exercise and its effect on TAT warrants further investigation to examine the protective 
effects of compression garments against VTE when combined with endurance 
exercise.  
Upon critical review of the literature, it is clear that questions relating to factors that 
may influence haemostasis within a well-trained and athletic population (including 
exercise duration and intensity, the time of day exercise is performed and the use of 
compression garments during prolonged-exercise), remain unanswered. Therefore, the 
series of studies within this thesis aimed to address the following questions:  
1. In well-trained cyclists, does a short-duration high-intensity exercise bout influence 
the coagulation and fibrinolytic systems and do these responses vary when exercising 
at different times of the day?  
2. Is a diurnal response present within TAT, TF, TFPI and D-Dimer in well-trained 
athletes? and  
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3. Can compression socks worn during a marathon (42.2km) alter the activation and 
balance of the haemostatic system?
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Chapter Three: Validity of power settings of the Wahoo KICKR Power Trainer 
 
An original version of this chapter has been published in the International Journal of 
Sports Physiology and Performance as a brief review and appears in the literature as: 
Zadow, E.K., Kitic, C.M., Wu, S.S.X., Smith, S.T. & Fell, J.W. “Validity of power 
settings of the Wahoo KICKR Power Trainer”. International Journal of Sports 
Physiology and Performance, 2016, 11, 1115-1117. 
Journal Impact Factor: 2.654 
Rationale 
In order to enable the investigation of coagulation activation in a short-duration high-
intensity bout of exercise (chapter five), a cycling ergometer with the ability to provide 
valid measures of power (a key measure of performance), was required. Ergometers 
that replicate cycling are important items of laboratory equipment and when used with 
cyclists’ own bicycles, is critical for ecological validity (the ability to accurately 
replicate the requirements of cycling), producing reliability of testing protocols, whilst 
removing a potential haemostasis variable (due to cycling position). This study was 
the first to assess the validity of power settings of the Wahoo KICKR Power Trainer 
and was therefore deemed most appropriate in the investigation of haemostatic 
activation within study three.  
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3.1 Abstract 
Purpose: The purpose of this study was to assess the validity of power output settings 
of the Wahoo KICKR Power Trainer (KICKR) using a dynamic calibration rig 
(CALRIG) over a range of power outputs and cadences. Methods: Using the KICKR 
to set power outputs, powers of 100-999W were assessed at cadences (controlled by 
the CALRIG) of 80, 90, 100, 110 and 120rpm. Results: The KICKR displayed 
accurate measurements of power between 250-700W at cadences of 80-120rpm with 
a bias of -1.1% (95%LoA: -3.6-1.4%). A larger mean bias in power was observed 
across the full range of power tested, 100-999W 4.2% (95%LoA: -20.1-28.6%), due 
to larger biases between 100-200W and 750-999W (4.5%, 95%LoA: -2.3-11.3% and 
13.0%, 95%LoA: -24.4-50.3%), respectively. Conclusion: When compared to a 
CALRIG, the Wahoo KICKR Power Trainer has acceptable accuracy reporting a small 
mean bias and narrow limits of agreement in the measurement of power output 
between 250-700W at cadences of 80-120rpm. Caution should be applied by coaches 
and sports scientists when using the KICKR at power outputs of <200W and >750W 
due to the greater variability in recorded power.  
Keywords: cycling, power, ergometry, calibration, training 
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3.2 Introduction 
With changes in cycling performance as small as 1% determining the difference 
between a finish on the podium as opposed to a finish within the peloton, the ability 
to accurately monitor training and competitive performances in highly trained cyclists 
is of high importance [231]. Ergometers that replicate cycling are important pieces of 
laboratory equipment that can be used to conduct fitness assessments, enable 
structured training sessions and monitor training responses [232]. With stationary 
laboratory ergometers, the resistance may be generated through mechanical friction 
[232], air resistance [233], or electromagnetism [234] in order to replicate the 
physiological demands of cycling. Standard stationary laboratory ergometers have 
demonstrated various limitations including the inability to precisely replicate the setup 
of a cyclist’s own bicycle (i.e. same components, dimensions, gearing and joint angles) 
[233, 235] and the dynamic demands associated with cycling on the road [234]. Given 
that cyclists may ride in excess of 35,000km per year, the ability to replicate individual 
training and race-specific variables as closely as possible is highly desirable [233]. 
Indeed, the use of a cyclist’s own bicycle in performance assessment as suggested by 
Paton and Hopkins [235], is critical for producing reliable results predictive of 
competitive performance. When accustomed to the exercise protocol and cyclists’ own 
bicycles are used, the ability to replicate the physiological demands of cycling [236] 
and movement economy are improved, enhancing the ecological validity in measures 
of performance [234, 236, 237]. 
To track meaningful changes in competitive performance from an ergogenic or 
training intervention, Hopkins et al. [237, 238] have suggested ergometer error/bias 
should be less than 2%. As such, the smaller reported coefficients of variation when a 
cyclist’s own bicycle is used are more likely to meet this stringent requirement within 
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performance assessments. To manipulate training techniques and to detect meaningful 
changes in performance, coaches and sports scientists need to be confident in the 
validity and reliability of power outputs of the cycling ergometers being used [231, 
239]. 
A recently available mobile cycle ergometer is the Wahoo KICKR Power Trainer 
(KICKR: Wahoo Fitness, Atlanta, GA), a Bluetooth 4.0 and ANT + enabled stationary 
power trainer allowing for the use of cyclists’ own bicycles attached via a 
SRAM/Shimano 10-speed cassette with electronic resistance provided. The KICKR is 
widely used amongst professional and recreational cyclists, however, to date, there is 
no independent scientific investigation examining the validity of power output 
generated by the KICKR. Therefore, the aim of the present study was to assess the 
validity of power measurements provided by the KICKR using a dynamic calibration 
device. 
3.3 Methods 
The validity of the KICKR power output was assessed by comparison with the power 
output of a dynamic calibration rig (CALRIG: Flinders University, Dynamic 
Calibrator 34118, Adelaide, Australia) at the crank of an attached bicycle, allowing a 
comparison of power data with an ecologically valid reference point based on first 
principles [240]. As per manufacturer requirements to overcome potential frictional 
losses, the CALRIG and the KICKR was operated for 30 min at 100-120rpm and 15 
min at 80-100rpm, respectively, immediately prior to the assessment of power over 
varying cadences. The assessment of power was conducted in standard laboratory 
conditions (18°C and 40% relative humidity). 
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The CALRIG used within this study has been previously described [236, 239] and is 
used to facilitate the application of a constant cadence to the crank rather than to set a 
power output. The CALRIG then quantifies the reaction torque (N.m) produced by the 
ergometer tested using a calibrated load cell, 1 m from the fulcrum point with angular 
velocity (Rad.s-1) recorded via a crystal-based timing device (10 MHz oscillator) 
[234]. A double universal joint connected to the axis of rotation (i.e. bottom bracket 
axle) via a spline drive-coupling device delivers the rotational mechanical drive. A 
bicycle was attached to the KICKR via the SRAM/Shimano Cassette. A range of 
power outputs (100-999W) were achieved by manually varying the resistance settings 
to the maximum power achievable (999W) within the Wahoo Fitness Application for 
the KICKR (Wahoo Fitness, 2014 (version 5.1.1)) using the ‘ergometer mode’ 
selection. Power output was increased by 50W every 3 min over 80, 90, 100, 110 and 
120rpm. Power produced by the CALRIG was sampled at 200Hz and recorded every 
second (1Hz), however, only data produced in the final minute of each stage was used 
for analysis purposes according to the methodology as used by Hopker et al. [241]. A 
standardised twenty-minute cool down was provided between each cadence tested. 
3.4 Statistical Analyses 
Measurements of validity (KICKR) were determined using bias and 95% limits of 
agreement (LoA) in accordance with the methods of Bland and Altman [242]. Data 
was analysed using GraphPad Prism 5 version 5.03 (La Jolla, CA, USA). The relative 
error in measurement of power of the KICKR was calculated by subtracting the power 
measured by the CALRIG from the power settings entered into the Wahoo KICKR. 
For the purpose of this study, relative measurement bias of <1.5%, 1.5-2.5% and 
>2.5% were deemed as highly accurate, moderately accurate and inaccurate, 
respectively [234]. 
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3.5 Results 
Overall absolute and relative bias and 95%LoA between the KICKR and the CALRIG 
over 100-999W and 80-120rpm as determined by Bland-Altman analysis are presented 
in Table 3.1.  
Absolute mean power (W) differences in measures of power from the KICKR to the 
CALRIG over 100-999W at 80-120rpm are presented in Figure 3.1. An increased 
difference between set and measured power above 750W was observed for cadences 
of 80, 90 and 100rpm (Figure 3.2). 
Average relative error (%) in measures of power from the dynamic calibration rig to 
the Wahoo KICKR Power Trainer over 80-120rpm are presented in Figure 2. Larger 
differences between the KICKR and CALRIG were observed at higher ranges of 
power (900-999W) at 80, 90, 100 and 110rpm (Figure 3.2). 
3.6 Discussion 
The present study is the first to assess the validity of power measurements provided 
by the Wahoo KICKR Power Trainer using a CALRIG. The results of this 
investigation show the KICKR has a small mean bias and narrow limits of agreement 
in the measurement of power output over 250-700W at cadences of 80-120rpm, with 
larger mean biases and wider limits of agreements observed at lower and higher set 
power outputs. 
The importance of measured power output for detecting changes within performance 
have been emphasised previously by Hopkins et al. [237, 238] who suggested to detect 
meaningful changes in performance due to ergogenic or training interventions in elite 
athletes, ergometer errors of <2% are required [237, 238]. When compared to a 
CALRIG, the mean bias of the KICKR of -1.1% (95%LoA: -3.5-1.4%, Table 3.1) 
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over 250-700W at cadences of 80-120rpm, falls within this recommended range for 
ergometer error. Our findings for the KICKR are consistent with the ergometer errors 
of the Velotron and SRM power meters of <1% in constant power trials of 250W and 
414W in comparison with a CALRIG as reported by Abbiss et al. [234]. Furthermore, 
an error of <1.3% for incremental power tests performed on the Velotron in 
comparison to a CALRIG was reported between 400W and 700W, similar to the 
KICKR’s accepted range of power output (250-700W). Larger mean biases and wider 
LoAs of 4.5% (95%LoA: -2.3-11.3%) and 13.0% (95%LoA:-24.4-50.3%) were 
observed for powers of 100-200W and 750-999W (Table 3.1), falling outside of the 
acceptable recommended ergometer error [237]. The KICKR’s mean bias in the power 
range of 250-700W is better than the reported biases of 2.3% and -2.5% for the SRM 
and PowerTap between 50-1000W [239]. Similar to Gardner et al. [239], greater 
variance in power at the lower and higher ends of measured power was observed 
across cadences of 80-120rpm. 
Despite the overall larger mean biases and limits of agreements observed across 
cadences at the lower (<250W) and higher (>750W) ranges of power (Table 3.1), it is 
clear these values are influenced by cadence selection. When evaluating cadences 
independently, Figure 3.2 shows a small mean bias of 0.8% between the KICKR and 
the CALRIG at the lower ranges of power (150-200W) at a cadence of 80rpm, and a 
bias of 0.9% can be seen at 120rpm at the higher range of power (750-950W), both 
falling within the accepted range for ergometer error as recommend by Hopkins [237]. 
Due to the stochastic nature of cycling and the constantly changing cadences at varying 
intensities, the validity of power across combined cadences have been reported for the 
present study’s findings. 
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3.7 Conclusion  
The KICKR provides valid readings of power output over 250-700W at cadences of 
80-120rpm. The KICKR appears to be suitable for laboratory training, performance 
assessments and talent identification purposes. Caution should be applied however at 
the lower and higher ranges of power (<200 and >750W) with the KICKR recording 
larger absolute and relative errors in comparison to the CALRIG. With power assessed 
to the highest operational range of the CALRIG, the validity of power output 
exceeding 999W (common in sprinting) remains to be investigated. 
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Figure 3. 1 Bland-Altman plot of the difference in absolute mean power output 
between the Wahoo KICKR Power Trainer (KICKR) and the dynamic 
calibration rig (CALRIG) at 80, 90, 100, 110, and 120rpm. Dashed lines 
represent the mean bias and 95% limits of agreement. Abbreviation: diff, 
difference. 
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Figure 3. 2 Relative error (%) of the Wahoo KICKR Power Trainer (KICKR) in 
comparison with the power produced by the dynamic calibration rig (CALRIG) over 
100-999W at cadences of 80-120rpm. Errors of <1.5%, 1.5-2.5% and >2.5% are 
colour coded as light grey, dark grey, and black respectively. 
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Table 3. 1 Bias and 95% LoA for absolute (W) and relative (%) differences in 
recordings of power at 100-999W for combined cadences of 80-120rpm. 
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Chapter Four: The reliability of a laboratory-based 4km cycle time trial on a 
Wahoo KICKR Power Trainer 
 
An original version of this chapter has been published in the open access Journal of 
Science and Cycling as an original investigation and appears in the literature as:  
Zadow, E.K., Fell, J.W. & Kitic, C.M. “The reliability of a laboratory-based 4km 
cycle time trial on a Wahoo KICKR Power Trainer”. Journal of Science and Cycling, 
2016, 5, 3, 23-27. 
Rationale 
Once the KICKR was demonstrated to provide valid measures of power output, the 
reliability of a short-duration high-intensity bout of exercise (i.e. the 4km cycling time 
trial) was then required. Time trials (TT) have been shown to provide reliable 
measures of performance, possessing relatively low measurement errors, with these 
errors reduced when assessed on repeated occasions. Additionally when cyclists own 
bicycles are used and attached to a cycling ergometer, the ability to replicate the 
physiological demands of cycling and movement economy are improved, enhancing 
the ecological validity of the time trial. Therefore, due to the reliability of the 4km TT 
when using the KICKR, the 4km TT was deemed suitable for use within the 
investigation of coagulation responses to TTs when completed on repeated occasions 
(study three, chapter five). While it would have been practical to publish a single 
validity and reliability publication, the International Journal of Sports Physiology and 
Performance requested the two components be split, with the validity of the Wahoo 
KICKR Power Trainer submitted as a brief report. 
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4.1 Abstract 
The purpose of the present study was to evaluate the reliability of a laboratory-based 
4km cycling time trial using a Wahoo KICKR Power Trainer. Twelve trained male 
cyclists (age: 34.0 ± 6.5 years; height: 1.78 ± 0.62 m; training per week: 11.9 ± 2.6 
hours) completed three 4km time trials on the Wahoo KICKR Power Trainer, with 
each time trial separated by a minimum of two days. During all time trials, mean power 
(W), cadence (rpm), speed (km.h-1), heart rate (bpm) and total time (s) were recorded 
with rating of perceived exertion (6-20) collected immediately post time trial. Average 
Intraclass Correlation Coefficients (ICC) between time trials (2v1, 3v2, 3v1) for power 
was 0.94 (95%CI: 0.85-0.98), cadence 0.73 (95%CI: 0.46-0.90), speed 0.54 (95%CI: 
0.22-0.82), heart rate 0.93 (95%CI: 0.84-0.98) and total time 0.64 (95%CI: 0.34-0.86). 
Mean reliability expressed as the coefficient of variation (CV) and typical error of 
measurement over the three time trials was 3.4%, 5.2%, 4.2%, 1.6% and 4.3% for 
power, cadence, speed, heart rate and total time, respectively. Average power 
measured during a laboratory-based 4km cycling time trial is highly reliable in trained 
cyclists making it a reliable method for monitoring cycling performance, however, 
caution should be applied when assessing cadence, speed and total time due to the 
larger typical errors when completed on the Wahoo KICKR Power Trainer.  
 
Keywords: reproducibility, power output, cycling, athletic performance, performance 
test 
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4.2 Introduction 
In professional cycling, small differences in performance can often determine the 
difference between a finish on the podium and a finish within the peloton; therefore, 
the ability to monitor training and competitive performance changes in highly trained 
cyclists is of high importance [231, 243]. To detect these meaningful changes within 
power output, laboratory based performance tests which replicate competitive 
performances have been shown to possess good test-retest reliability and have the 
precision to detect changes as small as 1% [237, 243, 244]. In addition, the knowledge 
of test-retest reliability may determine how sensitive a test is to monitor changes in 
performance, inform sample size calculations for research studies and enable the 
comparison of ergometer precision [237].  
Time trials (TTs), in which athletes complete a set amount of work in as short a time 
as possible, have been shown to provide coaches and sports scientists with the ability 
to monitor responses and detect changes associated with training and fatigue whilst 
providing accurate representations of the bioenergetics required in competitive cycling 
[237, 245]. In a review of the validity, reliability and sensitivity of measures of 
sporting performance, TTs of distances ranging from 5 to 40km, have been shown to 
be highly reliable in well-trained cyclists with coefficient of variations (CVs) of less 
than 5% [243], with smaller CVs of 1.9-2.4% observed when completed on cyclists’ 
own bicycles using a Kingcycle™ and SRM™ ergometer [246].  
When accustomed to the exercise protocol and cyclists’ own bicycles are used, the 
ability to replicate the physiological demands of cycling [236] and movement 
economy [247] are improved, enhancing the ecological validity in measures of 
performance [234, 237, 247]. Indeed, Lamberts et al. [231] reported low CVs of 0.7% 
and 1.7% in both 40km performance time and 40km mean power in cyclists who rode 
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their own bicycle on an electromagnetically braked cycle ergometer. The use of a 
cyclist’s own bicycle in performance assessments as suggested by Paton and Hopkins 
[235], is critical for producing reliable results predictive of competitive performance.  
The Wahoo KICKR Power Trainer (KICKR) is an electromagnetically braked 
portable ergometer, which allows cyclists to use their own bicycles. Indeed, the 
KICKR has been shown to provide valid measures of power [248], falling within the 
recommended range of ergometer error of <2% [237, 238]. However, the reliability of 
a laboratory-based 4km cycle time trial (TT) with cyclists using their own bicycle on 
the KICKR has yet to be reported. A 4km TT may simulate real world performance 
such as the 4 000m individual and team pursuit that features at the UCI Track Cycling 
World Championships. Therefore, the aim of the present study was to determine the 
reliability of a 4km cycling TT when completed on a Wahoo KICKR Power Trainer 
in trained cyclists. 
4.3 Methods 
4.3.1 Participants 
Twelve trained male cyclists (age: 34.0 ± 6.5 years, height: 1.78 ± 0.62 m, body mass: 
76.8 ± 9.6 kg) with minimum weekly cycling duration of 10 h and previous TT 
experience volunteered to participate in the study. Participants were provided with 
written description of the risks and benefits of this study and provided signed informed 
consent. Ethics was obtained from the Institutional Human Research Ethics 
Committee. Furthermore, this study conforms to the ethical standards of the Journal 
of Science and Cycling [249]. 
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4.3.2 Study Design 
In a repeated measures study design, participants performed three 4km cycling TTs in 
standard laboratory conditions (19 ± 1.2oC and 45 ± 7.5% relative humidity) over three 
separate occasions within a two-week period. Testing sessions were separated by a 
minimum of 48 and a maximum of 72 h with testing performed at the same time of 
day (± 1 h) to minimise the effects of diurnal variation. Participants were required to 
avoid strenuous activity (<24 h) and caffeine (<12 h) before and on the day of testing. 
Participants completed a 24 h food diary prior to their first visit and were required to 
replicate their diet as closely as possible before each subsequent visit. All sessions 
were performed using the same equipment. 
All TTs were performed on participants’ own bicycles fitted to the Wahoo KICKR 
Power Trainer (KICKR: Wahoo Fitness, Atlanta, GA). The KICKR was calibrated 
using the Wahoo Fitness Utility Application (Wahoo Fitness, 2014, version 2.5) prior 
to and immediately post each participant’s warm up before each TT. For a successful 
calibration, participants were required to reach a speed of 35.4km.h-1 (22 mph) and 
cease pedalling until 16.0 km.h-1 (10 mph) had been reached.  
A ten-minute self-selected intensity warm-up immediately followed the calibration 
process with participants free to alter their pedalling cadence and gear ratio as 
required. Immediately post warm-up, participants re-calibrated the KICKR with a 
standardised 60 s period of passive recovery provided following the re-calibration 
period, with a 10 s non-verbal countdown beginning the TT. Participants were 
instructed to perform the 4km TTs as fast as possible, commencing from a standing 
start position with no rolling resistance. Only feedback on distance elapsed was 
provided throughout each TT. A ten-minute cool-down of self-selected intensity 
immediately commenced upon completion of the 4km TT. During each TT, heart rate 
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was recorded at a beat by beat frequency (Wahoo Fitness Blue HR, Atlanta, GA) with 
speed, cadence and power output recorded at a frequency of 1 Hz via the Wahoo 
Fitness Application for the KICKR (Wahoo Fitness, 2014, version 5.1.1) and Wahoo 
Fitness Blue Speed and Cadence (Wahoo Fitness, Atlanta, GA), respectively. Rating 
of perceived exertion (RPE) for the TT was determined upon immediate completion 
of the TT using a 6-20 Borg Scale [250]. 
4.4 Statistical Analyses 
Average power, cadence, speed, heart rate and total time between TTs were 
logarithmically transformed and evaluated using Intraclass Correlation Coefficient 
(ICC) in combination with 95% confidence intervals (CI), analysed using an Excel 
spreadsheet for reliability [251]. Thresholds for assigning qualitative terms to the 
strength of within participant intraclass correlations were as follows: 0.5-0.69 low; 
0.7-0.79 moderate; 0.8-0.89 high; 0.9-1.0 nearly perfect [252]. Typical error expressed 
as a CV% of an absolute value with upper and lower 95% CI were examined between 
TTs using the Excel spreadsheet of Hopkins [251]. Based on previous research [237], 
a coefficient of variation lower than 3.5% was regarded as having high test-retest 
reliability. A one-way within-subject’s analysis of variance was used to assess 
differences in power output between trials using SPSS v23.0, with significance 
accepted at p<0.05. Due to a loss of signal of the cadence sensor as a result of operator 
error on one occasion, cadence data was obtained from 11 of the 12 cyclists.  
4.5 Results 
Mean (±SD) data for measures of power, total time, cadence, speed, heart rate and 
post-exercise ratings of perceived exertion for TTs 1, 2 and 3 are presented in Table 
4.1. The ICC for mean power and heart rate were nearly perfect at 0.97 (95%CI: 0.92-
0.99) with CVs < 2.4% between TT 1 and 2 (Table 4.2). Moderate to high ICCs of 
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0.87 (95%CI: 0.58-0.96), 0.70 (95%CI: 0.23-0.90) and 0.77 (95%CI: 0.36-0.93) were 
reported for cadence, speed and total time between TT 2 and 3 (Table 4.2). The 
average ICC and CV with 95%CI for measurements between TTs (2v1, 3v2, and 3v1) 
are presented in Table 4.2. Power output during the three time trials was not 
significantly different (p=0.051). 
4.6 Discussion 
The present study is the first to determine the reliability of a 4km cycle TT in trained 
cyclists on the Wahoo KICKR Power Trainer. The results of this investigation show 
that power within a 4km cycle TT when completed on the KICKR is highly reliable 
with a CV of 3.4% whereas measures of cadence, speed and total time were shown to 
be unreliable measures of performance with CV’s of 5.2%, 4.2% and 4.3%, 
respectively. 
The importance of detecting performance changes in athletes has been previously 
emphasized in a review by Hopkins et al. [237] with measures of performance required 
to show a strong relationship with competitive cycling performance [238, 246, 253]. 
Laboratory based TTs are frequently used to detect these changes due to the low 
coefficients of variation (<5%) observed when using various laboratory ergometers 
[237, 243]. When power output is the key performance variable in repeated TTs, lower 
CVs of 1.9-3.6% [246, 253, 254] are reported, indicating better test-retest reliability 
and a more direct method for monitoring of exercise performance [255]. For a 4km 
TT completed on the KICKR, our findings indicate this cycling test to be highly 
reliable for power output. We observed a mean CV of 3.4% (CI: 2.4-4.7%) and a 
within-subject ICC of 0.94 (CI: 0.89-0.98) across three TTs, with the lowest CV 
(2.4%; CI: 1.7-4.0%) observed between TTs one and two (Table 4.2). While highly 
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reliable, further research is required to quantify how changes in 4km TT on the KICKR 
reflect changes in on road performance. 
In the investigation of both short and longer duration TTs, mean power output for 
competitive and well-trained cyclists have been observed to consistently exceed 
250W, falling within the acceptable range of ergometer error for the Wahoo KICKR 
Power Trainer (250-700W and 80-120rpm) [248]. Indeed, on average, powers of 346± 
38W, 323± 35W and 303± 35W have been reported for a 4, 20 and 40 km cycling TT, 
respectively [246, 253, 256]. The average power of 344± 41W (Table 4.1) observed 
within the present study is consistent with previously reported power outputs for TTs 
of varying distances.  
To determine the reliability between TTs (within-subject variation), coefficient of 
variations for power output (2v1, 3v2, and 3v1) was evaluated (Table 4.2). Based 
upon previous studies investigating multiple performance TTs, learning effects have 
been proposed to contribute to lower CVs observed between TTs two and three (0.9-
2.1%) with larger CVs observed between TTs one and two (2.1-3.0%) [253, 254, 257, 
258]. To ensure the changes observed within repeated performances are not the result 
of a learning effect [259, 260], a single familiarisation session has been shown to 
establish a high degree of reliability and should precede experimental TTs [236, 254]. 
In contrast to previous findings, there appeared to be no learning effect within the 
present study in the absence of a familiarisation session with a larger CV of 3.8% (CI: 
2.7-6.5%) observed between TTs two to three when compared to TTs one to two (CV: 
2.4%, CI: 1.7-4.0%) (Table 2). It has been previously suggested that a familiarisation 
session may not always be necessary in trained cyclist [235, 253] with the lack of any 
learning effect from TT one to TT two observed due to the training status and previous 
TT experience of the cyclists recruited [261]. The larger CV observed between TTs 
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two to three can be attributable to an increase in average power output observed within 
the third and final TT (Table 4.1). With our findings similar to those observed by 
Jeukendrup et al. [261] in which performance was greater in the final TT, we propose 
the improved performance may be due to the participants knowledge that this was their 
final TT and thus may have been more motivated to complete this TT [258].  
With performance time popular in the assessment of reliability within cycling tests 
due to the ease of measurement, Sporer et al. [253], Palmer et al. [262] and Schabort 
et al .[263] have demonstrated time to be a reliable method for assessing laboratory 
based cycling TTs, with CVs of 0.8-1.7% for TTs ranging from 20 to 100 km in trained 
cyclists. The CV for total time to complete a 4km cycling TT in our study contrasts 
previous findings with a CV of 4.3% observed. In combination with the large typical 
errors observed within speed and cadence (Table 4.2), this suggests total time, speed 
and cadence should not be used as key performance outcomes when assessing cycling 
performance when using the KICKR. 
In conclusion, the mean power for a 4km TT performed on the Wahoo KICKR Power 
Trainer is highly reliable in trained cyclists. With a mean CV of 3.4% for power, a 
4km TT on the KICKR is able to detect cycling performance changes of 1.7% in 
trained cyclists. 
4.7 Practical Applications 
A 4km TT performed on the Wahoo KICKR Power Trainer is a reliable and therefore 
sensitive test for coaches and sports scientists to monitor responses associated with 
performance, training, fatigue and ergogenic aid use within trained cyclists when 
monitoring and measuring power output only. When assessing 4km TT performance 
on the Wahoo KICKR Power Trainer, cadence, speed and total time should not be 
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used due to greater variations in reliability observed within this study. The ability for 
cyclists to use their own bicycles when attached to the Wahoo KICKR Power Trainer 
is highly advantageous and critical for producing reliable results predictive of 
competitive performance.  
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Table 4.1 Mean and standard deviation for total time (s), power (W), cadence (rpm) 
and heart rate (bpm) measured during each 4km cycling time trial (TT). Ratings of 
perceived exertion (RPE) were measured upon completion of the 4km TT.  
 TT 1 TT 2 TT 3 Average 
Total Time (s) 416.4 ± 22.8 421.0 ± 29.9 410.8 ± 27.6 416.1 ± 26.8 
Power (W) 342 ± 42 341 ± 45 349 ± 37 344 ± 41 
Cadence  (rpm) 92 ± 10 93 ± 7 91 ± 8 92 ± 8 
Heart Rate (bpm) 174 ± 9 172 ± 8 171 ± 9 172 ± 9 
RPE 18.4 ± 1.6 18.1 ± 1.7 18.5 ± 1.5 18.3 ± 1.6 
Note that cadence n = 11. 
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Table 4.2 Mean within-participant intraclass correlation (ICC) and coefficient of 
variation (CV) between time trials. Data are presented as mean (95%CI). 
Note that cadence n = 11. 
 
 
 Power 
(W) 
Cadence 
(rpm) 
Speed 
(km.h-1) 
Heart Rate 
(bpm) 
Total Time 
(s) 
ICC 
(2 to 1) 
0.97 
(0.91- 0.99) 
0.78 
(0.36- 0.93) 
0.36 
(-0.24- 0.76) 
0.98 
(0.94- 1.00) 
0.51 
(-0.07- 0.84) 
ICC 
(3 to 2) 
0.92 
(0.75- 0.98) 
0.87 
(0.58- 0.96) 
0.70 
(0.23-0.90) 
0.91 
(0.70- 0.97) 
0.77 
(0.36- 0.93) 
ICC 
(3 to 1) 
0.80 
(0.45- 0.94) 
0.34 
(-0.29- 0.77) 
0.49 
(-0.08- 0.82) 
0.84 
(0.34- 0.29) 
0.52 
(-0.02- 0.84) 
Mean 0.94 
(0.85- 0.98) 
0.73 
(0.46- 0.90) 
0.54 
(0.22- 0.81) 
0.93 
(0.84- 0.98) 
0.64 
(0.34- 0.86) 
CV 
(2 to 1) 
2.4 
(1.7- 4.0) 
4.9 
(3.4- 8.8) 
4.5 
(3.1- 7.7) 
0.8 
(0.6- 1.4) 
5.0 
(3.4- 8.9) 
CV 
(3 to 2) 
3.8 
(2.7- 6.5) 
3.5 
(2.4- 6.2) 
3.9 
(2.7- 6.7) 
1.8 
(1.3- 3.3) 
3.7 
(2.6- 6.7) 
CV 
(3 to 1) 
3.8 
(2.7- 6.5) 
6.8 
(4.7- 12.2) 
4.4 
(3.1- 7.5) 
1.8 
(1.3- 3.2) 
4.1 
(2.9- 7.4) 
Mean 3.4 
(2.7- 4.7) 
5.2 
(4.1- 7.4) 
4.2 
(3.3- 5.9) 
1.6 
(1.2- 2.2) 
4.3 
(3.4- 6.1) 
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Chapter Five: Time of day and short-duration high-intensity exercise influences 
on coagulation and fibrinolysis 
 
This manuscript has been accepted as an original research investigation in the 
European Journal of Sports Science (Accepted December 15, 2017) and will appear 
in the literature as: 
Zadow, E.K., Kitic, C.M., Wu, S.S.X., Fell, J.W. and Adams, M.J. “Time of day 
and short-duration high-intensity exercise influences on coagulation and fibrinolysis” 
European Journal of Sports Science. 
Journal Impact Factor: 2.69 
Rationale 
 
With the KICKR and a 4km cycling TT shown to be valid and reliable for research 
purposes (chapter three and four), both were then used to investigate coagulation and 
fibrinolytic responses to a short-duration high-intensity bout of exercise in well-
trained cyclists. In addition, markers of coagulation and fibrinolysis have been shown 
to possess circadian rhythms, often peaking within the morning (0600-1200 h). 
Therefore, the time of day exercise is performed may influence the activation of the 
coagulation and fibrinolytic systems, with research currently scare within this field, 
especially when investigated in a well-trained population.  
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5.1 Abstract 
 
Exercise has been demonstrated to have considerable effects upon haemostasis with 
activation dependent upon the duration and intensity of the exercise bout. In addition, 
markers of coagulation and fibrinolysis have been shown to possess circadian rhythms, 
peaking within the morning (0600-1200 h). Therefore, the time of day exercise is 
performed may influence the activation of the coagulation and fibrinolytic systems. 
This study examined the effect of time of day and short-duration high-intensity 
exercise responses to coagulation and fibrinolysis. Fifteen male cyclists (VO2max: 60.3 
± 8.1 ml.kg-1.min-1) completed a 4km cycling time trial (TT) on five separate occasions 
at 0830, 1130, 1430, 1730 and 2030 h. Venous blood samples were obtained pre- and 
immediately post-exercise, and analysed for tissue factor (TF), tissue factor pathway 
inhibitor (TFPI), thrombin anti-thrombin complexes (TAT) and D-Dimer. Exercise 
significantly increases plasma concentrations of TF (p<0.0005), TFPI (p<0.0006), 
TAT complexes (p<0.0012), and D-Dimer (p=<0.0003). There was a time of day 
effect in pre-exercise TF (p=0.004) and TFPI (p=0.031), with 0830 greater than 1730 
(p+0.001), while 1730 was less than 2030 (p=0.008), respectively. There was no 
significant effect of time of day for TAT (p=.364) and D-Dimer (p=.228). Power 
output, TT time and heart rate were not significantly different between TTs (p>0.05); 
however, percentage VO2max was greater at 1730 when compared to 2030 h (p=0.04). 
Due to a time of day effect present within TF, peaking at 0830, caution should be 
applied when prescribing short-duration high-intensity exercise bouts within the 
morning in populations predisposed to hypercoagulability.  
Key words: Thrombin anti-thrombin III, D-Dimer, circadian rhythm, cycling 
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5.2 Introduction 
 
Exercise has long been recognised to have considerable effects upon haemostasis, with 
transient increases in blood coagulation [8, 10, 11], platelet aggregation [12] and 
fibrinolytic activity [8, 13, 14] well documented and observed to occur in both a 
healthy and clinical population (i.e. those possessing peripheral arterial disease) [40, 
264]. With haemostasis constantly active at low levels, the degree to which the 
coagulation, platelet and fibrinolytic systems are activated appear to be related to the 
intensity and duration of the exercise and the study population assessed [15, 51]. 
Indeed, activation of the coagulation system as indicated by markers of in-vivo 
thrombin generation, i.e. thrombin anti-thrombin complexes (TAT) and prothrombin 
fragment 1 + 2, have been shown to increase following both short-duration maximal 
exercise (<1h @~83% of VO2max) [19, 52, 172] and longer-duration strenuous exercise 
(>2h @ ~90% individual anaerobic threshold) [7, 10, 172]. However, conflicting 
responses for activation of coagulation, as indicated by TAT complexes, have been 
observed following short duration exercise of varying intensities [51, 52], with 
exercise performed at higher intensities resulting in significantly greater 
concentrations of TAT, suggesting coagulation activation occurs in an intensity 
dependent manner [40]. Other confounding factors such as the time of day in which 
the exercise is performed and individual responses to exercise however, may 
ultimately influence the overall coagulation response. 
It is well established that haemostatic markers are subject to circadian rhythms, with 
hypercoagulability, hypofibrinolysis and increased blood viscosity observed to occur, 
between 0600 and 1200 h [7, 25-27, 31, 45, 188, 190]. With an increase in the 
frequency of thromboembolic events reported to coincide with changes in haemostatic 
variables [28, 29, 265], and with exercise shown to activate the coagulation system [8, 
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10, 11], it has been suggested that exercise during the afternoon is the safest time of 
day to exercise, whilst early morning exercise should be avoided completely [30]. This 
recommendation remains directed at an “at risk/ untrained” population with no current 
guidelines for well-trained athletes and athletes at more risk of hypercoagulability, 
including master’s athletes and those with genetic mutations for blood clotting.  
The time of day at which an athlete exercises is often unavoidable as they are required 
to compete and train over the course of a 24-hour day based upon the scheduling of 
training and competition [266, 267]. Although numerous studies have investigated 
circadian variations in response to exercise [266-269], it remains unclear if 
coagulation responses to short-duration high-intensity exercise vary at different times 
of the day within a well-trained athletic population. Therefore, the primary aim of this 
study was to examine acute changes in the activation of coagulation following short-
duration high-intensity exercise at 0830, 1130, 1430, 1730 and 2030 h in well-trained 
male cyclists. In addition, we aimed to investigate if a time of day effect (circadian 
variation) was present within markers of haemostasis (Thrombin Anti-thrombin 
complex and D-Dimer, tissue factor (TF) and tissue factor pathway inhibitor (TFPI)).  
5.3 Methods 
5.3.1 Participants 
Fifteen well-trained male cyclists (mean ± SD: age: 41.5 ± 10.0 years, height: 1.8 ± 
0.6 m, body mass: 79.5 ± 9.4 kg, BMI: 24.2 ± 2.3 kg/m2, VO2max: 60.3 ± 8.1 ml.kg-
1.min-1) with previous TT experience and cycling a minimum of 10 h per week, 
volunteered to participate in the study. All participants were non-smokers, with no 
known history or clinical signs of metabolic conditions or coagulation disorders. 
Subjects were excluded from the study if they had a previous history of 
thromboembolism. Enrolled participants refrained from using medications that could 
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affect coagulation (i.e., aspirin and non-steroidal anti-inflammatory drugs) at least 2 
weeks before and throughout the testing period [102]. Participants were provided with 
a written description of the risks and benefits of the study and provided signed 
informed consent prior to their inclusion within the study. Any details that may 
disclose the identity of our participants have been omitted. All procedures performed 
in studies involving human participants were in accordance with the ethical standards 
of the institutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards.  
5.3.2 Study Overview 
Each participant was required to perform seven exercise sessions, no less than 2 and 
no greater than 7 days apart. Participants were required to avoid strenuous activity and 
caffeine (<24 h) before and on the day of testing itself, whilst avoiding food 3 h prior 
to testing. Participants completed a 24 h food and training diary for the day prior to 
their first visit and were required to replicate their diet and training as closely as 
possible before each subsequent visit. All exercise sessions were performed on the 
same equipment, using participants’ own bicycles fitted to the Wahoo KICKR Power 
Trainer (KICKR: Wahoo Fitness, GA, USA) which has been shown to be valid and 
reliable [248]. The 4km TT employed for this study has previously been shown to 
provide reliable results when completed on the Wahoo KICKR Power Trainer [270]. 
5.3.3 Preliminary Testing and Familiarisation 
During the initial exercise session, participants completed an incremental maximal 
exercise test to determine VO2max. The initial workload was 70W with increases of 
30W.min-1. Expired air was collected throughout the maximal exercise test using a 
metabolic cart (Parvo TrueOne; Parvomedics, UT, USA) at a frequency of 1 Hz and 
expressed as 30 s mean values. The metabolic cart was calibrated before each test 
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using alpha gases of known concentrations, according to the manufacturer’s 
requirements. 
Participants were familiarised with the laboratory environment and experimental 
exercise session (excluding the collection of venous blood) during their second visit 
to the laboratory. 
5.3.4 Experimental Sessions 
Experimental sessions three to seven required participants to complete a 4km cycling 
time trial (TT) over five different times of the day (0830, 1130, 1430, 1730 and 2030 
h) in standard laboratory conditions (20.8 ± 1.4₀C and 46.6 ± 6.2% relative humidity). 
The order of these exercise sessions was randomised and counterbalanced. Exercise 
sessions began with ten minutes of supine rest to collect resting measures of oxygen 
uptake (Parvo TrueOne, Parvomedics, UT, USA) and heart rate collected at a beat by 
beat frequency (Polar FT4; Polar; Kempele, Finland). Pre-exercise venous blood 
samples were collected immediately prior to exercise, along with the measurement of 
blood pressure (Aneroid Sphygmomanometer; Reister; Jungingen, Germany), lactate 
(Lactate Pro; Arkray, Kyoto, Japan) and tympanic temperature (Covidien Genius 2; 
Medtronic; Sheffield, United Kingdom).  
The exercise protocol consisted of a standardised ten minute warm up (5 min at 50%, 
3 min at 70% and 2 min at 80% of peak power measured during the incremental 
maximal exercise test), followed by 5 minutes of passive rest. Participants then 
completed a 4km TT as fast as possible, with heart rate recorded at a beat-by-beat 
frequency, and expired gases, power output, speed and cadence collected at a 
frequency of 1 Hz. Rating of perceived exertion (RPE) and effort provided for the TT 
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were determined upon immediate completion of the TT using a 6-20 Borg Scale [250] 
and a 0-10 (0= no effort, 10= maximal effort) visual analogue scale, respectively. 
Immediately upon TT completion, participants were required to lay in a supine 
position for a further ten minutes with the second (post-exercise) venous blood sample 
collected immediately at the beginning of the ten-minute period, along with the 
collection of blood pressure, lactate and tympanic temperature.  
5.3.5 Blood Sample Collection 
Blood samples were drawn without stasis by venepuncture from the antecubital fossa 
from participants in a supine position. Blood samples for determining markers of 
blood coagulation were collected into 3.8% sodium citrate Vacutainers® (Becton 
Dickinson, New Jersey, USA). Within 30 minutes of collection, citrated blood samples 
were centrifuged at room temperature for 15 minutes at 2,000 g. Plasma samples were 
aliquoted and stored at -80oC until required for analysis.  
5.3.6 Blood Sample Analyses 
Tissue factor (TF), total tissue factor pathway inhibitor antigen (TFPI), thrombin anti-
thrombin complexes (TAT) and D-Dimer were determined by enzyme-linked 
immunosorbent assay (ELISA) kits (Abcam, Melbourne, Australia), according to 
manufacturer’s instructions. Intra-assay coefficients of variation were below 6.1% and 
inter-assay coefficients below 6.9%. The minimal detectable dose for TF, TFPI, TAT 
and D-Dimer were ~4pg/mL, 14.9pg/mL, ~0.5ng/mL and 71pg/mL, respectively.  
Absorbances were determined using an infinite 200 PRO Spectrophotometer (Tecan 
Trading AG, Männedorf, Switzerland).   
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5.4 Statistical Analyses 
Sample size was calculated based upon an 11% difference in TFPI from the morning 
to the afternoon [31], with a power of 0.8 and an α 0.05, 11 participants were required, 
and 16 were recruited to account for potential dropouts. A Shapiro-Wilk test was used 
to assess normality of distribution with power output, total time trial completion time, 
%VO2max and heart rate data normally distributed, with pre- and post-exercise 
physiological, perceptual data and markers of haemostasis non-parametrically 
distributed. All statistical analyses were performed using GraphPad Prism version 5.03 
for Windows (GraphPad software, La Jolla California, USA). A one-way ANOVA 
with repeated measures was used to determine time of day effect within measures of 
power output, total time trial completion time and %VO2max, with a Bonferroni post 
hoc test used to determine any significant differences. Pre- and post-exercise 
physiological and perceptual data, markers of haemostasis and TF to TFPI ratio along 
with differences in the magnitude of change (post-pre) of haemostasis values were 
analysed for a time of day effect using a Friedman’s Test. A Wilcoxon matched-pairs 
signed rank test was used to determine differences between pre- and post-exercise 
physiological, perceptual and blood values for each marker of coagulation and D-
Dimer with Cohen’s d calculated from pre-post blood values (post minus pre, divided 
by pooled standard deviation). Effect size was interpreted as small <0.2, moderate 
>0.5 or large >0.8 [271]. All statistical tests were performed at the level of significance 
of p<0.05. Results are expressed as mean ± SD for normally distributed data, with 
non-parametric data reported as median (range), unless otherwise stated.  
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5.5 Results 
5.5.1 Performance, Physiological and Perceptual Responses to Exercise 
Performance, physiological and perceptual responses collected during and 
immediately post 4km TT at 0830, 1130, 1430, 1730 and 2030 h are presented in 
Table 5.1. No time of day effects were observed in mean power output (p=0.770), TT 
completion time (p=0.635), heart rate (p=0.677) and RPE (p=0.179). Due to 
equipment fault with the gas analyser for one participant, n=14 for the measure of 
%V02max. Significant main effects for time of day responses was observed for 
%VO2max (p=0.037) and effort provided (p=0.030), with %VO2max greater at 1730 
when compared to 2030 h and effort provided higher at 2030 h when compared to 
1430 and 1730 h (p=0.017 and p=0.036, respectively). 
5.5.2 Pre- and Post-Exercise Physiological Responses 
Pre- and post-exercise measures of tympanic temperature, blood lactate and blood 
pressure were collected at 0830, 1130, 1430, 1730 and 2030 h are presented in Table 
5.2. A main effect for time of day effects was observed for pre-exercise tympanic 
temperature (p=0.0003). Post-exercise tympanic temperature was not significantly 
different across the day (p=0.436). No time of day effects were observed in pre- and 
post-exercise blood lactate (p=0.945 and p=0.606, respectively), systolic blood 
pressure (p=0.547 and p=0.542, respectively) and diastolic blood pressure (p=0.950 
and p=0.990, respectively). 
5.5.3 Exercise and Coagulation Activity 
Coagulation responses to the 4km cycling TT when performed at 0830, 1130, 1430, 
1730 and 2030 h are presented in Table 5.3. Significant increases (p<0.05) were 
observed from pre- to post-exercise for TF, TFPI and TAT at all times of day (0830-
2030 h). There was a large post-exercise increase (d=0.77-1.03) at 1130 and 1730 h 
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for TFPI and a moderate to large increase in post-exercise TAT (d=0.52-0.83) at 0830, 
1130, 1430, 1730 and 2030 h (Table 5.3).  
5.5.4 Exercise and Fibrinolytic Activity 
Originally sixteen participants completed all requirements of the study, however, 
blood analysis results for fifteen participants are presented due to large outliers in 
blood results and a subsequent diagnosis of DVT, two months post completion of the 
present study. Large responses in D-Dimer pre-post exercise were observed for this 
participant with pre and post 0830 h results 35.1 and 29.5 times greater than the group 
mean (2250.9 ng/mL and 2653.0 ng/mL, respectively), well above normal values of 
D-Dimer <500ng/mL [111]. 
Fibrinolytic responses are presented in Table 5.3. Significant differences (p<0.05) 
were observed in pre- to post-exercise D-Dimer across all times of day (0830, 1130, 
1430, 1730 and 2030 h).  
5.5.5 Coagulation and Fibrinolysis Responses to Time of Day 
A significant main effect for time of day for pre-exercise TF (p=0.004) and TFPI 
(p=0.031) was observed, with TF greater at 0830 h when compared to 1730 h 
(p=0.0007) and TFPI lower at 1730 h when compared to 2030 h (p=0.008). There was 
no significant effect of time of day responses (0830-2030 h) on pre- TAT (p=0.364) 
and D-Dimer (p=0.228). The magnitude of post-exercise change for TF, TFPI, TAT 
and D-Dimer was not significantly different across the day (TF: p=0.375, TFPI: 
p=0.236, TAT: p=0.873 and D-Dimer: p=0.673, respectively) (Table 5.3).  
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Table 5.1 Power output (W), total time (m), %VO2max (ml.kg-1.min-1) and heart rate 
(bpm) measured during each 4km time trial. Ratings of perceived exertion (RPE) and 
effort were measured upon time trial completion. Data are presented as mean ± SD. 
+ significant difference from 1730 h (p<0.05), *significantly difference from 2030 h 
(p<0.05). 
 0830 1130 1430 1730 2030 Average 
Power (W) 324.5 ± 34.4 329.5 ± 34.0 327.1 ± 28.2 328.4 ± 31.9 327.6 ± 33.9 327.4 ± 32.5 
Total Time (min:sec) 7.16 ± 0.49 7.07 ± 0.50 7.04 ± 0.44 7.08 ± 0.41 7.09 ± 0.42 7.09 ± 0.45 
%V02max 
(ml-1.kg.min-1) 
85.5 ± 7.7 84.3 ± 7.6 83.7 ± 7.5 87.3 ± 8.4 +82.5 ± 8.4 84.7 ± 7.9 
Heart Rate (bpm) 164 ± 10 163 ± 11 162 ± 11 163 ± 13 162 ± 13 163 ± 12 
RPE (6-20) 18.4 ± 1.2 18.5 ± 1.6 17.9 ± 2.1 18.2 ± 1.4 18.9 ± 0.8 18.4 ± 1.4 
Effort (0-10) 9.1 ± 0.9 9.1 ± 0.9 *8.8 ± 1.0 *8.9 ± 0.8 9.4 ± 0.6 9.0 ± 0.9 
 
Note n= 15 for power, total time, heart rate, RPE, effort; n=14 for %VO2max due to 
equipment fault with gas analyser for one participant. 
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Table 5.2 Tympanic temperature (OC), systolic blood pressure (SBP (mmHg)), 
diastolic blood pressure (DBP (mmHg)) and blood lactate (Bla (mmol.L-1)) measured 
pre- and post-exercise at 0830, 1130, 1430, 1730 and 2030 h. Data are presented as 
mean ± SD. *significant difference from 0830 and 1130 h (p<0.05), + significant 
difference from 1430 and 1730 h (p<0.05). 
 0830 1130 1430 1730 2030 
Temp (OC)      
Pre 36.2 ± 1.4 36.8 ± 0.7 *37.3 ± 0.7 *37.3 ± 0.7 +36.9 ± 0.9 
Post 
 
36.4 ± 1.1 36.6 ± 1.2   37.9 ± 0.7   37.0 ± 1.1  36.6 ± 1.4 
SBP (mmHg)      
Pre 120.9 ± 7 123 ± 10 126 ± 9 124 ± 8 124 ± 6 
Post 
 
166 ± 18 164 ± 21 166 ± 19 158 ± 19 166 ± 17 
DBP (mmHg)      
Pre 76.8 ± 7.2 77.1 ± 7.2 77.1 ± 5.6 76.6 ± 7.6 78.3 ± 8.4 
Post 
 
72.8 ± 9.9 75.0 ± 10.9 74.2 ± 8.5 72.2 ± 11.5 73.9 ± 9.2 
BLa (mmol.L-1)      
Pre 1.5 ± 0.9 1.5 ± 0.5 1.4 ± 0.7 1.4 ± 0.6 1.6 ± 0.8 
Post 11.3 ± 2.4 10.8 ± 3.2 11.3 ± 3.2 10.8 ± 2.6 11.6 ± 3.0 
Note n=15
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Table 5.3 Tissue Factor (TF), Tissue Factor Pathway Inhibitor (TFPI), Thrombin Anti-Thrombin Complex (TAT) and D-Dimer and 
TF:TFPI ratio measured pre- and post-exercise at 0830, 1130, 1430, 1730 and 2030 h. Data are presented as median (range). + 
significant time of day difference (p<0.05) from 0830 h pre-exercise (TF); @ significant time of day difference (p<0.05) from 1730 h pre-
exercise (TFPI); * significant difference (p<0.05) between pre- and post-exercise values. d= effect size. 
 0830 1130 1430 1730 2030 
TF 
(pg/mL) 
Pre Post Pre Post Pre Post + Pre Post Pre Post 
 5.07 
(2.08-71.68) 
6.76 
(2.35-74.28) 
4.57  
(1.96-64.14) 
5.76 
(2.18-64.77) 
4.23 
 (1.70-48.0) 
5.86 
(2.07-48.34) 
4.01  
(0.00-50.43) 
5.13 
(1.86-54.35) 
4.25  
(0.00-62.50) 
4.78 
(0.00-67.86) 
∆ pre-post 1.18 (0.16-18.38) 0.67 (0.02-9.09) 1.48 (0.34-15.98) 1.34 (0.31-18.71) 0.79 (0.00-15.64) 
p value .0001* .0001* .0001* .0002* .0002* 
d 0.16 0.13 0.18 0.17 0.17 
TFPI 
(pg/mL) 
Pre Post Pre Post Pre Post Pre Post @Pre Post 
 38508 
(551-611413) 
45249 
(11529-78136) 
28553 
(396-70240)) 
44808 
(958-115657) 
33685  
(670-65600) 
37750 
(1016-72125) 
14223 
(710-73654) 
50017  
(521-114951) 
43281 
(710-73654) 
50588 
(1048-176515) 
∆ pre-post 10937 (1306-29927) 16057 (246-45417) 6745 (346-20744) 17194 (67-66507) 9272 (338-102862) 
p value <.0002* <.0002* <.0002* .0002* <.0002* 
d 0.63 0.77 0.46 1.03 0.61 
TAT 
(ng/mL) 
Pre Post Pre Post Pre Post Pre Post Pre Post 
 1.69 
(0.99-3.03) 
2.59 
(0.21-4.13) 
2.05 
(0.35-3.67) 
2.39 
(1.4-4.04) 
1.31 
(0.48-4.29) 
2.42 
(1.19-3.96) 
1.85 
(0.48-3.50) 
2.92 
(0.50-4.60) 
1.37 
(0.49-4.28) 
2.16 
(1.30-4.40) 
∆ pre-post 0.34 (0.07-2.53) 0.41 (0.04-1.60) 0.76 (-0.76-2.7) 0.53 (0.00-1.93) 0.66 (0.09-2.50) 
p value <.0001* .0012* .0002* <.0001* .0002* 
d 0.83 0.52 0.71 0.68 0.80 
D-Dimer 
(ng/mL) 
Pre Post Pre Post Pre Post Pre Post Pre Post 
 73.1 
(0.0-2250.0) 
83.3 
(0.0-2653) 
52.0 
(0.0-1175.0) 
137.3 
(1.9-1289.0) 
47.5 
(0.0-1027.0) 
128.6 
(0.0-9292.0) 
29.7 
(0.0-1202.0) 
123.1 
(0.0-2666.0) 
64.2 
(0.0-1434.0) 
121.1 
(0.0-593.9) 
∆ pre-post 
p value 
d 
14.1 (-59.6-402.4) 
<.0001* 
0.12 
85.3 (1.3-884.1) 
<.0001* 
0.39 
51.4 (-20.6-9199.0) 
.001* 
0.43 
86.5 (-37.5-1464.0) 
.0001* 
0.39 
46.5 (-840.4-210.5) 
.0003* 
0.38 
TF:TFPI ratio 
(x102) 
PRE 
 
0.011 
(0.000-0.282) 
POST 
 
0.012 
(0.000-0.209) 
PRE 
 
0.009 
(0.000-1.156) 
POST 
 
0.007 
(0.000-0.152) 
PRE 
 
0.005 
(0.0000-0.264) 
POST 
 
0.008 
0.001-0.138) 
PRE 
 
0.004 
(0.000-0.719) 
POST 
 
0.004 
(0.000-0.135) 
PRE 
 
0.000 
(0.000-
0.151) 
POST 
 
0.003 
(0.000-0.134) 
           
n=13 TFPI and TF to TFPI ratio due to removal of outliers
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5.6 Discussion 
 
The current study aimed to investigate acute coagulation responses to short-duration 
high-intensity exercise in a well-trained athletic population, whilst also comparing the 
responses to exercise performed at several times of the day. The present study is the 
first, to our knowledge, to investigate diurnal variation in coagulation responses within 
a well-trained athletic population; with acute coagulation, activation observed 
regardless of the time of day exercise was performed, as demonstrated by significant 
increases in post-exercise concentrations of TAT complexes and D-Dimer. 
Additionally, the results of this investigation also show a time of day response within 
the pre-exercise measure of TF and TFPI only.  
Although activation of blood coagulation as a result of increased blood 
hypercoagulability post-exercise has been well established [43, 167], the degree of 
coagulation activation has been demonstrated to be dependent upon numerous factors, 
with exercise duration and intensity shown to play a key role [40, 49, 50, 166]. Within 
the present study, when well-trained male cyclists completed a short duration 4km 
cycling TT, we observed a significant increase in the plasma concentration of TAT 
complexes (Table 5.3), conflicting the findings of previous studies [18, 51]. Indeed, 
previous research by Hilberg and associates [18, 51] in which short duration (90 s) 
maximal cycling and exhaustive incremental cycling exercise (mean 19.4 ± 3.4 min) 
completed by healthy male subjects, demonstrated no significant increases (p>0.05) 
in TAT complexes post exercise, when compared to baseline measures (1.56 ± 0.58 to 
1.54 ± 0.46 µg/l and 1.19 ± 0.22 to 1.45 ± 0.42 µg/l , respectively). In contrast to the 
findings of Hilberg et al. [18, 51] and comparable to the findings of the present study, 
a significant increase (p<0.01) in post-exercise TAT complexes was observed by 
Dufaux et al. [19] following a maximal incremental test in moderately trained males; 
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however, the mean duration of the protocol was unreported. This increase in TAT 
complexes may be due to the exhaustive nature of the exercise protocol, with 
exhaustive exercise well demonstrated to activate blood coagulation [167]. Indeed, 
when completing longer duration (1 h) running at intensities ranging from 68%VO2max 
to 83%VO2max [11], increased TAT complexes were reported to occur at the higher 
intensity only (p<0.05), suggesting that exercise intensity influences thrombin 
generation. In addition to the intensity (84.7%VO2max) and mean RPE of 18.4 ± 1.4 
observed within the present study (Table 5.1), our findings suggest a 4km cycling TT 
to be a high-intensity, high effort bout of exercise, resulting in an increase in 
hypercoagulability as reflected by an increased TAT complexes post exercise. 
Despite no time of day effect observed within pre-exercise measures of TAT and TF 
to TFPI ratio, higher mean values for both pre- and post-exercise samples of TAT and 
TF to TFPI ratio (Table 5.3) were observed within the morning (0830-1130 h). In 
addition, a significant main effect for a time of day response was observed for TF 
(p=0.004) with higher values observed at 0830 h when compared to 1730 h, whilst 
plasma concentrations of TFPI were lower at 1730 h when compared to 2030 h (Table 
5.3). TF (expressed by endothelial cells and leukocytes[72]), is the primary activator 
of cell-mediated coagulation, and TFPI is the major physiological regulator of TF-
induced coagulation [41]. Taken together, higher TF, TAT and TF to TFPI ratio 
suggests an overall increase in coagulation activation. This may occur due to an 
upsurge in haemodynamic forces, increasing laminar shear stress [115], and exposing 
TF to the blood stream. The exposure of TF results in an increased concentration of 
TAT complexes [19, 54] and a greater potential for thrombin generation following 
short-duration high-intensity exercise when completed within the morning (0830 and 
1130 h) in well-trained male cyclists. Whilst not statistically different for TAT, this 
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data suggests that caution should be employed when prescribing short-duration high-
intensity exercise in the morning for “at risk athletes” (i.e. older athletes and/or athletes 
with genetic pre-dispositions to venous thrombosis formation) to reduce the potential 
for hypercoagulability leading to thrombotic events to occur. 
Activation of the coagulation system following short duration high-intensity exercise 
is accompanied by simultaneous activation of fibrinolysis [42, 98, 116, 175, 272]. 
Similar to the findings of elevated D-Dimer concentrations (p<0.01) following 
moderate intensity exercise as reported by Molz et al. [14], significant elevations in 
post-exercise concentrations of D-Dimer (an in vivo marker of fibrin degradation) 
were reported within the present study following all five 4km cycling time trials (0830-
2030 h) (Table 5.3). When investigating the activation of the fibrinolytic system in 
response to exercise, previous studies [6, 9, 10, 37] have failed to disclose the time of 
day in which the exercise protocols were conducted, thus time of day effects on post-
exercise markers are rarely reported. The findings of the present study demonstrates 
that when completing a short-duration high-intensity TT at 0830, 1130, 1430, 1730 
and 2030 h, a time of day influence is present in the post-exercise activation of the 
fibrinolytic system occurs regardless of the time of day, corresponding with the 
reported increase in the activation of the coagulation system. 
Diurnal variations within markers of coagulation and fibrinolysis at rest have been 
reported previously, with increased hypercoagulability and hypofibrinolysis observed 
between morning and noon when compared with other times of the day [7, 25-27, 31, 
45, 188, 190]. In contrast to previous studies [7, 31, 273], we observed no significant 
time of day effects in pre-exercise markers of TAT spanning from 0830-2030 h; 
however, a main effect for time of day responses was observed for TF and TFPI (Table 
5.3). When investigating healthy men and women in the morning (0700-1000 h) and 
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afternoon (1500-2100 h), an absence of diurnal variations within TAT, TF and D-
Dimer are not unusual and have been previously reported by Jafri et al. [190] and 
Deguchi et al. [136]. Unlike TF, TAT and D-Dimer, diurnal variations of TFPI levels 
have been reported [31, 45]. Indeed, Pinotti et al. [31] observed a significant difference 
in TFPI activity with higher values in the morning (0800 h) when compared with the 
afternoon (1400 h) within healthy male participants. In contrast to the findings of 
Pinotti et al. [31], we observed a significant difference in pre-exercise TFPI activity, 
with the highest concentration observed at 2030 h and not in the morning (Table 5.3). 
This may be due to an increased concentration of TF pre-exercise at 2030 h; however, 
no significant differences observed within pre-exercise physiological measures (Table 
5.2) might explain why the increase in TF has occurred.  
Previous research has demonstrated morning surges to occur within blood pressure 
[115]. This places an increased laminar shear stress on the endothelium lining the 
blood vessels, which may account for an increase in TF, TFPI and TAT within the 
morning (Table 5.3), as demonstrated within the current study. We observed no 
significant differences in blood pressure (Table 5.2). Whilst blood pressure was not 
significantly different, pre-exercise tympanic temperature showed a significant time 
of day effect (p=0.0003), with significant responses observed between 0830 and 1130 
h when compared with 1430 and 1730 h (p<0.05) and between 1430, 1730 and 2030 
h TT (p<0.02) (Table 5.2). This is not uncommon, with core body temperature 
previously shown to peak between 1600 and 2000 h [266]. In an investigation into the 
effect of time of day on platelets, Aldemir et al. [7] reported higher evening core body 
temperature contributed to temperature-induced vasodilation, enhancing platelet 
release. However, the influence of body temperature on markers of coagulation and 
fibrinolysis is unknown and further research investigating this potential relationship is 
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therefore required. With elite and well-trained athletes required to compete in different 
environmental conditions for both national and international competitions, this 
potential relationship may have important implications for athlete’s overall health and 
well-being along with performance outcomes.  
The risk of athletes developing a venous thrombosis is relatively low (1 in 1000 people 
[44]) and is similar to that of the general population [33]. However, athletes are 
exposed to many acquired “athlete-specific” risk factors associated with 
hypercoagulability (i.e. long-haul travel, trauma, immobilisation after injury, 
haemoconcentration after exertion, and polycythaemia) [3] that may be enhanced 
when combined with a pre-existing conditions such as inheritable clotting disorders 
(i.e. Factor V Leiden or Prothrombin G20210A mutations) [32, 46, 47]. Whilst the 
results of the present study show acute activation of the coagulation and fibrinolytic 
systems regardless of time of day in well-trained cyclists, caution should be applied 
when prescribing short-duration, high-intensity exercise at different times of the day 
for “at risk athletes”, however, further research within these populations is therefore 
required. These includes the investigation of older athletes (such as master level 
athletes who may travel long haul to competitions) and particularly individuals with 
pre-existing acquired and/or genetic pre-dispositions to clotting. 
5.7 Conclusion 
In conclusion, a short-duration high-intensity exercise bout results in acute activation 
of the coagulation and fibrinolytic systems, regardless of the time of day the exercise 
task is performed, within this selected group of participants only. A time of day effect 
was observed within the pre-exercise measure of TF at 0830 h and TFPI at 2030 h, but 
not within other markers of coagulation (TAT) and fibrinolysis (D-Dimer); however, 
higher mean values for TAT were observed at 1130 h. Therefore, even in a well- 
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trained population, caution should be applied when completing short-duration high-
intensity exercise between 0830-1130 h. Whether these findings are applicable for 
older athletes, clinical populations and those with acquired or genetic predisposition 
to clotting requires further investigation.  
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Chapter 6: Compression socks and the effects on coagulation and fibrinolytic 
activation during marathon running 
 
This manuscript has been accepted as an original research investigation in the 
European Journal of Applied Physiology (Accepted June 30th, 2018) and will appear 
in the literature as: 
Zadow, E.K., Adams, M.J., Wu, S.S.X, Kitic, C.M., Singh, I., Kundur, A., Bost, N., 
Johnston, A.N.B., Crilly, J., Bulmer, A.C., Halson, S.L. & Fell. J.W. “Compressions 
socks and the effects on coagulation and fibrinolytic activation during marathon 
running”. European Journal of Applied Physiology. 
Journal Impact Factor: 2.130 
 
Rationale 
 
Whilst study three (chapter four) demonstrated the ability of a short-duration high-
intensity exercise bout to activate coagulation, the ability to attenuate haemostatic 
responses within exercise has rarely been investigated. With marathon running well 
demonstrated to activate the haemostatic system and marathons typically completed 
in the morning (when hypercoagulability is at its greatest, as observed in study three), 
study four provided a convenient opportunity to test whether the use of compression 
clothing would reduce haemostatic activation in athletes. 
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6.1 Abstract 
Purpose: Compression socks are frequently used in the treatment and prevention of 
lower-limb pathologies; however, when combined with endurance-based exercise, the 
impact of compression socks on haemostatic activation remains unclear. Objectives: 
To investigate the effect of wearing compression socks on coagulation and fibrinolysis 
following a marathon. Methods: Sixty-seven participants (43 males (mean±SD: age: 
46.7±10.3 y) and 24 females (age: 40.0±11.0 y), were allocated into a compression 
(SOCK, n= 34) or a control (CONTROL, n=33) group. Venous blood samples were 
obtained 24h prior to and immediately post-marathon, and were analysed for thrombin 
anti-thrombin complex (TAT), tissue factor (TF), tissue factor pathway inhibitor 
(TFPI), and D-Dimer. Results: Compression significantly attenuated the post-exercise 
increase in D-Dimer compared to the control group (median (range) SOCK: +9.02, -
0.34 to 60.7 ng/mL, CONTROL: +25.48, (0.95 to 73.24 ng/mL). TF increased 
following the marathon run (median (range), SOCK: +1.19 (-7.47 to 9.11) pg/mL, 
CONTROL: +3.47, (-5.01 to 38.56) pg/mL in all runners. No significant post-exercise 
changes were observed for TAT and TFPI (p>0.05). Conclusions: Whilst activation 
of coagulation and fibrinolysis was apparent in all runners post-marathon, wearing 
compression socks was shown to reduce fibrinolytic activity, as demonstrated by 
lower D-Dimer concentrations. Compression may reduce exercise-associated 
haemostatic activation when completing prolonged exercise.  
 
Key words: Compression, d-dimer, tissue factor, tissue factor pathway inhibitor, 
thrombin-anithrombin complexes  
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6.2 Introduction 
Whilst physical activity and exercise appear to protect against thromboembolic 
episodes [40], exercise has long been recognised to induce transient activation in blood 
coagulation [10], platelet aggregation [12] and fibrinolytic activity [14], increasing the 
potential for deep vein thrombosis (DVT). The degree to which these systems are 
activated are often dependent upon the duration and intensity of the exercise, together 
with the study population investigated [15]. Evidence for the activation of the 
coagulation system following strenuous endurance exercise (i.e., marathon distance, 
42.2 kilometres) are reflected by specific markers of in-vivo thrombin generation such 
as thrombin anti-thrombin complexes (TAT) [10, 152] and prothrombin fragment 1+2 
[20, 94, 95]. TAT has been widely used as a valuable marker of activated blood 
coagulation during exercise, with significant increases in TAT reported immediately 
post-marathon [10, 95, 152], and following endurance exercise of shorter duration [50, 
94]. 
The fibrinolytic system is activated in unison with the coagulation system, presumably 
to preserve haemostatic balance [152]. This has been demonstrated by elevated 
measures of D-Dimer, a marker of in-vivo fibrin degradation, in addition to TAT, 
immediately upon marathon completion [10, 16]. However, the regulation and 
activation of haemostasis is complex and involves many factors other than TAT and 
D-Dimer. 
Whilst 1 in 1000 athletes will experience a post-exercise thromboembolic event [2, 
44], exercise-induced haemostatic activation may not be detrimental to most 
participants. However, the risk of an adverse event  is compounded by underlying and 
acquired risk factors associated with  hypercoagulability such as oral contraceptive 
use and long-haul travel, and dehydration [274]. Several case studies documenting the 
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occurrence of deep vein thrombosis  in otherwise healthy athletes following endurance 
based exercise have been documented [2, 38], highlighting the potentially detrimental 
effects of athletic training that may in the worst case scenario, result in a fatality.  
Compression socks are frequently used for the treatment and prevention of lower 
extremity clinical pathologies, including DVT, with compression socks shown to 
maintain the coagulation and fibrinolytic balance through increases in both venous and 
arterial blood flow [223]. The benefits of clinical compression garments have been 
inferred by the sporting clothing industry, and their use continues to grow in popularity 
due to their proposed enhancement of exercise performance and recovery [227, 228], 
despite a lack of clear scientific evidence of their effects on physiology. The impact 
of compression socks on haemostatic activation during endurance exercise has rarely 
been investigated, with only one previous study with a small sample size (n=20) 
reporting a decrease in overall haemostatic activation following a marathon when 
compression socks were worn [24]. It was hypothesized that when worn during a 
marathon, compression socks will reduce haemostatic activation.The aim of this study 
was to investigate the effect of compression socks on exercise-induced activation of 
the coagulation and fibrinolytic systems when worn during prolonged endurance 
exercise.  
6.3 Methods 
6.3.1 Participants  
Forty-three males (mean ± SD: age: 46.7 ± 10.3 y, height: 1.80 ± 0.1 m, body mass: 
77.7 ± 13.1 kg) and 24 females (age: 40.0 ± 11.0 y, height: 1.60 ± 0.1 m, body mass: 
58.0 ± 9.3 kg) were recruited to participate in the study through an email sent to all 
registered marathon runners (n=6216), with runners also recruited the day before the 
2016 Gold Coast Marathon (Gold Coast, Queensland, Australia) at the Gold Coast 
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Exhibition Centre. All consenting study participants (recruited via email and the day 
prior to the marathon) were screened by the primary researcher to ensure all 
participants were non-smokers, with no known history or clinical signs of metabolic 
conditions or coagulation disorders. Participants were excluded from the study if they 
had a previous history of thromboembolism. Female participants were excluded if they 
were taking the oral contraceptive pill, with all participants required to be illness and 
injury free, whilst avoiding the use of anticoagulant (i.e., aspirin, heparin, and 
warfarin) and non-steroidal anti-inflammatory medications for at least two weeks 
before, and throughout the testing period. Furthermore, participants were to avoid the 
use of all types of compression garments whilst travelling to the Gold Coast and in the 
lead up to the marathon itself. Participants were provided with a written description of 
the risks and benefits of the study and provided signed informed consent prior to their 
inclusion within the study. Details that may disclose the identity of the subjects have 
been omitted. All human studies have been approved by the appropriate ethics 
committee and have therefore been performed in accordance with the ethical standards 
laid down in the 1964 Declaration of Helsinki.  
6.3.2 Study Overview 
This was a randomised control trial investigating the effects of compression socks on 
strenuous exercise-induced activation of coagulation and fibrinolysis. All participants 
recruited were randomly assigned using a computer generated code to either the 
control (CONTROL, 21 males and 12 females (n=33)) or the compression sock 
(SOCK, 22 males and 12 females (n=34)) group. Foot-to-knee compression socks 
were provided by 2XU (24/7 Compression Socks, 2XU North America LLC, 
Carlsbad, CA, USA) to participants within the SOCK group, with sock size dependent 
upon shoe size and self-reported lower leg circumference.  
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6.3.3 Marathon Characteristics 
The marathon began at 07:30 h and was completed on a flat terrain with no elevation, 
at an average temperature of 16.4 ± 4.3OC and 69.0 ± 20.4% relative humidity. 
6.3.4(1) PRE-Marathon Venous Blood Sample 
Twenty-four hours prior to the marathon, all participants reported to the Gold Coast 
Exhibition Centre between 10:00-14:00 h for the collection of a PRE-marathon venous 
blood sample. During this visit, participants within the SOCK group received their 
compression socks and were instructed to wear their socks to the marathon, during the 
marathon and following the marathon until the POST-marathon blood draw 
(immediately POST: ~10-20 min). Participants within the CONTROL group were 
instructed to refrain from wearing any type of compression garment prior to the first 
venous blood sample (PRE-marathon), and throughout the duration of the marathon 
and the recovery period (i.e. marathon completion until post-marathon venous blood 
sample collection).  
6.3.4(2) Post-Marathon Venous Blood Sample  
A second venous blood sample was collected immediately within 10-20 min upon 
completion of the marathon (POST) in a medical tent, less than 100m from the finish 
line between ~10:00- 14:00 h.  
6.3.5 Blood Sample Collection 
Blood samples were drawn without stasis by venepuncture from the antecubital fossa 
from participants in a supine position. Blood samples for determining markers of 
coagulation and fibrinolysis were collected into 3.8% sodium citrate Vacutainers® 
(Becton Dickinson, New Jersey, USA). Within four hours of collection, citrated blood 
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samples were centrifuged at room temperature for 15 min at 2,000 g. Plasma 
supernatant samples were aliquoted and stored at -80oC until required for analysis.  
6.3.6 Blood Sample Analyses 
Tissue factor (TF), tissue factor pathway inhibitor (TFPI), thrombin anti-thrombin 
complexes (TAT) and D-Dimer were determined by enzyme-linked immunosorbent 
assay (ELISA) kits (Abcam, Melbourne, Australia) according to manufacturer’s 
instructions. Inter-assay coefficients of variation were below 6.2% and Intra-assay 
coefficients were below 5.9%. The minmal detectable dose for TF, TFPI, TAT and D-
Dimer were ~4pg/mL, 14.9pg/mL, ~0.5ng/mL and 71pg/mL, respectively. All 
samples were measured in duplicate. Absorbance for each marker was read using an 
infinite 200 PRO Spectrophotometer (Tecan Trading, AG, Männedorf, Switzerland). 
Changes in plasma volume were calculated for TF, TFPI, TAT and D-Dimer as 
described in the literature according to the method of Dill and Costill [275]. 
6.3.7 Statistical Analyses 
A Shapiro-Wilk test was used to assess normality of distribution, with all markers of 
haemostasis (TAT, TF, TFPI and D-Dimer) non-parametrically distributed. All 
statistical analyses were performed using GraphPad Prism version 5.03 for Windows 
(GraphPad software, La Jolla California, USA). Baseline participant characteristics 
(age, weight, BMI, training volume), overall marathon finishing time, differences 
between groups in PRE- and POST-marathon measures of haemostasis (TAT, TF, 
TFPI and D-Dimer), along with differences in the magnitude of change (PRE-POST), 
were analysed using a Mann-Whitney U Test. Cohen’s effect sizes (d) were calculated 
from PRE-POST blood values within and between conditions (CONTROL vs SOCK), 
calculated as dNP = Z/√N where NP is non-parametric, Z is the z-score calculated from 
Wilcoxon Signed Rank test and N is the number of participants, and interpreted as 
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small <0.2, moderate >0.5 or large >0.8 [271]. Results are presented as median 
(range), unless otherwise stated. 
6.4 Results 
Participant Characteristics 
There were no significant differences in baseline characteristics between groups for 
age, mass, body mass index (BMI) and training volume (h.wk1) (all p>0.05) (Table 6. 
1).  
Coagulation and Fibrinolytic Responses 
PRE- and POST- marathon coagulation and fibrinolytic results for CONTROL and 
SOCK groups are presented in Table 6.2. Plasma concentrations of TAT, TF, TFPI 
and D-Dimer did not differ between groups at baseline (p=0.328, p=0.063, p=0.278 
and p=0.807, respectively). Significant increases in PRE- to POST-marathon 
measures of TF and D-Dimer were observed in both the CONTROL (p=0.001 and 
p=0.001, respectively) and SOCK group (p=0.040 and p=0.001, respectively), whilst 
no significant changes in TAT and TFPI were observed (all p>0.27) (Table 6.2). The 
magnitude of post-exercise increase in D-Dimer was smaller in the SOCK group 
(9.03,-0.34 to 60.8 ng/mL) compared to the CONTROL group (25.5, 0.95 to 73.2 
ng/mL; p=0.008, dNP=0.43) (Figure 6.1). The difference between the CONTROL and 
SOCK groups in the magnitude of post-exercise change was small for TAT, TFPI and 
TF (all dNP <0.24) (Table 6.2). 
Marathon Finish Time 
No significant differences (p=0.106) were observed in official marathon finishing 
times when comparing the SOCK and CONTROL groups (4:29:23 ± 1:17:19 and 
4:27:26± 1:16:15, respectively). 
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6.5 Discussion 
The aim of this study was to investigate the effect of compression socks on strenuous 
exercise-induced activation of the coagulation and fibrinolytic systems of haemostasis 
following a marathon. Wearing compression socks during a marathon attenuated the 
post-exercise increase in D-Dimer concentration. In addition, acute activation of 
coagulation and fibrinolysis were observed immediately POST-marathon, as reflected 
by significant increases in plasma concentrations of TF and D-Dimer, regardless of 
whether SOCKS were worn.  
Within the present study, and in line with previous research [20, 152, 180], marathon 
running was associated with elevated concentrations of D-Dimer. Indeed, our findings 
are similar to those of Siegel et al. [180] in which a significant increase in post-
marathon concentrations of D-Dimer (177 ± 137 to 529 ± 279 ng/mL; p<0.001) were 
observed within 4 h of marathon completion. When worn during a marathon, 
compression socks were shown to reduce the magnitude of increase in POST-
marathon concentrations of D-Dimer (Figure 6.1), contrasting the findings of Zaleski 
et al. [24] in which concentrations of D-Dimer did not differ when compression socks 
were worn versus not worn at any given time point (i.e. pre-, post- +24 h post- 
marathon). However, Zaleksi et al. [24] failed to present the pre- and post-marathon 
data for D-Dimer itself; therefore, these findings should be interpreted with caution. 
Compression socks and pneumatic calf compression devices appear to increase 
fibrinolytic activity [22] through inhibiting components associated with Virchow’s 
Triad (i.e. venous stasis, hypercoagulability and vessel wall damage), ultimately 
reducing the risk of thrombosis formation. Indeed, in a case study by Zaleski et al. 
[229] plasma concentrations of D-Dimer were reported to be ~30% lower in a single 
runner with a genetic pre-disposition to blood clotting (i.e. F5 1691 A risk allele, 
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Factor V Leiden mutation) when compression socks were worn versus not worn over 
two marathon runs. Therefore, when worn during a marathon, compression socks may 
reduce the potential for clot formation, as indicated by reduced D-Dimer (clot 
fibrinolysis) formation. However, research on the use of compression socks to 
maintain the balance of both the coagulation and fibrinolytic systems during prolonged 
strenuous exercise is limited; therefore, further investigations are required to verify 
the findings of the present study and those of Zaleski et al. [24, 229]   
In agreement with previous research [94, 95, 152], simultaneous activation of the 
coagulation system was observed in all participants as indicated by significant 
increases in TF (the primary activator of the TF-coagulation pathway [272]), 
regardless of whether compression socks were worn (Table 6.2). The present findings 
are in contrast to those of Weiss et al. [77] who failed to demonstrate a significant 
increase in post-exercise concentrations of TF (205 ± 43 to 218 ± 47 pg/mL; p>0.05, 
d=0.29) albeit in a shorter duration (1 h) maximal run, suggesting the duration of the 
exercise itself may be a factor in exercise-induced activation of coagulation. In 
addition, when comparing the magnitude of change between the CONTROL and 
SOCK group, a non-significant difference with a small ES was observed within 
plasma concentrations of TF (Figure 6.1), suggesting compression socks do not 
“dampen” the activation of the coagulation system when completing a marathon run. 
However, in order to confirm these findings, further research investigating a more 
extensive range of well-known markers of coagulation activation are therefore 
required.  
When combined with muscular activity, compression socks reduce venous stasis, 
whilst increasing the volume and velocity of blood flow in the deep venous system, 
resulting in decreased blood pooling in the distal calf veins (i.e. posterior tibial vein, 
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anterior tibial vein, and peroneal vein), reducing haemostatic activation and increasing 
fibrinolytic potential [223, 229]. Indeed, with a greater range of participants wearing 
compression socks (n=34) versus a control group (n=33) within the present study, our 
findings are in contrast with those of Zaleski et al. [24], who reported post-marathon 
plasma concentrations of TAT to be 17% lower (p=0.07) in runners assigned to the 
sock group when compared to the control group. In addition, when worn during the 
2013 Hartford marathon, compression socks were shown to reduce the magnitude of 
change in post-marathon concentrations of TAT (d= 3.00). Several published studies 
have demonstrated significant post-marathon increases in plasma concentrations of 
TAT [10, 95, 152]; however, this was not the case within the present study despite 
similar runner characteristics (age, training volume and marathon finish times), blood 
collection and sample analyses procedures. The absence of a post-exercise increase in 
TAT within the CONTROL and SOCK groups is unusual, however our findings are 
similar to those of Parker et al. [152] in which no significant increases in TAT were 
observed post-marathon within a control group, when investigating the effects of 
travel and marathon running combined. However, Parker et al. [152] found a 
significant increase in TAT was observed after the marathon in the runners that had 
travelled more than four hours to compete (TRAVEL: 5.0 ± 4.0 to 12.9 ± 15.6 µg/L 
vs CONTROL: 4.0 ± 1.2 to 6.1 ± 1.2 µg/L; p=0.04, d=0.81). Therefore the impact of 
air-travel in combination with endurance-based exercise, is of particular interest, with 
an upsurge in national and international participation in varying duration endurance-
based events (i.e. triathlons, marathons and Iron Man competitions), highlighting the 
need for further research, especially with an aging population.  
When completing prolonged strenuous exercise (i.e. 42.2km marathon), runners are 
exposed to ‘running-specific’ risk factors increasing the risk for venous thrombosis 
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generation through repetitive micro-trauma resulting in foot strike haemolysis, 
dehydration and endothelial damage [274, 276]. Increased thrombosis risk  may be a 
direct result of an upsurge in haemodynamic forces, increasing laminar shear stress 
[115], and exposing TF to the blood stream, initiating the coagulation cascade and 
resulting in an increased concentration of TAT complexes [54]. Indeed, an increase in 
markers indicative of tendency for coagulation activation following the marathon was 
observed in both the CONTROL and SOCK group, as demonstrated by the relatively 
similar effect sizes (CONTROL, small to moderate and SOCK, small to large, 
respectively) for plasma concentrations of TF. Therefore, within the present study, 
coagulation and fibrinolytic activation was observed within both the CONTROL and 
SOCK group, with lowered activation observed within the runners assigned to the 
SOCK group.  
6.6 Practical Applications 
Whilst compression socks are frequently used within the sporting industry to enhance 
exercise performance and aid recovery, the use of compression socks within 
endurance-based exercise, may reduce the potential for thrombosis development. 
When compression socks are not worn when completing a marathon run, our results 
demonstrate an increase in plasma concentrations of D-Dimer, suggesting an increased 
potential for thrombin generation. Therefore, the use of compression socks when 
completing a marathon run may benefit endurance-based athletes. To date, 
investigations into the use of compression socks and haemostatic activation in 
prolonged strenuous exercise is limited, thus further research is required to confirm 
the findings of the present study and those of Zaleski et al. [24]  
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6.7 Limitations 
This study was not without limitations. Whilst participants were excluded from 
participating if they had a known and previous history of thromboembolism, 
participants were not screened for genetic mutations for thrombophilia including 
Factor V Leiden mutation. The influence of travel on markers of haemostasis were not 
controlled for within the present investigation, however, previous investigations have 
identified that air travel augments haemostatic activation immediately following a 
marathon [102, 152]. 
6.8 Conclusions 
Whilst activation of coagulation and fibrinolysis was apparent in all runners following 
the marathon, our results suggest an increase in fibrinolytic activity as reflected by an 
increase in D-Dimer, when compression socks were not worn throughout a marathon 
run. Therefore, compression socks may assist in the reduction of exercise-associated 
coagulation and fibrinolytic activation when completing prolonged strenuous exercise, 
however, further research is required make firm conclusions regarding the beneficial 
effects of compression socks.  
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Variable CONTROL (n=33) SOCK (n=34) P value 
Age (years) 45.2 ±11.5 43.5 ±10.5 0.662 
Weight (kilograms) 69.9 ±15.6 71.4 ±14.9 0.512 
Body mass index (kg.m-2) 23.2 ±3.5 23.8 ±3.1 0.379 
Training volume 
(hour:min:wk-1) 
5:02 ±2:13 4:39 ±1:58 0.147 
Official finishing time 
(hour:min:secs) 
4:27:26 ± 1:16:15 4:29:23 ±1:17:19 0.106 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.1 Mean (± SD) baseline measures of physical and performance characteristics 
for the SOCK versus CONTROL participants. 
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Table 6.2 Thrombin Anti-Thrombin Complex (TAT), Tissue Factor (TF), Tissue Factor Pathway Inhibitor (TFPI), D-Dimer measured 
pre- and post-marathon for the CONTROL and SOCK group. Data are presented as median (range). * significant difference between 
pre- and post-marathon values within group. dNP = effect size. 
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Figure 6.1 Median (range) magnitude of change (∆) between PRE-POST measures of 
a) Thrombin Anti-Thrombin complexes (TAT), b) Tissue Factor (TF), c) Tissue Factor 
Pathway Inhibitor (TFPI), and d) D-Dimer for the CONTROL and SOCK group. 
dNP=effect size.  
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Chapter Seven: Discussion 
 
The overarching aim of this thesis was to investigate factors that may influence the 
overall haemostatic response, including activation of the coagulation and fibrinolytic 
systems, in trained and well-trained athletes. The activation of these systems may lead 
to the development of VTE. Yet known risk factors for VTE specific to an athletic 
population have previously been examined in untrained healthy populations only [7-
9]. As such, results from these studies may not be directly applicable to an athletic 
population. To help further understand these risk factors and their influence on 
haemostasis in trained athletes, four studies were undertaken during this PhD. Better 
understanding of these factors may reduce the potential for the onset and development 
of VTE, resulting in the maintenance of overall athlete health and well-being whilst 
minimising detrimental performance outcomes.  
The major outcomes from this thesis are:  
i) the KICKR is a valid ergometer for measuring cycling power output,  
ii) a 4km cycling TT, when completed on the KICKR, is a reliable 
performance test for trained cyclists,  
iii) a short-duration high-intensity TT significantly activates the coagulation 
and fibrinolytic systems in well-trained cyclists, regardless of the time of 
day,  
iv) TF and TFPI only are influenced by time of day, suggesting an increased 
activation of coagulation to occur in the morning, and  
v) when worn during a marathon, compression socks reduce exercise-
associated fibrinolytic activity as reflected by lower D-Dimer 
concentrations.  
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Study one (chapter three) is the first investigation to assess the validity of power output 
of the Wahoo KICKR Power Trainer (KICKR: a cycling ergometer enabling cyclists 
to use their own bicycles) using a dynamic calibration rig (CALRIG). Ergometer errors 
of <2% are required to detect meaningful changes in performance [237, 258] with the 
KICKR demonstrated to provide valid measures of power output, possessing a small 
mean bias and narrow limits of agreement of (-1.1% (95%LoA: -3.6 to 1.4%)) when 
assessed over 250-700W at 80-120rpm. 
These findings for the KICKR are consistent with the ergometer errors of the Velotron 
and Schoberer Rad Messetechnik (SRM) power meters (<1%) when compared with a 
CALRIG [234]. When cyclists’ own bicycles are used, the KICKR possesses a smaller 
ergometer error than the PowerTap (1.8%) [277], the Axiom PowerTrainer (2.2%) 
[278], the SRM (2.3%) [239] and the Ergomo Pro (2.3-4.1%) [279], respectively. 
Conversely, at the lower and higher ranges of power output (100-200W and 750-
999W), larger mean biases outside of the acceptable range for ergometer error [237] 
were observed, with the findings for the KICKR similar to those of Gardener and 
colleagues [239] for other power measurement methods.  
To investigate the scientific rigor of the KICKR for performance testing, study two 
(chapter four) examined the reliability of a 4km cycling TT when performed on the 
KICKR, using trained cyclists. The 4km TT was proven to be highly reliable for the 
measurement of power output only, with a coefficient of variation (CV) of 3.4%, 
falling below the required CV of 5% [243]. Additionally, the average power in which 
the TTs were performed (344 ± 41W) fell within the validated range of power when 
performed on the KICKR (250-700W (study one, chapter three)). Thus, the 4km TT 
was demonstrated to be a reliable measure of performance when performed on the 
KICKR and suitable for research purposes implemented within study three. 
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Study three (chapter five) employed both the KICKR and a 4km TT to investigate 
acute changes in the activation of coagulation and fibrinolysis following short-
duration high-intensity exercise at different times of the day (0830, 1130, 1430, 1730 
and 2030 h) in well-trained cyclists. Activation of the coagulation system as 
demonstrated by significant post-exercise increases in TAT complexes have been 
reported in long duration exercise bouts (>20 min) [19, 50]. However, a lack of 
consensus and published research exists as to whether coagulation is activated in 
shorter duration exercise bouts of less than 20 min. When completing a 4km cycling 
TT (mean duration 7.09 ± 0.45 min) using well-trained cyclists, significant activation 
of the coagulation system (as demonstrated by higher post-exercise TAT 
concentrations) was observed.   
The elevated post-exercise TAT in study three is in contrast to previous research 
investigating coagulation activation via plasma concentrations of TAT in healthy 
trained populations undertaking exercise bouts of less than 20 minutes [18, 51] 
(Figure 7.1). Hilberg and associates found no significant increases (p>0.05) in TAT 
when compared to baseline measures upon immediate completion of 90 s maximal 
isokinetic cycling (1.56 ± 0.58 to 1.54 ± 0.46 µg/l; p>0.05) [18] or a maximal 
incremental cycling test of mean duration: 19.4 ± 3.4 min (1.30 ± 0.20 to 1.45 ± 0.42 
µg/l) [51]. The absence of a post-exercise increase in TAT complexes may be due to 
factors such as the training status of the individuals investigated, with training status 
demonstrated to attenuate post-exercise increases in TAT [280]. However, with 
relatively similar VO2max observed within study three (60.3 ± 8.1ml.kg-1.min-1) and the 
studies of Hilberg and associates (56.0 ± 8.1ml.kg-1.min-1) [18] and (59.1 ± 6.5ml.kg-
1.min-1) [51], this is unlikely to account for the significant increase in post-exercise 
TAT observed when completing a 4km TT. These differences might better be 
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explained by the amount of time spent above a critical exercise intensity for activation 
of coagulation pathways. Indeed, when completing longer-duration (1 h) running at 
intensities ranging from 68%VO2max to 83%VO2max [11], higher concentrations of 
TAT were observed at 83%VO2max only (p<0.05), suggesting the length of time spent 
at a sustained higher intensity influences thrombin generation. Similarly, Hilberg and 
associates [281] found a 33% increase in post-exercise thrombin generation (as 
reflected by TAT complexes) following 60 to 90 min of sustained cycling at 90% 
individual anaerobic threshold.  
The findings within the studies of Weiss et al. [11] and Hilberg et al. [281] highlight 
the importance of not only the intensity in which exercise is performed, but the 
duration that the intensity is maintained, as key factors influencing coagulation 
activation. Interestingly, whilst Hilberg et al [51] and Dufaux et al. [19] implemented 
similar exercise protocols (maximal incremental cycling tests), Dufaux and associates 
[19] reported significantly higher concentrations of TAT after the exercise. These 
differing findings may be a result of a longer duration maximal exercise test (~23 min) 
in the study of Dufaux and colleagues [19], with participants possibly spending a 
greater amount of time at higher exercise intensities (~5-10 min) than the participants 
in the study by Hilberg et al. [51]. The post-exercise increase in TAT complexes 
observed within study three after approximately seven minutes of intense exercise 
(85%VO2max) is comparable to the findings of Dufaux and associates [19]. Therefore, 
in order to observe exercise-induced coagulation activation, exercise duration may 
require exercise intesnities between or above 83-85%VO2max and approaching seven 
minutes duration to elicit significant changes in TAT. The findings of study three 
suggests that a 4km TT is both long enough and when performed at an intensity high 
enough, results in activation of the coagulation system.  
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It is well established that haemostatic markers are subject to circadian rhythms when 
measured under resting conditions, with hypercoagulability and hypofibrinolysis 
observed to occur between 0600 and 1200 h [7, 25, 26, 188, 190]. However, this has 
only been investigated in untrained and sedentary individuals. Therefore, study three 
aimed to investigate if time of day effects were present within pre-exercise 
concentrations of TAT, TF, TFPI and D-Dimer in well-trained cyclists. Despite no 
statistically significant time of day effects observed for TAT or D-Dimer (p>0.2), a 
significant main effect for time of day was observed for TF (p=0.004), and TFPI 
(p=0.031). Study three is the first to my knowledge to demonstrate a time of day effect 
in TF (in the absence of exercise) (Figure 7.1), and may be a direct result of an upsurge 
in haemodynamic forces [115], exposing TF to the blood stream and promoting 
thrombin generation at 0830 h, supporting the notion of morning hypercoagulability. 
Diurnal variations of TFPI levels have been previously reported [31, 45], with higher 
values observed in the morning (0800 h), when compared to the afternoon (1400 h) in 
healthy male participants [31]. The findings of study three are in contrast to those of 
Pinotti et al. [31], with study three reporting higher TFPI concentrations observed at 
2030 h (median (range): 43,281 (710 to 73,654 pg/mL)) compared to 0830 h (median 
(range): 38,508 (551 to 61,143 pg/mL)). The higher pre-exercise TFPI at 2030 h in 
study three may be linked to the higher (but not significantly) pre-exercise 
concentrations of TF and D-Dimer also observed at 2030 h. Whilst the majority of 
thromboembolic events peak within the morning [28], a secondary peak has been 
reported to occur between 1800 to 2000 h [282], which may provide a potential 
explanation for the higher concentrations of TFPI, TF and D-Dimer at 2030 h. 
Additionally, Iversen et al. [26] previously demonstrated D-Dimer to peak at both 
0900 and 2300 h (when measured under resting conditions), which may have resulted 
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in the increased concentration of TFPI as a compensatory mechanism to the increased 
concentrations of TF and D-Dimer. However, this remains speculative with no 
conclusive evidence. Therefore, further investigations are required to confirm a 
secondary peak in coagulation and fibrinolytic activation within a well-trained 
population. 
The findings of study three provide valuable insight into haemostatic responses within 
a well-trained population, when completing a short-duration, high-intensity bout of 
exercise. No time of day effects were observed for the exercise-induced activation of 
coagulation and fibrinolysis, with activation occurring to a similar magnitude 
regardless of the time of day exercise was performed (Figure 7.1). However, study 
three found a time of day effect within the pre-exercise measures of TF and TFPI, but 
not within the markers of TAT and D-Dimer, a novel finding for the markers and study 
population assessed (Figure 7.1). Whether these findings are applicable to older 
athletes and those with acquired or genetic predispositions to clotting remains unclear, 
highlighting the need for further examination.  
Whilst study three demonstrated the ability of a short-duration high-intensity exercise 
bout to activate coagulation, the ability to attenuate haemostatic responses to exercise 
bouts has rarely been investigated. Although compression socks are recommended to 
wear during long-haul travel to diminish the risk of VTE [36], whether compression 
socks reduce the activation of haemostasis when worn during exercise is relatively 
scarce [24, 283]. Therefore, study four (chapter six) aimed to investigate the effect of 
compression socks on the activation of haemostasis following a marathon run 
(42.2km).  
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Whilst frequently used within the sporting industry to enhance exercise performance 
and recovery, only a single study on the impact of compression socks on haemostatic 
activation during endurance-based exercise [24] has been published alongside a single 
case study [229]. When worn during a marathon run in study four, compression socks 
were shown to reduce the magnitude of increase in concentrations of D-Dimer, 
contrasting the findings of Zaleski and associates [24] (Figure 7.1), who found 
concentrations of D-Dimer did not differ between the sock wearing group versus the 
control group at any given time points (pre-, post-, +24 h post-marathon). The lack of 
significant difference observed for D-Dimer between the sock and control group may 
be due to the relatively small sample size (n=20 total (n=10 sock, n=10 control)) 
potentially masking the true response of D-Dimer to marathon running. Compression 
socks appear to decrease fibrinolytic activity [22] through the inhibition of 
components associated with Virchow’s Triad (i.e. reduced venous stasis, 
hypercoagulability and vessel wall damage), which may account for the attenuation of 
D-Dimer levels within runners assigned to the compression sock group. 
In a case study by Zaleski et al. [229], plasma concentrations of D-Dimer were 
reported to be ~30% lower in a runner with a genetic predisposition to blood clotting 
(F5 1691 A risk allele, Factor V Leiden mutation) when compression socks were worn 
versus not worn over two marathon runs. Similar to the findings of study four, when 
worn during a marathon compression socks may reduce the potential for clot formation 
as indicated by reduced D-Dimer formation (Figure 7.1). However, there is a paucity 
of research into the use of compression socks to maintain the balance of both the 
coagulation and fibrinolytic systems during prolonged strenuous exercise (Figure 
7.1), with further investigations required to confirm the findings of study four and 
those of Zaleski and associates [24, 229].  
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In agreement with previous research [94, 95, 152], study four demonstrated some 
activation of the coagulation system in all participants as indicated by significant 
increases in TF post-marathon [272], regardless of whether compression socks were 
worn. However, these findings for TF were not evident with regards to TAT 
complexes and in contrast to those of Zaleski et al. [24] who found a significant post-
marathon increase in TAT complexes, with average TAT concentrations reported to 
be lower and approaching significance (p=0.07) in runners wearing compression 
socks. The differences between study four and Zaleski et al. [24] for TAT may be 
linked to the interaction between intensity and duration (as proposed within study three 
as a key factor for thrombin generation) and the sample size investigated.  
The argument for an intensity and duration relationship may be supported by the 
differences in mean marathon finish times, with the runners in the study of Zaleski et 
al. [24] completing the marathon in an overall faster time of 4h 11min 38sec and 
therefore at a potentially higher exercise intensity, when compared to the finish time 
of 4h 28min 23 sec for participants in study four. Additionally, and as previously 
mentioned, the findings of Zaleski et al. [24] for TAT may be a type 1 error, due to 
the research potentially being underpowered as evident from the small sample size of 
only 20 participants. Based upon these findings, a standard marathon run does not 
elicit post-exercise increases in TAT complexes due to the low intensities marathons 
are typically completed at, with previous research within this field underpowered 
(Figure 7.1). Future research should investigate the relationship between TAT and 
overall intensity when undertaking marathon running.  
Alongside activation of the coagulation system, marathon running was also 
demonstrated to increase fibrinolytic activity. Therefore, this study has demonstrated 
that compression socks may assist in the reduction of exercise-associated fibrinolytic 
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activation when completing prolonged marathon running (Figure 7.1). However, 
further research is required to make firm conclusions regarding the beneficial effects 
of compression socks on haemostatic responses, especially in athletes who are 
travelling long distances to the event, older athletes and those with acquired or genetic 
predispositions to hypercoagulability.  
7.1. Directions for future research 
Identified as a valid cycling ergometer (study one) and a reliable measure of 
performance (study two), the KICKR and a 4km cycling TT was deemed suitable for 
research purposes within study three. Whether TTs of varying distances are reliable 
when completed on the KICKR is yet to be determined. Therefore, further 
investigation into the reliability of longer duration TTs when completed on the KICKR 
will assist researchers in the correct selection of a measure of performance when 
investigating haemostatic responses to exercise of varying distances and durations.  
No time of day response for coagulation and fibrinolytic activation was observed when 
completing a short-duration high-intensity exercise bout in study three. The short 
duration of the exercise bout itself may have potentially masked the influence of time 
of day on the coagulation and fibrinolytic systems; however, whether a longer duration 
TT when completed at different times of the day will influence haemostatic responses 
is yet to be determined. Further research is therefore required to clarify if longer 
duration TTs will reveal a time of day influence on haemostatic responses to exercise 
in well-trained athletes. 
The activation of the coagulation and fibrinolytic systems upon completion of a 4km 
TT was confirmed in study three, regardless of the time of day exercise was performed. 
Whether master level athletes and athletes with genetic predispositions to 
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hypercoagulability respond in a similar manner to the findings of study three remains 
unclear, with research currently lacking within this population. Thus, it is of interest 
to understand the acute haemostatic responses to exercise of short-duration and high-
intensity within these populations and in particular if the time of day in which the 
exercise task is performed influences the activation of the haemostatic system. The 
outcomes of this research may assist with the implementation of preventative 
strategies including external mechanical prophylaxis to minimise the risk of 
potentially adverse outcomes (i.e. VTE). 
Whilst acute activation of the coagulation and fibrinolytic systems were demonstrated 
in exercise with a mean duration of 7 min (study three), whether these findings are 
directly transferable to well-trained athletes from other sports comprising of similar-
duration high-intensity events (i.e. 3000 m run, 800 m swim), has yet to be 
investigated. With the exercise mode often responsible for the variability observed 
within previous research [9, 112, 284], the investigation of haemostatic responses to 
differing modes of exercise remains unclear with a lack of research investigating this 
variable. Future research should focus on the examination of haemostatic responses to 
exercise of varying modes within a well-trained population in an attempt to contribute 
to this area of research. These findings may assist with exercise mode prescription to 
reduce the risk and onset of VTE in athletes returning to exercise following injury.  
When worn during a marathon run, compression socks reduced fibrinolytic activity in 
healthy runners (study four). Whether similar haemostatic responses are present when 
compression socks are worn during a marathon within athletes of: varying fitness 
levels, ages and genetic predispositions to clotting remains unconfirmed. More 
research is required to clarify the haemostatic responses within these populations of 
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athletes to determine if compression socks may be used as an effective preventative 
measure. 
Additionally, the combined effects of travel, compression garments and marathon 
running on haemostatic activation warrants further investigation, with only a limited 
number of studies completed within this field [24, 152, 283]. Limitations within these 
previous studies have included smaller sample sizes, in addition to the failure of the 
authors to provide detailed methodology making interpretation of findings difficult. 
Further investigations are therefore required using healthy and well-trained marathon 
runners and standardised study protocols to adequately assess haemostatic responses 
to travel, compression garments and exercise. Additionally, the influence of travel and 
marathon running have failed to collect post-travel venous blood samples upon arrival 
to the destination with future research required to collect pre-travel, immediately post-
travel and pre-exercise venous blood samples. These post-travel blood samples are 
crucial in the evaluation of coagulation and fibrinolytic markers (more specifically, D-
Dimer) to determine if elevated markers pre-exercise may increase the risk for 
thrombosis when combined with endurance-based exercise. These findings will be of 
benefit to athletes undertaking travel via the implementation of VTE preventative 
measures including: the use of compression garments or short-term anticoagulant 
therapy, in order to compete either professionally or recreationally. 
 7.2. Conclusion 
The overall outcomes from this series of studies demonstrate that factors including the 
duration of exercise influence coagulation responses within a well-trained population, 
findings previously limited to apparently healthy and untrained populations only 
(Figure 7.1). In addition, this thesis contributes to the scarce literature available on 
the use of compression garments on haemostatic responses in endurance-based 
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exercise, establishing that the use of sports compression socks may be beneficial in 
reducing the risk of VTE. The outcomes of this thesis may assist coaches, sports 
scientists and the athletes themselves to consider preventative measures for VTE, 
especially in athletes deemed to be most “at risk”.  
7.3 Practical Applications 
Based upon the findings of studies 3 and 4, some practical/ clinical applications may 
be relevant. For example, due to a time of day effect observed within TF, peaking 
within the morning (0830 h), caution should be applied when prescribing short-
duration high-intensity exercise bouts at 0830 h, especially in athletes who are 
predisposed to hypercoagulability (i.e. genetic thrombophilia, increasing age). Whilst 
compression socks are frequently used within the sporting industry to enhance 
exercise performance and aid recovery, the use of compression socks within 
endurance-based exercise may reduce the potential for thrombosis development. 
When compression socks are not worn when completing a marathon run, our results 
from study 4 demonstrate an increase in plasma concentrations of D-Dimer, 
suggesting an increased potential for thrombin generation. Therefore, the use of 
compression socks and haemostatic activation in prolonged strenuous exercise is 
limited, thus further research is required to confirm the findings of the present study 
and those of Zaleski et al. [24]
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Figure 7.1 Schematic representation of the overall outcomes and key findings of this PhD (indicated in blue boxes) in relation to 
exercise and haemostasis, when compared to previous research (white boxes). 
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Abstract 
Purpose: The purpose of this study was to assess the reliability of power output 
measurements of a Wahoo KICKR Power Trainer (KICKR) on two separate 
occasions, separated by fourteen months of regular use (~1 h per week). Methods: 
Using the KICKR to set power outputs, powers of 100-600W in increments of 50W 
were assessed at cadences of 80, 90 and 100rpm which were controlled and validated 
by a dynamic calibration rig (CALRIG). Results: A small mean bias of 0.8% 
(95%LoA: -8.3-8.9%) was observed over 100-600W at 80-100rpm between Trial 1 
and Trial 2. Small mean biases with acceptable limits of agreement were observed at 
80rpm (1.2%, 95%LoA: -5.9-8.3%), 90rpm (0.1%, 95%LoA: -7.8-5.5%) and 100rpm 
(1.0%, 95%LoA: -1.6-3.6%). Intraclass correlation coefficients (ICC) with 95% 
confidence intervals (CI) for mean power (W) between trials was 1.00 (95%CI: 1.00-
1.00) with a typical error (TE) of 3.1W and 1.6% observed between Trial 1 and Trial 
2. Conclusion: When assessed at two separate time points fourteen months apart, the 
KICKR has acceptable reliability for combined power outputs of 100-600W at 80-
100rpm, reporting overall small mean biases with acceptable limits of agreement and 
low TE. Coaches and sports scientists should feel confident in the power generated by 
the KICKR over an extended period of time when performing laboratory training and 
performance assessments. 
Keywords: reproducibility, power, ergometry, training 
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Introduction 
Advancements in the technology of cycling ergometers have been shown to provide 
increasing accuracy in the measurement of power output. The measurement of power 
throughout cycling is one of the key determinants of performance and is vital for 
evaluating individual differences in performances, monitoring the effectiveness of 
both training/ergogenic aids, whilst providing a true representation of the performance 
capabilities of both recreational and elite cyclists.1 Ergometers which enable the use 
of cyclists own bicycles have been shown to produce reliable results predictive of 
competitive performance whilst replicating movement economy and enhancing 
ecological validity in the transfer of power from a laboratory setting to the field.2 
Therefore, the ability of a cycling ergometer to consistently record reliable measures 
of power output with a high degree of precision is of significant importance.  
It is important for coaches and sports scientists to ensure the power measuring device 
they are using as part of research/athlete support is reliable.3 To track meaningful 
changes in competitive performance from an ergogenic or training intervention in elite 
athletes, ergometer error/bias should be less than 2%.4 However, the majority of 
validity and reliability assessments on cycling ergometers have been assessed over 
individual occasions,5,6 with evidence suggesting older ergometers may show greater 
biases when reliability is investigated over an extended period of time.7,8 With changes 
in performance as small as 1% often determining the difference between a finish on 
the podium or within the peloton, the ability to continuously track and monitor changes 
in performance on the same piece of equipment over an extended period of time is 
therefore required. 
The Wahoo KICKR Power Trainer (KICKR: Wahoo Fitness, Atlanta, GA) allows for 
the attachment of cyclists’ own bicycles and has previously been shown to provide 
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valid measures of power output,9 falling within the manufacturers claims of accuracy 
(± 3%). However, whether the Wahoo KICKR Power Trainer continues to provide 
continuous reliability over an extended period after regular use (i.e., research, 
performance assessments and training) has yet to be investigated. Therefore, the 
purpose of this study was to assess the reliability of power output measurements of the 
Wahoo KICKR Power Trainer on two separate occasions, separated by fourteen 
months of regular use.  
Methods 
The reliability of the KICKR power output was assessed on two separate occasions, 
fourteen months apart after ~120 experimental time trials (~60 h duration), by 
comparison with the power output of a dynamic calibration rig (CALRIG: Flinders 
University, Dynamic Calibrator 34118, Adelaide, Australia) as previously 
described.5,9 Both assessments of power were conducted in standard laboratory 
conditions (18.5 ± 3.5○C and 41.5 ± 3.5% relative humidity). 
A bicycle was attached to the KICKR via the SRAM/Shimano cassette. Power outputs 
of 100-600W were achieved by manually varying the resistance settings within 
‘ergometer-mode’ within the Wahoo Fitness Application for the KICKR (Wahoo 
Fitness, 2014 (version 5.1.1)). Power was increased by 50W every 3 min at fixed 
cadences of 80, 90 and 100rpm. Power measured by the CALRIG was sampled at 
200Hz and recorded every second (1Hz), with data produced in the final minute of 
each stage used for analysis purposes, according to the methodology of Hopker et al.6 
A standardised twenty-minute cool down was provided between each assessment 
cadence. 
Statistical Analysis 
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Sustained reliability of power from the KICKR was determined using bias and 95% 
limits of agreement (LoA) in accordance with the methods of Bland and Altman.10 The 
relative error (%) in measurement of power was calculated by subtracting the power 
measured by the CALRIG in Trial 2 from the power measured by the CALRIG in Trial 
1, divided by the average measured power of Trial 1 and Trial 2. The absolute error 
(difference in watts) was calculated by subtracting the CALRIG Trial 2 power from 
CALRIG Trial 1 power with all data analysed using GraphPad Prism 5, version 5.03 
(La Jolla, CA, USA). In accordance with previous research, 5 relative measurement 
bias of <1.5%, 1.5-2.5% and >2.5% were deemed as highly reliable, moderately 
reliable and inaccurate, respectively. Using an Excel spreadsheet for reliability,11 
intraclass correlation coefficient (ICC) in combination with 95% confidence intervals 
(CI), was used to determine the degree of association between the logarithmically 
transformed recorded CALRIG power at Trial 1 and Trial 2. Absolute (W) and relative 
(%) typical errors (TE) were calculated by dividing the standard deviation of the 
difference between Trial 1 and 2 by the square root of 2.  
Results 
Overall, small relative (%) and absolute biases (W) of 0.8% (95%LoA: -3.7-5.3%) and 
0.3W (95%LoA: -8.3-8.9W), respectively, were observed between trials over 100-
600W and 80-100rpm. Biases of 1.2% (95%LoA: -5.9-8.3%); 0.1% (95%LoA: -7.8-
5.5%); and 1.0% (95%LoA: -1.6-3.6%) with absolutes biases of 0.2W (95%LoA: -9.9-
10.3W); -1.1W (95%LoA: -2.2-2.4W) and 1.8W (95%LoA: -6.9-10.4W) were 
observed over 80, 90 and 100rpm and 100-600W, respectively. At the lower ranges of 
power (100-200W) over 80-100rpm, biases for relative (3.1% (95%LoA: 3.0-9.2%)) 
and absolute (4.0W (95%LoA: -2.5-10.6W)) measures of power, were larger than the 
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relative and absolute biases of 0.2% (95%LoA: -1.7-2.1%) and 0.3W (95%LoA: -6.1-
6.7W) observed between 250-500W over 80-100rpm.  
Average relative error (%) in measures of power from the CALRIG between trials over 
100-600W and 80-100rpm are presented in Figure 1. Errors >2.5% were observed at 
the lower ranges of power (100-150W) at 80rpm with moderate errors for 90rpm also 
observed at 100-150W. Moderate errors at 100rpm were reported for power ranging 
from 100-350W with overall power from 200-600W at 80-100rpm demonstrated to be 
highly accurate, with relative errors of <1.5% reported. 
An ICC with 95% CI of 1.00 (95%CI: 1.00-1.00) was observed for mean power 
reported by the CALRIG between Trials 1 and 2, using the KICKR over 100-600W 
and 80-100rpm. The Bland-Altman plot (Figure 2) clearly illustrates the average 
absolute differences in recorded power across the same range and cadence. There was 
a between trial typical error of 3.1W and 1.6%. 
Discussion  
The purpose of the current study was to examine the reliability of power measurements 
provided by the Wahoo KICKR Power Trainer on two separate occasions, fourteen 
months apart. The main findings from the study suggests the KICKR to have high test-
retest reliability, falling within the recommended range for ergometer error, with low 
typical errors reported for measures of power output over an extended period of regular 
use. 
The accuracy of an ergometer to record reliable measures of power over an extended 
period of time is of importance, with ergometer errors of <2% required for monitoring 
changes in cycling performance.4 Whether ergometer error remains low over extended 
periods of time is rarely investigated, with only one previous study to have reported 
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this.7 On two separate occasions 11 months apart, Gardner et al.7 reported similar 
reproducibility (~2.5% error) between the SRM and PowerTap mobile power trainers, 
suggesting good long-term reliability, however, falling outside the recommended 
range for ergometer error.4 In contrast to the findings of Gardner et al.,7 the KICKR 
was shown to have high test-retest reliability when compared to the CALRIG on two 
separate occasions, falling within the recommended range for ergometer error, with an 
overall small mean bias of 0.8% and a low typical error of 1.6%. Similar to Hopker et 
al.6 and Gardner et al.,7 we observed greater discrepancies within the lower ranges of 
power outputs (100-200W), with an overall large mean bias of 3.1% (95%LoA:-3.0-
9.2%) and 4.0W (95%LoA:-2.5-10.6W), with average relative errors of 5.1, 3.0 and 
1.3%, respectively, at cadences of 80-100rpm (Figure 1). This discrepancy may have 
arisen from a systematic error/consistent bias in the reading of power provided by the 
KICKR at the lower ranges of power, regardless of cadence.4 
Despite large biases at the lower ranges of power, a small bias of 0.2% (95%LoA: -
1.7-2.1%) was reported for power ranging from 250-500W, falling within the 
manufacturers claims for accuracy (± 3%). With mean power for competitive and well-
trained cyclists observed to consistently exceed 250W,12 this falls within the 
acceptable range of ergometer error for the KICKR (250-500W and 80-100rpm). 
However, as previously reported,9 accuracy of power measures of the KICKR are 
influenced by cadence selection.  
When assessed over 100-600W for Trial 1 and 2, small biases of 1.2% (95%LoA: -
5.9-8.3%), 0.1% (95%LoA: -7.8-5.5%) and 1.0% (95%LoA:-1.6-3.6%) were reported 
for 80, 90 and 100rpm, respectively. However, when assessed at 100rpm, a mean error 
of 2.1% was observed for powers of 100-350W (Figure 1). Regardless, with the 
KICKR falling within the acceptable range for ergometer error as reported by 
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Hopkins,4 coaches and sports scientists should feel confident in the reliability of power 
generated by the KICKR over an extended period, enabling accurate monitoring of 
performance changes. 
Conclusions 
In conclusion, when assessed at two separate time points fourteen months apart, the 
results of the present study suggest that the Wahoo KICKR Power Trainer has 
acceptable reliability for combined power outputs of 100-600W at 80-100rpm, falling 
within the recommended range for ergometer error. Coaches and sports scientists 
should feel confident in the power generated by the KICKR over an extended period 
of time following regular use when performing laboratory training, performance 
assessments and for talent identification purposes. 
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Table A.1 Ratio bias and 95%rLoA for differences in recordings pf Power at 100-
600W at 80-100rev.min-1 
 
 
 
 
 
 
 
 
 
Figure A.1. Relative error (%) between dynamic calibration rig (CALRIG) measured 
power at Trial 1 and Trial 2 over a set power range of 100-600W using the Wahoo 
KICKR Power Trainer (KICKR), and cadences of 80-100rev.min-1. Errors of <1.5%, 
1.5-2.5% and >2.5% are colour coded as green, yellow and red. 
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Figure A.2. Bland-Altman plot of the mean difference in absolute power output (W) 
between Trial 1 and Trial 2 over 100-600W as recorded by the Wahoo KICKR Power 
Trainer (KICKR) and the dynamic calibration rig (CALRIG) over 80-100rev.min-1. 
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Appendix C, i: Participant Information Sheet 
 
Project Title: The effect of travel and marathons on haemostasis 
Investigators  A/Prof James Fell 
Dr Murray Adams 
Ms Nerolie Bost 
Dr Shona Halson 
   Dr Cecilia Shing 
                                     Ms Emma Zadow 
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Dr Andrew Bulmer 
Dr Indu Singh 
 
Location  School of Health Sciences 
   Locked Bag 1322 
   University of Tasmania 
   Launceston, Tasmania 7250 
 
Contact   Miss Emma Zadow 
  
   Emma.Zadow@utas.edu.au    
 
Invitation 
You are invited to participate in this study as you are: 
1. Competing in the 2016 Gold Coast Marathon 
Introduction 
While exercise has been shown to be beneficial for overall health and wellbeing, it has been well 
reported that the duration and intensity of the exercise itself may lead to a transient increase in the 
activation of the coagulation system, resulting in an increased risk for thrombosis (i.e. blood clot) 
development. Furthermore, prolonged travel is also implicated with increased risk of blood clot 
development and athletes often travel long distances to compete in major events such as the Gold Coast 
Marathon.  Such clots can be potentially fatal and avoidance is the safest option.  However, there has 
been minimal research to investigate the interaction between prolonged travel and prolonged exercise, 
such as a marathon, on the markers associated with an increased risk of blot clots. 
Several clothing companies that produce sports compression garments make claims that the 
compression clothing can also be of benefit for reducing blood clot risks associated with travel.  It may 
be that wearing compression garments, such as compression socks, during a marathon, or in the post-
race period may be of benefit for reducing the blood markers associated with increased risk of blood 
clots.  However, there has been limited research to investigate these claims. 
Participants 
We require 80 healthy marathon runners competing in the 2016 Gold Coast Marathon. You need to be 
in good health with no major injuries or illness, known blood clotting disorders, or taking any 
anticoagulant medication such as aspirin, heparin, warfarin etc.  As a possible participant in this study, 
you will be asked to visit a testing location on three occasions (24 hours before, immediately after and 
24 hours after the race). Each visit would require approximately 15 minutes to complete for a total of 
45 minutes. 
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During your initial visit, you will complete a health-screening questionnaire and provide information 
about your training, general health and travel to the event.  You will then provide a small sample of 
blood taken from a vein in the front area of your elbow region.  Some participants will then be provided 
with compression socks to wear during the race.   
After the race, you will need to attend the testing location as soon as possible to provide another blood 
sample.  You will also complete a questionnaire that asks questions about your race, such as your 
performance, effort, and any illness or injury.  If you are treated for a medical event either during or 
after the race information will be collected about the nature of the medical event.  Some participants 
will then be provided with compression socks to wear for the next 24 hours. 
The final visit will occur approximately 24 hours after you finished the race.  At this visit, a final blood 
sample will be collected and you will complete another brief questionnaire about how you have 
recovered and an indication of food, fluid and activity levels over the past 24 hours.  
A pair of compression socks will be given to you during this visit if you have not previously received 
any.  
Blood Collection 
Throughout this study, you will be asked to provide three venous blood samples (15-20ml equal to 
about 3-4 teaspoons).  These samples will be analysed for markers associated with increased risk of 
blood clotting and inflammation, muscle damage, protein and electrolyte levels. 
Voluntary Participation 
It is important that you understand that your involvement in this study is voluntary and we will respect 
your right to decline. There will be no consequences to you if you decide not to participate, and this 
will not affect your treatment/ service. If you decide to discontinue participation at any time, you may 
do so without providing an explanation. If you withdraw, all information you have provided will be 
destroyed. All information will be treated in a confidential manner, and your name will not be used in 
any publication arising out of the research. All of the research will be kept on a password-protected 
computer of the primary researcher. 
Possible Benefits 
Participants who complete this study will be provided a report of the key findings via email (if they 
agree to provide their email address).  The findings of the study will identify potential risk factors for 
blood clots in athletes and whether strategies to reduce the risk, such as compression clothing before or 
after a race, are effective. 
Possible Risks 
It is possible during the collection of venous blood samples, participants could experience discomfort 
and potential bruising at the site of collection, the discomfort would not be greater than venous blood 
samples a participant may have provided for past medical reasons (i.e. standard medical blood test). 
Nevertheless, if a participant does experience undue pain from this procedure, the researcher will 
immediately attend to the area with compression and ice. 
Distribution of Results 
All of your test results will remain confidential and will be coded, with the code kept separated from 
your personal details. Results will be electronically stored on a password protected computer hard-drive 
of the primary researcher. Only the researchers involved in this study will have access to data 
identifying you by name. 
Alternative Uses of Data 
All data collected during this study will be stored for a minimum of five years. During this period, data 
collected from this study may be used for scientific purposes other than those outlined above. At no 
time will private or identifiable participant information be used. Any data provided for alternative use 
will be coded as to eliminate the ability to identify the participant. 
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Questions 
If you would like to discuss any aspect of this study, please feel free to contact the following 
investigators: 
A/Prof James Fell, James.Fell@utas.edu.au, +61 3 6324 5485 
Dr Murray Adams, Murray.Adams@utas.edu.au, +61 3 6324 5483   
Ms Nerolie Bost, nerolie.bost@health.qld.gov.au, +61 7 5687 5273 
Dr Cecilia Kitic, Cecilia.Kitic@utas.edu.au, +61 3 6324 5484 
Ms Emma Zadow, Emma.Zadow@utas.edu.au, 04 
Dr Shona Halson, Shona.Halson@ausport.gov.au 
Dr Andrew Bulmer a.bulmer@griffith.edu.au  
Dr Indu Singh i.singh@griffith.edu.au  
Dr Amy Johnston, amy.johnston@health.qld.gov.au 
A/Prof Julia Crilly, julia.crilly@health.qld.gov.au 
This study has been reviewed and approved by the Gold Coast Hospital and Health Service 
(GCHHS) Human Research Ethics Committee, Tasmanian Health and Medical Human Research 
Committee and Griffith University Human Research Ethics Committee. Should you wish to discuss 
the study with someone not directly involved, in relation to matters concerning policies, information about the 
conduct of the study or your rights as a participant, or should you wish to make an independent complaint, 
you can contact the Chairperson of GCHHS Human Research Ethics Committee  on  Ph.:  + 61 7 5687 3879 or 
email:  GCHEthics@health.qld.gov.au
You will need to quote ethics reference number  HREC/16/QGC/48 
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Appendix C, ii: Study Timeline 
Saturday 2nd July: 10:00 am to 2:00 pm: 
• Please report to the registration area located at the Gold Coast Convention and
Exhibition Centre (Gold Coast Highway, Broadbeach), Office 3 on level 1, between
Hall 3 and 4 (Figure 1).
 
• We will collect the following information from you:
1. Informed Consent
2. Medical history and Questionnaire
3. Height and Weight
4. First blood sample
• You will also be randomly allocated to either the compression or non- compression
sock group, with the compression socks to be worn during the marathon.
• You will be provided with a wristband (below image) to be worn during the
marathon. This is so we can identify you as registered participants within our study
and so we can direct you to the medical tent in order to collect your post marathon
blood samples.
Sunday 3rd July: Marathon Day (within 1-hour post marathon completion) 
• If you have been assigned to the compression sock group, please wear these
throughout your marathon run 
Please ensure you have placed your wristband on. 
• A helper will be located at the finish line of the marathon and will direct you to the
medical tent (Figure 2), where we will:
1. collect your second blood sample
2. Ask you to complete a post exercise questionnaire
• You will then be randomly allocated to either the compression or non-compression
sock group (with compression socks provided) to be worn throughout your recovery
(24 hours post marathon), prior to your final blood sample being collected.
Monday 4th July: 10:00 am to 2:00 pm 
• Please report to the medical tent (where your blood samples were collected
immediately after the marathon) to complete the following:
1. Provide your third and final blood sample
2. Complete a follow up questionnaire
• If you have not been provided with compression socks at this stage, you will then be
provided with some throughout this visit.
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Appendix C, iii: Participant Recruitment Questionnaire 
Demographic Information: 
Athlete Name: 
Age: 
Sex:   M   F 
Height: _________________________Weight: ______________________ 
Describe your current physical activity/ exercise levels: 
1. Frequency (average sessions per week) _______________
2. Duration (average minutes per session) __________________
Have you trained/ competed using compression garments before? 
YES  /  NO 
If yes, I use it for (tick all applicable): training/recovery/sleep/travel/other 
Brand (i.e. 2XU, skins): _____________________________________________ 
Type of compression (i.e. socks, leggings, sleeves):  
Gold Coast Marathon Details: 
1. Are you registered to complete the marathon?      Y / N
2. Registration/ bib number:
3. What is your expected finishing time for the Gold Coast Marathon: ____(h)
_____(m)
Travel Information: 
4. What will be your primary mode of transport to the event?
Airplane  Car/ Bus/Train  Boat
5. Which state of Australia or country from outside Australia are you travelling from
to participate in the Gold Coast marathon?
6. What is your expected travel time? (i.e. 3 hours).
Travel time: ____ (h): ______ (m)   Breaks between travel: _________
7. When are you departing the location (Q3)?
Date and time: ________________________
8. When are you arriving at the Gold Coast?
Date: _____________________
Time: _____________________
9. When are you leaving/ departing the Gold Coast?
Date/ time: __________________________
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10. Did you wear or do you intend to wear compression garments when travelling to the
Gold Coast?
YES  /  NO
General Health and Medical Screening: 
11. Are you currently in good health with no major injuries or illnesses?
YES  /  NO
   Further information: 
12. Are you on the oral contraceptive pill?
YES  /  NO
13. Do you have any blood clotting disorders or metabolic conditions? (i.e. have
Cardiovascular disease or Diabetes)
YES   /  NO
   Further information: 
14. Are you on any anti-coagulation/ blood thinning medications? (i.e. aspirin, warfarin,
heparin)
YES  /  NO
  Further Information: 
15. Do you have a family history of blood clotting disorders? (i.e. mother/ father, which
clotting disorder they may have)
YES  /  NO
 Further information: 
16. Do you have a previous history of venous thrombosis? (i.e. deep vein thrombosis or
pulmonary embolism).
YES  /  NO
   Further Information: 
17. Is there a family history of venous thrombosis? (i.e. mother/ father, age of
thrombosis)
YES  /  NO
  Further Information: 
 General: 
18. Are you available to provide all three (pre marathon (+24 h), immediately post
marathon and 24 h post marathon) required blood samples between 10 am and 2
pm?
YES  /   NO
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  Appendix C, iv: Informed Consent 
Title of Project: The effect of travel and marathons on haemostasis 
The investigators conducting this research project abide by the principles governing the ethical conduct 
of research and, at all times, undertake to protect the interest, comfort and safety of all athletes. 
This form and accompanying Participant Information Document have been given to you for your own 
protection. They outline the experimental procedures and explain possible risks. 
Your signature on this form will indicate that: 
• I acknowledge that the nature, purpose and contemplated effects of the project as far as it
affects me, has been fully explained to my satisfaction by the research worker and my consent
is given voluntarily.
• The details of the procedure proposed have also been explained to me, including the
anticipated length of time it will take, the frequency with which the procedure will be
performed, and an indication of any discomfort, which may be expected. I understand that my
involvement requires:
• Completion of questionnaires, providing a venous blood sample and, possibly, the
wearing of compression socks.
• I understand that there are the following risks or possible discomfort:
• Bruising or discomfort at the site of blood collection
• I have been informed that all information and results will remain confidential (disclosed only
to myself) and the results of any tests involving me will not be published so as to reveal my
identity.
• I understand that I am free to withdraw from the project at any stage and any of my
data/specimens that have been collected.  My withdrawal will not affect my legal rights, my 
medical care or my relationship with the hospital or my doctors.
• I understand that I will be given a signed copy of this patient information sheet and consent
form.  I am not giving up my legal rights by signing this consent form.
• I understand that the trial will be conducted in accordance with the latest versions of the
National Statement on Ethical Conduct in Human Research 2007 and applicable privacy
laws.
Name of participant: __________________________________  
 Signature of participant:_______________________  Date:____________ 
• I have explained this project and the implications of participation in it to this volunteer and I
believe that the consent is informed and that he/she understands the implications of
participation.
Name of investigator: ______________________________________ 
Signature of investigator: _________________________ Date:_____________ 
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Appendix C, v: “Does wearing compression socks during a marathon influence 
coagulation and fibrinolytic activation?” Conference Poster 
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Appendix C, iv. European Journal of Applied Physiology manuscript acceptance 
letter 
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Appendix D, i: European Journal of Sports Science manuscript acceptance letter 
